glucose, (beta-d)-isomer has been researched along with Diabetes Mellitus, Adult-Onset in 1729 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.12) | 18.7374 |
| 1990's | 1 (0.06) | 18.2507 |
| 2000's | 31 (1.79) | 29.6817 |
| 2010's | 1067 (61.71) | 24.3611 |
| 2020's | 628 (36.32) | 2.80 |
| Authors | Studies |
|---|---|
| Grinevich, AA; Kosyakova, NI; Safronova, VG; Tikhonova, IV | 1 |
| Anjos, PM; Fagundes-Netto, FS; Nogueira-Machado, JA; Volpe, CM | 1 |
| Hand, DL; Hand, WL; Vasquez, Y | 1 |
| Siekierka, H; Szczepanik, A; Wierusz-Wysocka, B; Wykretowicz, A; Wysocki, H | 1 |
| Anderson, DC; Lenton, J; Puxty, JA; Winocour, PH | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Hauske, S; Packer, M; Pocock, SJ; Zannad, F; Zeller, C | 1 |
| Brueckmann, M; Butler, J; Fitchett, DH; George, JT; Inzucchi, SE; Mattheus, M; Ofstad, AP; Sattar, N; Vaduganathan, M; Verma, S; Wanner, C; Zinman, B | 1 |
| Ginsberg, HN; Lund, SS; Neubacher, D; Salsali, A; Sattar, N | 1 |
| Abdelaziz, MA; Belal, F; El-Domany, RA; Shaldam, M | 1 |
| Kainz, M; Schiferer, A; Tschernko, E; Wohlrab, P; Zapletal, B | 1 |
| Muthu, K; Sundaram, R; Vasu, G | 1 |
| Aktas, G; Bilgin, S; Duman, TT; Erge, E; Kahveci, G; Kiran, M; Kurtkulagi, O; Tel, BMA | 1 |
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Tahara, A | 2 |
| Mendoza, VL; Punzalan, FER; Tumanan-Mendoza, BA | 1 |
| Jiang, LL; Li, FF; Liu, BL; Ma, JH; Yan, RN; Ye, L; Zhang, P | 1 |
| Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH | 1 |
| Chenchula, S; Padmavathi, R; Varthya, SB | 1 |
| Arieta, CEL; Barreto, J; Breder, I; Breder, JC; Carvalho, LSF; Chaves, FRP; Cintra, RMR; Fernandes, VHR; Kimura-Medorima, ST; Munhoz, DB; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC | 1 |
| Kumar, S; Mittal, A; Sharma, S | 1 |
| Fang, Z; Hu, L; Li, C; Liu, M; Wu, Q; Zhang, W; Zou, F | 1 |
| Bai, L; Ding, Y; Fan, Y; Fatima, M; Gao, J; Han, T; Wang, C; Zhang, Y | 1 |
| Ferreira, JP; Inzucchi, SE; Mattheus, M; Meinicke, T; Steubl, D; Wanner, C; Zinman, B | 1 |
| Aishima, S; Anzai, K; Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Isoda, H; Kage, M; Kawaguchi, A; Kawanaka, M; Kessoku, T; Kitajima, Y; Kubotsu, Y; Kurai, O; Nakajima, A; Nakajima, T; Nonaka, M; Oeda, S; Ono, M; Tajiri, R; Takahashi, H; Takamori, A; Tanaka, K; Yoneda, M | 1 |
| Cherney, D; Chertow, GM; Correa-Rotter, R; Dwyer, JP; Greene, T; Heerspink, HJL; Kosiborod, M; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Raja, UY; Saravanan, P | 1 |
| Aiwale, A; Ghag, S; Pawar, R; Trailokya, AA; Zalke, A; Zargar, AH | 1 |
| Bluhmki, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Lachin, JM; Ofstad, AP; Ohneberg, K; Salsali, A; Schmoor, C; Schumacher, M; Wanner, C; Zannad, F; Zinman, B | 1 |
| Anker, SD; Butler, J; Sattar, N; Verma, S | 1 |
| Sahu, JK; Sharma, S; Suryavanshi, VD | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 3 |
| Chen, G; Wang, H; Zhang, W; Zhou, J | 1 |
| Acuna-Castillo, C; Aranda, M; Bustos, C; Calfío, C; Cubillos, FA; Del Campo, A; Díaz-Castro, F; Fajardo, A; Milla, LA; Pastene-Navarrete, ER; Rojo, LE; Salamanca, C; Troncoso, R; Villarroel, CA | 1 |
| Dludla, PV; Mazibuko-Mbeje, SE; Mthembu, SXH; Mthiyane, FT; Muller, CJF; Muvhulawa, N; Tshiitamune, A; Ziqubu, K | 1 |
| Boulton, DW; Chang, R; Naagaard, MD; Någård, M; Tang, W | 1 |
| Chan, YY; Chang, KC; Chang, SH; Hung, MJ; Lai, EC; Lin, SJ; Shao, SC | 1 |
| Bartuś, S; Budaj, A; Dąbrowski, M; Drożdż, J; Gellert, R; Grąbczewska, Z; Grzelakowska, K; Jaguszewski, MJ; Jankowski, P; Kubica, A; Kubica, J; Legutko, J; Lesiak, M; Leszek, P; Małyszko, J; Michalski, P; Mitkowski, P; Navarese, EP; Nessler, J; Niezgoda, P; Pawlaczyk, K; Siller-Matula, J; Stolarek, W; Stompór, T; Wolnik, B | 1 |
| Banerjee, SK; Barge, SR; Bharadwaj, S; Borah, JC; Boruwa, J; Deka, B; Dutta, PP; Ghosh, A; Kamboj, P; Kandimalla, R; Kashyap, B; Manna, P; Pal, U; Rahman, S; Saikia, S; Samanta, SK; Sheikh, Y; Swargiary, D; Talukdar, NC; Tuli, D | 1 |
| Birkenfeld, AL; Dannecker, C; Fritsche, A; Fritsche, L; Häring, HU; Heni, M; Hummel, J; Kantartzis, K; Kullmann, S; Machann, J; Peter, A; Preissl, H; Stefan, N; Veit, R; Vosseler, A; Wagner, R | 1 |
| Hamaoka, T; Hirai, T; Inoue, O; Kato, T; Kawashiri, MA; Mukai, Y; Murai, H; Sakata, K; Sugimoto, H; Takamura, M; Takashima, S; Takata, S; Usui, S | 1 |
| Bessette, LG; Brodovicz, KG; Déruaz-Luyet, A; Glynn, RJ; Najafzadeh, M; Paik, JM; Patorno, E; Pawar, A; Schneeweiss, S; Wexler, DJ | 1 |
| Jeon, HJ; Ku, EJ; Lee, DH; Oh, TK | 2 |
| Borlaug, BA; Burkhoff, D; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Videbæk, L | 1 |
| Brand, SB; Kansal, AR; Koitka-Weber, A; Kuti, E; Pfarr, E; Reifsnider, OS; Stargardter, M; Ustyugova, A; Wang, C; Wanner, C | 1 |
| Fukuda, A; Hamada, K; Higashikawa, T; Iguchi, M; Ishigami, K; Ito, T; Izumida, T; Kanda, T; Kasamaki, Y; Kiyosawa, J; Kuroki, K; Maekawa, N; Mizuno, T; Mori, H; Morita, T; Nakahashi, T; Okuro, M; Saito, A; Sangen, R; Takagi, S; Takeshima, K; Usuda, D; Yamada, S | 1 |
| Ishihara, H; Kohno, G; Koike, M; Saito, H; Takubo, M; Watanabe, K | 1 |
| Egocheaga, I; Escobar, C; Obaya, JC; Pallarés, V | 1 |
| Barreto, J; Bonilha, I; Breder, I; Cintra, RM; Coelho-Filho, OR; Cunha, JS; de Carvalho, LSF; Guerra-Junior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW | 1 |
| Ehlers, LH; Ejskjaer, N; Frary, EC; Holmgaard, P; Lamotte, M; Ramos, MC; Sandgaard, S | 1 |
| Hirayama, K; Iwaki, Y; Kobayashi, M; Maruyama, H; Ohgi, K; Shimohata, H; Takayasu, M; Yamashita, M | 1 |
| Barbancho, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Lara, JP; López-Carmona, MD; López-Sampalo, A; Millán-Gómez, M; Osuna-Sánchez, J; Pérez-Belmonte, LM; Ricci, M; Sanz-Cánovas, J | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Nowicki, M; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC; Wittmann, I | 1 |
| Doumas, M; Karagiannis, A; Kassimis, G; Papadopoulos, C; Patoulias, D; Vassilikos, V | 1 |
| Chung, WJ; Deruaz-Luyet, A; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Sheu, WH; Tan, EC; Ustyugova, A; Yabe, D; Yasui, A | 1 |
| Constantino, MI; D'Souza, M; McGill, M; Middleton, TL; Twigg, SM; Wong, J; Wu, T; Yue, DK | 1 |
| Ferrannini, E; Lim, S; Shin, Y; Sohn, M | 1 |
| Anker, SD; Kaku, K; Lund, SS; Mattheus, M; Pocock, S; Wanner, C; Yasui, A | 1 |
| Bergrath Washington, E; Brand, S; Desai, NR; Pimple, P; Reifsnider, OS; Shetty, S | 1 |
| Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L | 2 |
| Binder, H; Daiber, A; Gori, T; Jünger, C; Koeck, T; Lackner, KJ; Münzel, T; Prochaska, JH; Rapp, S; Schulz, A; Wild, PS | 1 |
| Bosch, A; Fromm, MF; Gemeinhardt, A; Gessner, A; Kannenkeril, D; Maas, R; Mayr, A; Schmieder, RE; Staerk, C | 1 |
| Bhatt, DL; Gause-Nilsson, I; Kolkailah, AA; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Chaitoff, A; Fischer, MA; Gong, J; Niforatos, JD | 1 |
| Packer, M; Zannad, F | 1 |
| Albai, A; Braha, A; Cipu, D; Potre, O; Timar, B; Timar, R; Vasiluță, L | 1 |
| Bhosle, D; Chavan, S; Kardile, S | 1 |
| Connelly, KA; Deva, DP; Ge, Y; Jimenez-Juan, L; Mazer, CD; Ng, MY; Pourafkari, M; Quan, A; Rai, A; Ramanan, V; Roifman, I; Teoh, H; Verma, S; Yan, AT | 1 |
| Brandt, NH; Ersbøll, M; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wolsk, E; Zerahn, B | 1 |
| El Medany, AMH; Ghazala, RA; Hammadi, SHM; Khalifa, HM; Zakaria Mohammed, HS | 1 |
| Khine, A; Kwok, J; Lin, E | 1 |
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
| Katakami, N; Maeda, N; Mita, T; Sato, Y; Shimomura, I; Watada, H | 1 |
| Jardine, MJ; O'Hara, DV | 1 |
| Barkhof, F; IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Schrantee, A; van Bloemendaal, L; van Ruiten, CC; Veltman, DJ | 1 |
| Aluri, KZ; Chertow, GM; Cusick, MM; Goldhaber-Fiebert, JD; Handley, TJ; Joyner, AKC; Owens, DK; Salomon, JA; Tisdale, RL | 1 |
| Bové, KB; Nilsson, M; Prescott, E; Suhrs, HE; Zander, M | 1 |
| Han, L; Ma, J; Tong, X; Wei, Y; Wu, T; Zhang, L; Zhao, L | 1 |
| Hanaguri, J; Kushiyama, A; Kushiyama, S; Nagaoka, T; Watanabe, M; Yamagami, S; Yokota, H | 1 |
| Inzucchi, SE; Kahl, S; Ofstad, AP; Roden, M; Sattar, N; Schüler, E; Wanner, C; Zinman, B | 1 |
| Hasebe, M; Ito, K; Kondo, Y; Satoh, S; Tamura, H; Terauchi, Y | 1 |
| Gómez-Huelgas, R; Lara, JP; Miramontes-González, JP; Osuna-Sánchez, J; Pérez-Belmonte, LM | 1 |
| Balcı, C; Ismayilov, R | 1 |
| Akyüz, A; Araç, E; Aslan, B; Boyraz, B; Çap, M; İnci, Ü; Işık, F; Karahan, MZ; Kaya, İ; Okşul, M; Yıldız, H | 1 |
| Capel, M; Escobar, C; Morales, C; Pérez-Alcántara, F; Pomares, E; Simón, S | 1 |
| Saengklub, N; Wichaiyo, S | 1 |
| Arima, H; Fujita, Y; Horibe, K; Ida, S; Itoh, R; Kondo, K; Maegawa, H; Miura, K; Miyazawa, I; Morino, K; Murata, K; Ohashi, N; Sato, D; Tanaka-Mizuno, S; Ugi, S; Yanagimachi, T; Yoshimura, M | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Moore, CM | 1 |
| Akasaka, H; Fujio, Y; Fukuda, M; Iwakura, K; Kamide, K; Nakatani, S; Ogihara, T; Okamura, A; Rakugi, H; Shintani, A; Sugimoto, K; Takiuchi, S; Taniuchi, S; Yamamoto, K | 1 |
| Andersen, CF; Gustafsson, F; Højlund, K; Jensen, J; Kistorp, C; Køber, L; Larsen, JH; Møller, JE; Omar, M; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Angermann, CE; Biegus, J; Blatchford, JP; Borleffs, CJW; Brueckmann, M; Collins, SP; Comin-Colet, J; Ferreira, JP; Fu, M; Janssens, SP; Kiss, RG; Kosiborod, M; Ma, C; Mentz, RJ; Nassif, ME; Ponikowski, P; Psotka, MA; Sakata, Y; Salsali, A; Schirmer, H; Schou, M; Schulze, PC; Spinarova, L; Teerlink, JR; Tromp, J; Volterrani, M; Voors, AA; Wranicz, JK; Zeymer, U; Zieroth, S | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; DeFronzo, RA; Gastaldelli, A; Lavryneko, O; Solis-Herrera, C; Triplitt, C | 1 |
| Kiyakbaev, G; Kokhan, E; Medovchshikov, V | 1 |
| García, Á; Gil-Rojas, Y; Lasalvia, P | 1 |
| Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z | 1 |
| Ansari, IA; Bhatt, SP; Dutta, K; Ghosh, A; Gupta, R; Mahajan, H; Misra, A; Pandey, RM; Pandey, S; Tyagi, K; Venugopal, VK | 1 |
| Joshi, D; Narula, S; Rohilla, R; Singh, H; Singh, J; Singla, M | 1 |
| Seki, H; Watanabe, H; Yorozu, T | 1 |
| Frullone, S; Gambardella, J; Lombardi, A; Macina, G; Mone, P; Morgante, M; Pansini, A; Santulli, G | 2 |
| Balasubramanian, P; Elsaesser, A; Ferreira, JP; Inzucchi, SE; Ofstad, AP; Wanner, C; Zinman, B | 1 |
| Lim, GB | 2 |
| Agarwal, R; Doi, K; Elsaesser, A; Hauske, SJ; Ritter, I; Steubl, D; Wanner, C; Wheeler, DC | 1 |
| Chen, S; Coronel, R; Hollmann, MW; Weber, NC; Zuurbier, CJ | 1 |
| Birnie, E; Burggraaf, B; Castro Cabezas, M; de Herder, WW; Fernández Arroyo, S; Huisbrink, J; Mulder, MT; Pouw, NMC; Rensen, PCN; van de Geijn, GM; van der Zwan, EM; van Vark-van der Zee, LC | 1 |
| Davies, M; Fielding, BA; Herring, RA; Jackson, N; Mendis, J; Middleton, B; Parsons, I; Russell-Jones, DL; Shojaee-Moradie, F; Stevenage, M; Umpleby, AM | 1 |
| Anker, SD; Fitchett, DH; Inzucchi, SE; Lauer, S; Pernille Ofstad, A; Sander, LE; Vedin, O; Verma, S; Wanner, C; Yaggi, HK; Zinman, B | 1 |
| Aijaz, SS; Iqbal, Y; Zafar, Y | 1 |
| Heni, M; Hummel, J; Kullmann, S | 1 |
| Xu, W; Xu, X; Yan, Y; Zhuo, Q | 1 |
| Asseri, SM; Ebrahim, HA; El-Agawy, MSE; El-Shafey, M; El-Sherbiny, M; Eldosoky, M; Elsherbini, DMA; Elsherbiny, NM | 1 |
| Isganaitis, E; Karlsson, C; Laffel, LM; Norjavaara, E; Ratnayake, J; Shehadeh, N; Tamborlane, WV; Van Name, M | 1 |
| Bjornstad, P; Nelson, RG; Tommerdahl, KL | 1 |
| Larkin, HD | 1 |
| Bonny, O; Burnier, M; Ghajarzadeh-Wurzner, A; Harmacek, D; Muller, ME; Pruijm, M; Zanchi, A | 1 |
| Bogdanffy, MS; Knight, B; Ku, WW; Phillips, JA; Smith, JD; Taub, ME; Yuan, J | 1 |
| Chen, Y; Deng, X; Fang, Y; Kan, Q; Liu, Y; Man, H; Shang, J; Shi, X; Tang, S; Wang, D; Wang, L; Wang, P; Wei, W; Yang, H; Yang, J; Yuan, H; Yuan, Q; Zhang, C; Zhang, Y | 1 |
| Boulton, DW; Hamrén, B; Melin, J; Parkinson, J; Penland, RC; Rekić, D; Tang, W | 1 |
| Bodicoat, DH; Chatterjee, S; Davies, MJ; Edwardson, CL; Gray, LJ; Khunti, K; King, JA; Poulin, B; Redman, EL; Sargeant, JA; Stensel, DJ; Waheed, G; Waller, HL; Webb, DR; Wilding, JPH; Willis, SA; Yates, T | 1 |
| Adamson, C; Bengtsson, O; Damman, K; de Boer, RA; Docherty, KF; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vaduganathan, M; Verma, S | 1 |
| Barkatestrong/Strong, H; Khaladkar, K; Mohan, B; Suryawanshi, S | 1 |
| Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC | 1 |
| Belohlávek, J; Bengtsson, O; Butt, JH; Chiang, CE; Dewan, P; Docherty, KF; Drożdż, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Agarwal, R; Elsäßer, A; Hauske, SJ; Kadowaki, T; Levin, A; Nangaku, M; Ritter, I; Steubl, D; Tuttle, KR; Wanner, C; Wheeler, DC | 1 |
| Birkenfeld, AL; Dannecker, C; Fritsche, A; Häring, HU; Heni, M; Hummel, J; Kullmann, S; Machann, J; Peter, A; Wagner, R | 1 |
| Gong, Y; Jiang, L; Pei, Z; Wang, A; Wu, Y; Xia, L | 1 |
| IJzerman, RG; Kok, MD; Kramer, MHH; Nieuwdorp, M; Serné, EH; Smits, MM; van Raalte, DH; van Ruiten, CC | 1 |
| Xiang, G; Yue, L; Zhang, J; Zhu, G | 1 |
| IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Ten Kulve, JS; van Ruiten, CC; Veltman, DJ; Wijdeveld, M | 1 |
| Miyagi, K; Miyazaki, R | 1 |
| Aylward, P; Bhatt, DL; Cahn, A; Dalby, AJ; Dellborg, M; Dimulescu, D; Furtado, RHM; Gause-Nilsson, I; Goodrich, EL; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Oude Ophuis, AJM; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Adel, SMH; Fazeli, S; Jorfi, F; Mombeini, H; Rashidi, H | 1 |
| Franch-Nadal, J; Gallego Estébanez, M; Hunt, B; Malkin, SJP; Martín, V; Vidal, J | 1 |
| Chen, Y; He, J; Hu, Q; Li, W; Li, X; Su, L; Zhao, L | 1 |
| Bello, E; Bhatwadekar, AD; Dhami, H; Leley, SP; Luo, Q; Mathew, D | 1 |
| Honda, Y; Imajo, K; Kessoku, T; Kirikoshi, H; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Saito, S; Taguri, M; Yoneda, M | 1 |
| Chi, PJ; Hsieh, YJ; Hsu, BG; Lee, CJ; Lu, CW | 1 |
| Hiramoto, K; Horikawa, T; Ooi, K; Tanaka, S | 1 |
| Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Sumin, M; Udell, JA; Vedin, O; Zwiener, I | 1 |
| IJzerman, RG; Nieuwdorp, M; van Ruiten, CC; Veltman, DJ | 1 |
| Huh, Y; Kim, YS | 1 |
| Bezan Petric, U; Fukazawa, A; Hu, MC; Ishizawa, R; Kim, HK; Mizuno, M; Smith, SA; Vongpatanasin, W; Wang, Z | 1 |
| Chen, HC; Yang, AY | 1 |
| Fang, J; Gong, Q; Sun, J; Sun, Q; Wang, H; Wei, F; Zhang, J; Zhang, R | 1 |
| Ekinci, EI; Lecamwasam, A | 1 |
| Hao, Z; Zhang, Y | 1 |
| Iwamoto, M; Kadowaki, T; Kubota, N; Kubota, T; Sakurai, Y; Shioda, S; Wada, N; Yamauchi, T | 1 |
| Chen, J; Huang, Y; Li, T; Lin, X; Lin, Y; Lu, H; Xian, J; Yang, Z; Zhang, Q | 1 |
| Fujiki, S; Imai, T; Inomata, T; Kashimura, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Shimabukuro, M; Suzuki, M; Tanaka, A; Uehara, H | 1 |
| Bardhi, O; Bloom, MD; Sattari, M | 1 |
| Nishikawa, Y; Supakul, S; Takase, T; Teramura, M | 1 |
| Dai, X; Hao, H; Li, Y; Ou, T; Wang, D; Wang, R; Wang, W; Yong, H | 1 |
| Abdelkader, NF; Elbaset, MA; Ibrahim, SM; Moustafa, PE | 1 |
| Shao, G | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F | 1 |
| Distaso, M; Ferrannini, E; Raggi, F; Solini, A; Tricò, D | 1 |
| Kurata, Y; Nangaku, M | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Goodrich, EL; Leiter, LA; McGuire, DK; Mosenzon, O; Oyama, K; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Dural, İE; Ersoy, İ; Sarı, A | 1 |
| Solini, A; Tricò, D | 1 |
| AlHummiany, B; Allwood-Spiers, S; Berry, C; Brooksbank, KJM; Campbell, RT; Chong, V; Coyle, L; Docherty, KF; Dreisbach, JG; Gillis, KA; Hall Barrientos, P; Jhund, PS; Kuehn, B; Labinjoh, C; Lang, NN; Lee, MMY; Lennie, V; Mangion, K; Mark, PB; McConnachie, A; McMurray, JJV; Murphy, CL; Petrie, CJ; Petrie, JR; Petrie, MC; Radjenovic, A; Roditi, G; Sattar, N; Sharma, K; Sourbron, S; Speirits, IA; Thompson, J; Welsh, P; Wetherall, K; Woodward, R; Wright, A | 1 |
| Seetharaman, R | 1 |
| Campeau, MA; Leask, RL | 1 |
| Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T | 1 |
| Bengtsson, O; Biering-Sørensen, T; Butt, JH; DeFilippis, EM; Dewan, P; Docherty, KF; Fiuzat, M; Jhund, PS; Johansen, ND; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD; Vaduganathan, M | 1 |
| Bellante, R; Berra, C; Bolla, A; Chebat, E; Cimino, V; D'Addio, F; Desenzani, P; Fiorina, P; Folli, F; Franzetti, I; Gandolfi, A; Gazzaruso, C; Genovese, S; Ghelardi, R; Girelli, A; Lazzaroni, E; Loretelli, C; Lunati, ME; Manfrini, R; Montefusco, L; Morpurgo, PS; Muratori, F; Muratori, M; Nasr, MB; Orsi, E; Pastore, I; Plebani, L; Rossi, A; Scaranna, C; Tinari, C; Vallone, L | 1 |
| Huang, K; Liu, J; Sun, S; Wang, Y; Xie, X; Zhou, W; Zhu, D; Zhu, Q | 1 |
| Matsumoto, K; Tsuboi, N; Ueda, H; Yokoo, T | 1 |
| Gu, N; Liang, B | 2 |
| Barreto, J; Bonilha, I; Breder, I; Breder, J; Coelho, OR; Coelho-Filho, OR; de Carvalho, LSF; do Carmo, HR; Kimura-Medorima, ST; Lima, M; Luchiari, B; Matos-Souza, JR; Moura, FA; Munhoz, D; Nadruz, W; Oliveira, A; Oliveira, D; Quinaglia, T; Sposito, AC; Wolf, V | 1 |
| Abdallah, DM; Ahmed, KA; El-Abhar, HS; Fleifel, AM; Soubh, AA | 1 |
| Alam, MJ; Arava, S; Banerjee, SK; Bugga, P; Katare, P; Maulik, SK; Meghwani, H; Mohammed, SA | 1 |
| Biegus, J; Ponikowski, P | 1 |
| Aksu, E; Aykan, AÇ; Balcıoğlu, AS; Çelik, E; Göçer, K; Şahin, M | 1 |
| Dixen, U; Fenger, M; Goetze, JP; Holst, JJ; Jørgensen, NB; Madsbad, S; Madsen, PL; Richter, EA; Thirumathyam, R; Van Hall, G; Vejlstrup, N | 1 |
| Nakajima, T; Node, K; Oyama, JI; Shimizu, T; Shiraki, A; Yokota, T | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Heerspink, HJL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Schechter, M; Wilding, JPH; Wiviott, SD; Yanuv, I; Zelniker, TA | 1 |
| Al Habeeb, W; Alcocer-Gamba, MA; Bachus, E; Belohlavek, J; Borleffs, CJW; Cabrera Honorio, JW; Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Dobreanu, D; Drozdz, J; Fang, JC; Han, Y; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Merkely, B; O'Meara, E; Petersson, M; Pham, VN; Saraiva, JFK; Shah, SJ; Solomon, SD; Tereshchenko, SN; Thierer, J; Vaduganathan, M; Vardeny, O; Verma, S; Wilderäng, U; Zaozerska, N | 1 |
| Bengtsson, O; Butt, JH; Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Docherty, KF; Gasparyan, SB; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kondo, T; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Petersson, M; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M | 1 |
| Fan, M; Jiang, R; Jin, W; Jing, C; Piao, C; Sun, L; Zhang, Q; Zhang, Y | 1 |
| Ahn, SH; Cho, Y; Choi, YJ; Hong, S; Kim, SH; Lee, E; Lee, YH; Seo, DH; Seo, S; Suh, YJ | 1 |
| Chen, C; Chen, X; Cui, L; Huang, L; Xiao, Z; Xiong, X | 1 |
| Capece, U; Cinti, F; Cocchi, C; Crea, F; D'Amario, D; Ferraro, PM; Giaccari, A; Giordano, A; Gugliandolo, S; Guzzardi, MA; Indovina, L; Iozzo, P; Leccisotti, L; Lorusso, M; Mezza, T; Sorice, GP | 1 |
| Abidi, H; Ahmed, M; Khan, A; Khan, IA | 1 |
| Slomski, A | 2 |
| Baldi, S; Dardano, A; Di Bello, V; Fabiani, I; Natali, A; Nesti, L; Pinnola, S; Pugliese, NR; Sciuto, P; Trico, D | 1 |
| Chen, K; Liu, J; Qin, S; Qin, Y; Wang, C; Wu, X; Xiao, W; Yang, Y; Zhang, X | 1 |
| Abdelmalak, NS; Hammad, RW; Latif, R; Sanad, RA | 1 |
| Ma, F; Wang, H; Wu, Y; Zhang, J | 1 |
| Giri, S; Guha, A; Lanfear, DE; Ortiz, PA; Palaniyandi, SS; Pan, G; Roy, B; Thandavarayan, RA | 1 |
| Doumas, M; Karagiannis, A; Katsimardou, A; Papadopoulos, C; Patoulias, D; Zografou, I | 1 |
| Calabria, S; Cricelli, C; Dondi, L; Lapi, F; Maggioni, AP; Marconi, E; Martini, N; Medea, G; Parretti, D; Pedrini, A; Piccinni, C; Ronconi, G | 1 |
| Deng, L; Xu, G; Yang, Y | 1 |
| Connelly, KA; Deva, DP; Jimenez-Juan, L; Mazer, CD; Moses, S; Quan, A; Teoh, H; Verma, S; Yan, AT | 1 |
| Prázný, M | 1 |
| Aleksandric, M; Fülöp, T; Gumprecht, J; Kamenov, Z; Medvedchikov, A; Prázný, M; Rosenzweig, D; Suplotova, L | 1 |
| Bai, Z; Chen, L; Chen, Z; Liu, T; Luo, J; Xiao, Y; Xie, T; Yu, L; Zhang, C; Zhao, X | 1 |
| Lee, CC; Liu, JJ; Liu, SC; Sun, FJ; Zeng, YH | 1 |
| Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU | 1 |
| Cui, Y; Dong, Z; Fu, Y; He, X; Li, Y; Ma, Y; Xun, X | 1 |
| Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE | 1 |
| Davidson, JA; Hew, FL; Hussein, Z; Mohamed, M; Sukor, N | 1 |
| Ageev, FT; Ametov, AS; Antsiferov, MB; Arutyunov, GP; Cherkashin, DV; Fomin, IV; Galstyan, GR; Galyavich, AS; Gilyarevskiy, SR; Glezer, MG; Ilyin, MV; Khalimov, IS; Khasanov, NR; Lebedeva, AI; Lopatin, YM; Nedogoda, SM; Salukhov, VV; Tarlovskaya, EI; Tereshchenko, SN; Villevalde, SV; Vinogradova, NG; Yakushin, SS; Zhirov, IV | 1 |
| Bergenheim, K; Briggs, A; Darlington, O; Garcia Sanchez, JJ; Heerspink, HJL; McEwan, P; McMurray, JJV; Miller, R; Wheeler, DC | 1 |
| Khine, A; Lin, E | 1 |
| Catharina de Beer, J; Ker, J; Miller-Janson, H; Snyman, J; Stander, M | 1 |
| Bright-Davies, C; Noble-Bell, G | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Dhingra, NK; Filippatos, G; Januzzi, JL; Lam, CSP; Nordaby, M; Packer, M; Pedro Ferreira, J; Pfarr, E; Pocock, SJ; Sattar, N; Verma, S; Zannad, F | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Rossing, P; Sjöström, CD; Wheeler, DC | 1 |
| Güzel, T; İnci, Ü | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Goodrich, EL; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Pollack, R; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Ahmed, SA; Barge, SR; Bharadwaj, S; Borah, JC; Gurumayum, S; Saikia, K; Sheikh, Y; Swargiary, D; Thakur, D | 1 |
| Auguste, BL; Poon, S; Yau, K | 1 |
| Advani, A; Cherney, DZI; Dubrofsky, L; Kugathasan, L | 1 |
| Atlım, HT; Aydemir, M; Doğruel, H; Sarı, R; Yılmaz, N | 1 |
| Bayes-Genis, A; Núñez, J | 1 |
| Beernink, JM; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Laverman, GD; McMurray, JJV; Persson, F; Rossing, P; Sjöström, CD; Toto, RD; Wheeler, DC | 1 |
| Al-Mubarak, AA; Bomer, N; Damman, K; Heerspink, HJL; Schomburg, L; van der Meer, P; van Veldhuisen, DJ; Voors, AA; Weening, EH | 1 |
| Bég, SA; Dar, MS; Kaspers, S; Marx, N; Mattheus, M; Ofstad, AP; Wanner, C | 1 |
| Iijima, Y; Ito, R; Manda, N; Miwa, T; Nakayama, M; Odawara, M; Shikuma, J; Tanaka, A; Tomiyama, H; Yakou, F | 1 |
| Dokuzova, S; Krstevska, B; Nakov, Z; Nakova, VV; Prosheva, T | 1 |
| Gustafson, KM; Kellon, EM | 1 |
| Cauchon, M; Lanthier, L; Plourde, ME; Viau-Trudel, A | 1 |
| Al Thani, NA; Hasan, M; Yalcin, HC | 1 |
| Altiok, E; Böhm, M; Grebe, J; Keszei, AP; Korbinian Hartmann, NU; Lehrke, M; Marx, N; Rau, M; Thiele, K | 1 |
| Higashi, Y; Hirai, H; Hisauchi, I; Inagaki, S; Kamei, N; Kono, T; Kurozumi, A; Maruhashi, T; Node, K; Okada, Y; Oshita, C; Shimabukuro, M; Sonoda, S; Sugimoto, K; Taguchi, I; Takahashi, K; Tanaka, A; Teragawa, H; Torimoto, K | 1 |
| Dionisi-Vici, C; Maiorana, A; Tagliaferri, F | 1 |
| Desai, RJ; Everett, BM; Fu, EL; Levin, R; Patorno, E; Schneeweiss, S; Solomon, SD; Vaduganathan, M | 1 |
| Atanasov, AG; Bartel, I; Horbańczuk, JO; Jóźwik, A; Koszarska, M; Strzałkowska, N; Tzvetkov, NT; Wang, D; Wierzbicka, A | 1 |
| Alduraibi, RK; Alrebdi, YM; Altowayan, YF | 1 |
| Harris, E | 1 |
| Chertow, GM; Heerspink, HJL; Schechter, M | 1 |
| Patoulias, D | 1 |
| Agarwal, N; Khan, P; Parveen, R; Pathak, M; Saha, N | 1 |
| Choi, YJ; Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lim, J; Na, JO; Park, JB; Rhee, TM | 1 |
| Lam-Chung, CE | 1 |
| Rawat, R; Varshney, A | 1 |
| Cui, C; Guo, X; Liu, J; Qiao, Q; Shi, M; Wang, J; Wang, Q; Wang, W; Wang, Y; Xu, J; Zhang, C; Zhang, H; Zhang, X | 1 |
| Ohshiro, Y | 1 |
| Gunji, R; Kakiuchi, S; Kaku, K; Kurihara, Y; Naito, Y; Senda, M; Utsunomiya, K | 1 |
| Boulton, DW; Cain, V; Dekkers, CCJ; Greasley, PJ; Heerspink, HJL; Sjöström, CD | 1 |
| Candido, R; Cucinotta, D; Graziano, G; Manicardi, V; Nicolucci, A; Rocca, A; Rossi, MC; Tuccinardi, F | 1 |
| Avogaro, A; Bonora, BM; Fadini, GP; Vigili de Kreutzenberg, S | 1 |
| Chen, M; Chen, W; Chen, Y; Li, P; Wang, B; Wang, G | 1 |
| Dykhoff, HJ; Karaca-Mandic, P; McCoy, RG; Montori, VM; Ross, JS; Sangaralingham, L; Shah, ND | 1 |
| Cayón Blanco, M; Gómez-Fernández, P; Hidalgo Santiago, JC; López Saez, JB; Maraver Delgado, J | 1 |
| Bundgaard Anker, CC; Jeppesen, PB; Rafiq, S | 1 |
| Buch, A; Dunsky, A; Eldor, R; Keinan-Boker, L; Kis, O; Lopez, A; Marcus, Y; Osher, E; Rubin, A; Sofer, Y; Stern, N | 1 |
| Ishida, K; Kaspers, S; Kohler, S; Koiwai, K; Lund, SS; Nishimura, R; Salsali, A; Tanaka, Y | 1 |
| Handelsman, Y | 2 |
| Al-Huniti, N; Dunyak, J; Higashimori, M; Ichikawa, K; Nagase, M; Ueda, S | 1 |
| Aoki, K; Azushima, K; Hanaoka, M; Haruhara, K; Hosokawa, S; Inazumi, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, R; Kobayashi, Y; Kondo, Y; Misumi, T; Ohki, K; Ono, S; Orime, K; Osada, U; Sasaki, H; Shibasaki-Kurita, T; Tamura, K; Terauchi, Y; Wakui, H; Yamada, T; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Baldi, S; DeFronzo, RA; Ferrannini, E; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Abraitienė, A; Ametov, AS; Gaàl, Z; Gumprecht, J; Janež, A; Karasik, A; Kaser, S; Lalić, K; Mankovsky, BN; Moshkovich, E; Past, M; Prázný, M; Radulian, G; Schernthaner, G; Smirčić Duvnjak, L; Tkáč, I; Trušinskis, K | 1 |
| Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD | 1 |
| Al-Omran, M; Bhatt, DL; Connelly, KA; Dhingra, N; Hess, DA; Leiter, LA; Mason, T; Mazer, CD; Quan, A; Rotstein, OD; Sabongui, S; Teoh, H; Terenzi, DC; Trac, JZ; Verma, S; Yan, AT; Zinman, B | 1 |
| Iizuka, K; Kato, T; Liu, Y; Mizuno, M; Nonomura, K; Takao, K; Yabe, D; Yasuda, M | 1 |
| Chan, YY; Chang, KC; Chien, RN; Hung, MJ; Kao Yang, YH; Lai, EC; Lin, SJ; Shao, SC | 1 |
| Cooper, ME; Koitka-Weber, A; Perkovic, V; Pfarr, E; Schernthaner, G; von Eynatten, M; Wanner, C; Woerle, HJ | 1 |
| Bae, JC; Hwang, YC; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Lee, EY; Lee, S; Suh, S; Won, JC | 1 |
| Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Mattheus, M; Vedin, O; Wanner, C; Zinman, B | 1 |
| Avogaro, A; Cazzetta, G; Devangelio, E; Fadini, GP; Felace, G; Li Volsi, P; Poli, M | 1 |
| Austin, B; Drazner, MH; Fong, MW; Givertz, MM; Gordon, RA; Husain, M; Inzucchi, SE; Jermyn, R; Katz, SD; Khariton, Y; Kosiborod, M; Lamba, S; Lanfear, DE; LaRue, SJ; Lindenfeld, J; Malone, M; Margulies, K; McGuire, DK; Mentz, RJ; Mutharasan, RK; Nassif, ME; Pitt, B; Pursley, M; Scirica, BM; Tang, F; Umpierrez, G; Windsor, SL | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Cowen, J; Leader, R; Rajeev, SP | 1 |
| Fagbote, C; Genovese, N; Hawley, CE; Li, J; Paik, JM; Triantafylidis, LK | 1 |
| Chan, YY; Chang, KC; Chen, HY; Hung, MJ; Kao Yang, YH; Lai, EC; Shao, SC; Yang, NI | 1 |
| Ishihara, H; Kosakai, Y; Sugitani, T; Yamaguchi, S | 1 |
| Goto, R; Kamimura, K; Kimura, A; Ko, M; Nagoya, T; Nishina, H; Niwa, Y; Sakai, N; Shinagawa-Kobayashi, Y; Terai, S | 1 |
| Chin, R; Haneda, M; Hayashi, N; Hirase, T; Kaku, K; Kansal, A; Kaspers, S; Murata, T; Okamura, T; Sakamaki, H; Shibahara, T; Ustyugova, A; Yasui, A | 1 |
| Chen, X; Ouyang, J; Wang, H; Yang, J; Yao, G | 1 |
| Bergenstal, RM; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Kaspers, S; Kiš, SG; Monteiro, P; Toural, E; Zinman, B | 1 |
| Packer, M | 2 |
| Chilton, R; Sheikh, O; Solis-Herrera, C | 1 |
| Moist, L | 2 |
| Gorgojo-Martínez, JJ; Hallén, N; Hunt, B; Malkin, SJP; Martín, V | 1 |
| Ahmad, K; Haider, K; Haider, MR; Pathak, A; Rohilla, A; Yar, MS | 1 |
| Hashimoto, N; Kawai, H; Ohara, T; Onishi, T; Sawada, T; Shimane, A; Takaya, T; Taniguchi, Y; Uzu, K; Yasaka, Y | 1 |
| Ibuka, T; Kato, J; Kubota, M; Mizutani, T; Ohnishi, M; Sakai, H; Shimizu, M; Shirakami, Y; Tanaka, T | 1 |
| Ali, SN; Dang-Tan, T; Ericsson, Å; Hansen, BB; Hunt, B; Kallenbach, K; Malkin, SJP; Valentine, WJ | 1 |
| Hsu, JC; Lin, LY; Su, MM; Wang, CY; Yang, WS | 1 |
| Kato, ET; Sabatine, MS; Wiviott, SD | 1 |
| Elghazaly, H; Hajiev, S; Singh, P | 1 |
| Bai, XY; Sun, Q; Tang, Y; Zhang, M; Zhou, QL; Zhou, YF | 1 |
| Ferrannini, E; Gastaldelli, A; Guja, C; Han, J; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Kaneko, T; Lee, J; Pfarr, E; Shiki, K; Sone, H; Tachibana, Y; Tajima, N | 1 |
| Bhatt, DL; Braunwald, E; Verma, S | 1 |
| Asrih, M; Gariani, K | 1 |
| Connelly, KA; Connelly, PW; Gilbert, RE; Goldenberg, RM; Hare, GMT; Jüni, P; Leiter, LA; Mazer, CD; Mistry, N; Quan, A; Shehata, N; Teoh, H; Thorpe, KE; Verma, S; Yan, AT; Zinman, B; Zuo, F | 1 |
| Detsch, JM; Lacerda, CS; Marino, EC; Marques, K; Pechmann, LM; Polesel, MG; Sanches, CP; Scharf, M; Vianna, AGD | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Tanaka, M; Yamakage, H | 1 |
| Petrie, MC | 1 |
| Cain, V; Correa-Rotter, R; Heerspink, HJL; Sartipy, P; Scholtes, RA; Sjöström, CD; Stefánsson, BV; Toto, RD; van Raalte, DH | 1 |
| Araki, E; Asano, M; Fujii, H; Kim, H; Langkilde, AM; Ohashi, H; Okabe, T; Thoren, F; Tomonaga, O; Uchigata, Y; Watada, H; Yajima, T | 1 |
| Cho, H; Park, JH; Seo, I; Shim, HM | 1 |
| DeVore, AD; Ezekowitz, JA; Felker, GM; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Mahaffey, KW; Sharma, A; Udell, JA; Wu, J | 1 |
| Cahn, A; Cernea, S; Raz, I | 1 |
| Abd El-Twab, SM; Abdel-Moneim, A; El-Shahawy, A; Elden, ZE; Taha, M; Yousef, AI | 1 |
| Chin, R; Ikeda, R; Iliev, H; Kaku, K; Naito, Y; Ochiai, K; Yasui, A | 1 |
| Gong, M; Lee, S; Li, G; Liu, T; Meng, L; Shao, Q; Tse, G; Zhang, Z; Zhao, J; Zhao, Y | 1 |
| Brandt, NH; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, S; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wiberg, M; Wolsk, E; Zerahn, B | 1 |
| Arcidiacono, B; Brunetti, A; Brunetti, FS; Caroleo, P; Chiefari, E; Corigliano, DM; Foti, DP; Mirabelli, M; Puccio, L; Vero, R | 1 |
| Tahara, A; Takasu, T | 3 |
| Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Janista, C; Jurišić-Eržen, D; Kaspers, S; Woo, V; Zinman, B | 1 |
| Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH | 1 |
| Canivell, S; Franch-Nadal, J; Gratacòs, M; Mata-Cases, M; Mauricio, D; Real, J; Vlacho, B | 1 |
| Dumann, E; Haller, H; Menne, J; Schmidt, BMW | 1 |
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
| Ambrosio, G; Anker, S; Bauersachs, J; Chioncel, O; Coats, AJS; Cosentino, F; De Boer, RA; Filippatos, G; Hill, L; Huelsmann, M; Jhund, PS; Komajda, M; Lopatin, Y; Lund, LH; Lyon, A; Metra, M; Mullens, W; Petrie, MC; Piepoli, M; Polovina, MM; Ponikowski, P; Rosano, GMC; Sari, I; Seferović, J; Seferović, PM; Thum, T; Volterrani, M | 1 |
| Davids, M; Herrema, H; Kramer, MHH; Nieuwdorp, M; van Bommel, EJM; van Raalte, DH | 1 |
| Harrison, SL; Lane, DA; Lip, GYH | 1 |
| Anker, SD; Böhm, M; Brueckmann, M; Fitchett, D; George, JT; Inzucchi, SE; Marx, N; Mattheus, M; Ofstad, AP; Slawik, J; Verma, S; Wanner, C; Zinman, B | 1 |
| Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Coates, PT; Salehi, T | 1 |
| Aguiar, C; Birne, R; Branco, P; Calado, J; Matos, P; Melo, M; Monteiro, P; Polónia, J; Silva-Nunes, J | 1 |
| Docherty, KF; Jhund, PS; McMurray, JJV; Solomon, SD | 1 |
| Cherney, DZI; Hantel, S; Inzucchi, SE; Koitka-Weber, A; Mayer, GJ; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B | 2 |
| Beltrán-Romero, LM; León-Jiménez, D; Miramontes-González, JP; Moreno-Obregón, F | 1 |
| Bjornstad, P; Nelson, RG; Pavkov, ME | 1 |
| Ablasser, K; Alber, H; Berger, R; Kaulfersch, C; Kolesnik, E; Leitner, K; Lichtenauer, M; Mader, A; Moertl, D; Oulhaj, A; Pferschy, PN; Reiter, C; Rieder, T; Saely, CH; Sailer, S; Siller-Matula, J; Sourij, H; Tripolt, NJ; Verheyen, N; von Lewinski, D; Weidinger, F; Zechner, PM | 1 |
| de Boer, RA; Rienstra, M; Silljé, HHW; Westenbrink, BD; Yurista, SR | 1 |
| Fuchigami, A; Higa, M; Hirose, T; Hiyoshi, T; Ichijo, T; Inoue, I; Iso, K; Kitazawa, T; Kumashiro, N; Okada, Y; Shigiyama, F; Yoshii, H | 1 |
| Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H | 2 |
| Al-Bazz, DY; Wilding, JP | 1 |
| Cauchon, M; Dussault, C; Huard, G; Lanthier, L; Plourde, MÉ | 1 |
| Del Parigi, A; Lee, C; Liu, D; Pratley, R; Tang, W | 1 |
| Baer, PC; Freitag, J; Geiger, H; Koch, B; Schubert, R | 1 |
| Foresto, RD; Gonzalez, DE; Ribeiro, AB | 1 |
| Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y | 1 |
| Chen, C; Chen, Y; Cowley, MA; Huang, L; Huang, Z; Qi, X; Veldhuis, JD; Wang, C; Zhang, Y; Zhu, S | 1 |
| Nakajima, Y; Okada, J; Okada, S; Osaki, A; Ozawa, A; Pessin, JE; Saito, T; Shimoda, Y; Yamada, E; Yamada, M; Yokoo, H | 1 |
| Al-Omran, M; Bhatt, DL; Chowdhury, B; Connelly, KA; Hess, DA; Kabir, MG; Luu, AZ; Luu, VZ; Mazer, CD; Pan, Y; Quan, A; Sabongui, S; Teoh, H; Verma, S | 1 |
| Heerspink, HJL; Koomen, JV; Kroonen, MYAM; Laverman, GD; Petrykiv, SI; Stevens, J | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Masuda, D; Yamashita, S | 1 |
| Chang, YP; Chen, LM; Cheng, Y; Han, F; Han, Z; Li, CJ; Li, T; Li, XY; Lu, YH; Meng, ZY; Sun, B; Xue, M | 1 |
| Ferrannini, E; Katsiki, N; Mazidi, M; Ofori-Asenso, R | 1 |
| Hirota, Y; Komada, H; Miura, H; Morita, Y; Nakamura, T; Ogawa, W; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Tamori, Y; Yamada, T | 1 |
| Ackermans, MT; Bouter, KEC; Dallinga-Thie, GM; Jansen, H; Nieuwdorp, M; Schierbeek, H; Schimmel, AWM; Serlie, MJ; van Bommel, EJM; van Harskamp, D; van Raalte, DH | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; McMurray, J; Rossing, P; Stefansson, BV; Toto, R; Wheeler, DC | 1 |
| Knudsen, JS; Munk, NE; Pottegård, A; Thomsen, RW; Witte, DR | 1 |
| Fujii, S; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Koshida, R; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Chan, YY; Chang, KC; Hung, MJ; Kao Yang, YH; Lai, EC; Lin, YH; Shao, SC | 1 |
| Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Ghanim, H; Green, K; Hejna, J; Makdissi, A | 2 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C | 1 |
| Boulton, DW; Chu, L; Greasley, PJ; Helmlinger, G; Johansson, S; Penland, RC; Peskov, K; Sokolov, V; Tang, W; Yakovleva, T | 1 |
| de Boer, RA; Keefe, D; Kozlovski, P; Núñez, J; Proot, P; Wang, Y | 1 |
| Dronamraju, N; Garcia-Sanchez, R; Hockings, PD; Johansson, L; Johnsson, E; Maaske, J; Wilding, JPH | 1 |
| Bajaj, HS; Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Miyauchi, T | 1 |
| Adam, M; Connelly, K; Meagher, P | 1 |
| Aizawa, Y; Fujita, S; Ikeda, Y; Okabe, M; Sato, T; Yuasa, S | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Shimatsu, A; Tanaka, M; Yamakage, H | 1 |
| Broedl Md, UC; Coleman, RL; Fitchett, D; George, JT; Gray, AM; Holman, RR; Woerle, HJ; Zinman, B | 1 |
| Eriksson, JW; Greasley, PJ; Hammarstedt, A; Hedberg, J; Heerspink, HJL; Ju, W; Mulder, S; Nagaraj, SB; Nair, V; Oscarsson, J | 1 |
| Tsuda, K | 1 |
| Amemiya, H; Asakura, T; Iemitsu, K; Ishikawa, M; Ito, S; Kanamori, A; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Matsuba, I; Matsuzawa, Y; Minagawa, F; Minami, N; Miyakawa, M; Mokubo, A; Shinoda, K; Takai, M; Takeda, H; Takihata, M; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y | 1 |
| Alper, E; Deyneli, O; Esin, A; Meriçöz, Ç; Sezer, H; Yazıcı, D | 1 |
| Alva, H; Aravind, SR; Asirvatham, A; Balamurugan, R; Barkate, H; Chawla, M; Dharmalingam, M; Gaikwad, R; Goyal, R; Kadam, P; Katare, S; Kodgule, R; Mohan, B; Paramesh, S; Pendse, A; Shembalkar, J; Suryawanshi, S; Tandon, M; Thacker, H; Vaidyanathan, S | 1 |
| Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Jsg-Nafld, JSGON; Kamada, Y; Kawaguchi, T; Kawanaka, M; Koseki, M; Nakajima, A; Nozaki, Y; Okanoue, T; Ono, M; Sumida, Y; Takahashi, H; Tokushige, K; Yoneda, M; Yoshida, Y | 1 |
| Bami, K; Connelly, KA; Gandhi, S; Garg, V; Gilbert, RE; Ho, E; Jüni, P; Leiter, LA; Leong-Poi, H; Mazer, CD; Ong, G; Quan, A; Teoh, H; Thorpe, KE; Verma, S; Yan, AT; Zahrani, M; Zinman, B; Zuo, F | 1 |
| Fernandez-Fernandez, B; Ortiz, A; Porrini, E; Soler, MJ | 1 |
| van Bommel, EJM; van Raalte, DH | 1 |
| Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B; Zwiener, I | 1 |
| Bhatt, DL; Bonaca, M; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Hadjadj, S; Jermendy, G; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Cui, L; Hao, Z; Li, G; Sun, Y; Yan, D | 1 |
| Choy, AMJ; Donnan, PT; Fathi, A; Gandy, S; George, J; Houston, JG; Khan, F; Lang, CC; Mohan, M; Mordi, IR; Pearson, ER; Singh, JSS; Struthers, AD; Vickneson, K | 1 |
| Chen, S; Jiang, B; Le, L; Lv, Q; Xiang, J; Xiao, P | 1 |
| Alves-Martinez, P; Carranza-Naval, MJ; Del Marco, A; Garcia-Alloza, M; Herrera, M; Hierro-Bujalance, C; Infante-Garcia, C; Lubian-Lopez, S; Suarez, J | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ishiyama, M; Ito, M; Moriwaki, K; Omori, T; Takeuchi, T | 1 |
| Kondo, Y; Konishi, H; Kyohara, M; Nakaguchi, H; Oiwa, K; Terauchi, Y | 1 |
| Altay, H; Cahn, A; Çavuşoğlu, Y; Celik, A; Demir, S; Kılıçaslan, B; Nalbantgil, S; Raz, I; Temizhan, A; Yıldırımtürk, Ö; Yılmaz, MB | 1 |
| Granger, CB; Mahaffey, KW | 1 |
| Chopey, IV; Debreceni, KO; Feysa, SV; Griadil, TI; Hechko, MM; Mykhalko, YO | 1 |
| Fadini, GP | 1 |
| Hess, DA; Terenzi, DC; Verma, S | 1 |
| Heerspink, HJL; Koomen, JV; Stevens, J | 1 |
| Ai, M; Anai, M; Fujishiro, M; Inazawa, T; Inoue, M; Ishihara, H; Kitazawa, T; Kuroda, H; Ohashi, H; Seino, H; Yamada, M | 1 |
| Moorthy, M; Palanisamy, UD; Perera, A; Ton, SH | 1 |
| Ghosal, S; Sinha, B | 1 |
| Andreadou, I; Balampanis, K; Bamias, A; Birba, D; Dimitriadis, G; Ikonomidis, I; Iliodromitis, E; Kalogeris, A; Katogiannis, K; Kountouri, A; Kousathana, F; Lambadiari, V; Parissis, J; Pavlidis, G; Thymis, J | 1 |
| Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Yang, HC; Ye, Y | 1 |
| Bgatova, NP; Dashkin, MV; Khotskina, AS; Klein, T; Klimontov, VV; Konenkov, VI; Korbut, AI; Muraleva, NA; Orlov, NB; Taskaeva, IS; Zavyalov, EL | 1 |
| Diaz, LJ; Eickhoff, MK; Faber, J; Frimodt-Møller, M; Jensen, MT; Olsen, FJ; Persson, F; Rossing, P | 1 |
| Arıkan, AA; Baycelebi, G; Gokosmanoglu, F; Onmez, A | 1 |
| Fonseca, VA; Shao, H; Shi, L | 1 |
| Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P; Wintzell, V | 1 |
| Gra-Menendez, S; Iacobellis, G | 1 |
| Adamski, J; Artati, A; Boor, P; Droste, P; Haj-Yehia, E; Kappel, B; Klinkhammer, BM; Lehrke, M; Lopaschuk, GD; Marx, N; Maxeiner, S; Moellmann, J; Schütt, K; Verma, S | 1 |
| Gabay, L; Nakhleh, A; Shehadeh, N; Zloczower, M | 1 |
| Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A | 1 |
| Beetz, N; Bertulis, J; Lang, B; Lee, J; Lingvay, I; Lippert, C; Loley, C; Manning, LS; Schuler-Metz, A; Sennewald, R; Terada, D | 1 |
| Ferreira, JP; Fitchett, D; George, JT; Kraus, BJ; Lauer, S; Ofstad, AP; Rossignol, P; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| Clark, D; Iliev, H; Kaspers, S; Kinduryte Schorling, O; Lee, J; Zwiener, I | 1 |
| Hashikata, T; Ikutomi, M; Jimba, T; Kakuda, N; Katsushika, S; Kishi, M; Matsushita, M; Ohnishi, S; Sato, T; Shindo, A; Yamasaki, M; Yokoyama, M | 1 |
| Aronson, R; Gerstein, HC; Hall, S; Harris, S; Hramiak, I; Liu, YY; McInnes, N; Sigal, RJ; Sultan, F; Woo, V | 1 |
| Ahmad, T; Bellumkonda, L; Butler, J; Collins, S; Cox, Z; Fleming, J; Griffin, M; Inzucchi, SE; Ivey-Miranda, J; Jacoby, D; Jeon, S; Mahoney, D; Maulion, C; Rao, VS; Riello, R; Siwakoti, K; Suda, N; Testani, JM; Turner, JM; Wilson, FP | 1 |
| Avogaro, A; Consoli, A; Fadini, GP; Morieri, ML; Purrello, F; Sesti, G | 1 |
| Ding, LL; Gu, JS; Li, KK; Li, LL; Liu, SY; Qiu, M | 1 |
| Ahn, DJ; Lee, IH | 1 |
| Aroda, VR; Brady, EM; Davies, MJ; Gregg, EW; Khunti, K; Sargeant, JA; Tippins, F; Webb, DR; Zaccardi, F | 1 |
| Fitchett, DH; George, JT; Inzucchi, SE; Khunti, K; Mattheus, M; Ofstad, AP; Wanner, C; Zinman, B | 1 |
| Gastelum, AA; Latif, A; Reddy, JT; Sood, A | 1 |
| Mareev, VY; Tsygankova, OV; Veretyuk, VV | 1 |
| Heerspink, HJL; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Ruiter, D; Smits, MM; Touw, DJ; van Bommel, EJM; van Raalte, DH | 1 |
| Armstrong, GP | 1 |
| El-Domiaty, H; El-Nabi, SH; Fayez Ewida, S; Hanna, G; Saleh, S; Shabaan, A | 1 |
| Higashi, Y; Hisauchi, I; Machii, N; Matsuzawa, Y; Node, K; Okada, Y; Shima, KR; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamaoka-Tojo, M | 1 |
| Almdal, TP; Bagge Hansen, K; Holm Schultz, H; Klarskov, CK; Lommer Kristensen, P; Møller Christensen, T; Pedersen-Bjergaard, U; Persson, F; Snorgaard, O | 1 |
| Bobade, PS; Dhote, AM; Ganorkar, SB; Patil, MR; Sharma, SS; Shirkhedkar, AA | 1 |
| Heilmann, C; Taniguchi, A; Watada, H; Yamamoto, F; Yamauchi, T; Yarush, L; Yasui, A | 1 |
| Ayers, CR; de Albuquerque Rocha, N; Hughes, C; Jin, ES; Malloy, CR; Neeland, IJ | 1 |
| Kim, HJ; Kim, JJ; Seong, JM; Sohn, HS | 1 |
| Brown, AJM; Gandy, S; Houston, JG; Lang, CC; McCrimmon, R; Struthers, AD | 1 |
| Rasouli, N | 1 |
| Fujii, S; Gunji, R; Kakiuchi, S; Kaku, K; Koshida, R; Kurihara, Y; Senda, M; Utsunomiya, K | 1 |
| Choi, YH; Jeong, IK; Kwon, HS; Lee, BW; Lee, SH; Min, KW; Yoo, SJ; Yoon, KH | 1 |
| Hara, K; Hatano, M; Hayashino, Y; Iida, S; Ikegami, Y; Isshiki, M; Ito, D; Kitazato, H; Noda, M; Saito, D; Sakuma, I; Satoh-Asahara, N; Shimada, A; Shiojima, I; Sumita, T; Takahashi, K | 1 |
| Aravind, SR; Chowdhury, S; Joshi, SR; Mithal, A; Mohan, V | 1 |
| Chin, HJ; Ferrannini, E; Lim, S; Moon, JH; Shin, Y | 1 |
| Anker, SD; Böhm, M; Brueckmann, M; Fitchett, D; George, JT; Kaspers, S; Mahfoud, F; Mancia, G; Marx, N; Ofstad, AP; Wanner, C; Zinman, B; Zwiener, I | 1 |
| Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K | 2 |
| Patel, AB; Verma, A; Waikar, SS | 1 |
| Chappard, D; Gault, VA; Mabilleau, G; Mieczkowska, A; Millar, P | 1 |
| Hayashi, I; Kaneto, H; Katakami, N; Kawashima, S; Kosugi, K; Kuribayashi, N; Maeda, K; Mita, T; Nakamura, T; Ohtoshi, K; Okada, Y; Osonoi, T; Ryomoto, K; Sato, Y; Shimomura, I; Shiraiwa, T; Sumitani, S; Taki, H; Torimoto, K; Tsugawa, M; Umayahara, Y; Watada, H; Yamamoto, T; Yasuda, T; Yokoyama, H; Yoshii, H | 2 |
| Bantis, K; Daikidou, D; Dimitriadis, C; Kasimatis, E; Papagianni, A; Papanikolaou, A; Sampani, E; Sarafidis, P | 1 |
| Akamizu, T; Ariyasu, H; Furukawa, Y; Furuta, H; Inaba, H; Iwakura, H; Kishimoto, S; Kitahara, C; Matsuno, S; Morita, S; Nishi, M; Takeshima, K; Uraki, S | 1 |
| Jackson, K; Moseley, KF | 1 |
| Cui, X; Feng, J; Gu, L; Hong, T; Lang, S; Le, Y; Liu, J; Wang, H; Wei, R; Wei, T; Yang, J; Yang, K | 1 |
| Nekeman, S; Uyl-de Groot, CA; Van der Linden, N; Van Olst, S | 1 |
| Raj, GM; Wyawahare, M | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Heerspink, HL; Helmlinger, G; Nieves, EH; Penland, RC; van Raalte, DH | 1 |
| Deng, X; Hu, S; Li, Z; Ma, Y; Wang, Y | 1 |
| Li, M; Song, J; Ying, M; Zhuang, Y | 1 |
| Blonde, L; Lavernia, F | 1 |
| Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD | 1 |
| Alenina, N; Bader, M; Crespo-Garcia, S; Dechend, R; Ebrahim, M; Golic, M; Grune, J; Haase, N; Herse, F; Heuser, A; Kintscher, U; Kräker, K; Luft, FC; Müller, DN; Reichhart, N; Strauß, O | 1 |
| Feng, X; Gao, G; Gu, Q; Li, Q; Yuan, L; Zhang, Y | 1 |
| Capehorn, MS; Catarig, AM; Johansen, P; Lawson, J; Lingvay, I; Paine, A; Sandberg, A; Shaw, R | 1 |
| Chuang, SM; Lee, CC; Liu, SC; Sun, FJ; Zeng, YH | 1 |
| Isaka, H; Kaibara, A; Saito, M; Sakatani, T; Toyoshima, J | 1 |
| Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Kooy, A; Langkilde, AM; Leiter, LA; Litwak, L; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Ahmed, MA; Chen, H; Liu, D; Song, F; Wu, H | 1 |
| Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Correa-Rotter, R; Douthat, W; Dwyer, JP; Escudero, E; Furuland, H; Górriz, JL; Greene, T; Haller, H; Heerspink, HJL; Hou, FF; Isidto, R; Kang, SW; Kashihara, N; Khullar, D; Langkilde, AM; Lindberg, M; Mark, PB; McMurray, JJV; Nowicki, M; Pecoits-Filho, R; Persson, F; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Umanath, K; Van Bui, P; Wheeler, DC; Wittmann, I | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J | 1 |
| Chen, P; Jiang, J; Lin, L | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Ofstad, AP; Packer, M; Pfarr, E; Pocock, SJ; Zannad, F | 1 |
| Aso, Y; Iijima, T; Jojima, T; Sakurai, S; Tomaru, T; Usui, I | 1 |
| Chen, F; Chen, ZQ; Li, L | 1 |
| Raz, I; Sabatine, MS; Wiviott, SD; Zelniker, TA | 1 |
| Brown, A; Gandy, S; Houston, JG; Lang, CC; McCrimmon, R; Mordi, IR; Ramkumar, PG; Struthers, AD | 1 |
| Asseburg, C; Brennan, A; Clarke, PM; Feenstra, T; Gray, A; Herman, WH; Isaman, DJ; Kuo, S; Lamotte, M; Leal, J; McEwan, P; Nilsson, A; Palmer, AJ; Patel, R; Pollard, D; Ramos, M; Sailer, F; Schramm, W; Shao, H; Shi, L; Si, L; Smolen, HJ; Tew, M; Willis, MS; Ye, W; Zhang, P | 1 |
| Cain, V; Correa-Rotter, R; Greasley, PJ; Heerspink, HJL; Sartipy, P; Sjöström, CD; Stefánsson, BV; Wheeler, DC | 1 |
| Anker, SD; Butler, J; Fonarow, GC; Handelsman, Y; Hernandez, AF; Khan, MS; Kosiborod, MN; McGuire, DK; McMurray, JJV; Rosenstock, J; Vaduganathan, M; Verma, S | 1 |
| Ai, S; Blažek, P; Brittenham, GM; Chen, D; Chen, YP; Cortez, LM; Daude, N; Deisenhofer, I; Dwivedi, G; Eskandari-Sedighi, G; Fegan, PG; Friedrich, L; Fu, B; Gotoh, M; Grebmer, C; Green, G; Habibi, A; Hadadi, M; Hattori, R; Hectors, SJ; Hegde, AR; Iwata, H; Jabłońska, J; Jafari, R; Kantenwein, V; Karami, S; Kato, M; Kawanishi, H; Kluska, M; Koehne de González, AK; Kolb, C; Kulkarni, VI; Lan, NSR; Lan, X; Lennerz, C; Li, C; Li, Q; Li, X; Li, Y; Lim, MA; Lin, CH; Lin, XJ; Liu, R; Manne, ASN; Murase, Y; Mutalik, S; O'Connor, M; Pranata, R; Prince, MR; Rankin, JM; Rao, RR; Raut, SY; Reents, T; Sassa, N; Schaarschmidt, C; Seko, S; Shi, W; Shmeit, K; Sim, V; Spincemaille, P; Sun, G; Sun, J; Tsuzuki, T; Varmira, K; von Olshausen, G; Walker, MJ; Wang, Y; Wang, Z; Waterhouse, GIN; Weigand, S; Westaway, D; Xu, XM; Yang, J; Yeap, BB; Yi, X; Zhang, J; Zhang, M; Zhang, Y; Zheng, J; Zhou, M | 1 |
| Bento-Oliveira, A; Blázquez-Sánchez, MT; Chen, B; Colabufo, NA; Cristóvão, JS; Dätwyler, P; de Almeida, RFM; de Matos, AM; Diniz, A; El Idrissi, IG; Ernst, B; Fernandez-Bolaños, JG; Garwood, C; Gomes, CM; Lopes, PEM; López, Ó; Machuqueiro, M; Marcelo, F; Ning, K; Nunes, R; Oliveira, MC; Rauter, AP; Souza, CS | 1 |
| Kosiborod, MN; McGuire, DK; Verma, S | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; Mann, JFE; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Ismail-Beigi, F; Khamseh, ME; Malek, M; Reza Babaei, M; Sohrabi, M; Taheri, H; Zamani, F | 1 |
| Asai, K; Hoshika, Y; Ishikawa, M; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Ogano, M; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K | 1 |
| Chudasama, D; Kovil, R; Padhye, D; Raj, V; Saboo, B; Shah, K; Shaikh, N | 1 |
| George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC | 1 |
| Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD | 1 |
| Eliasson, B; Inzucchi, SE; Johansen, OE; Kasai, T; Marx, N; Neeland, IJ; Wanner, C; Wojeck, BS; Yaggi, HK; Zinman, B; Zwiener, I | 1 |
| Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; van Hall, G; Vilsbøll, T | 1 |
| Cui, L; Hao, Z; Li, G; Liu, Y; Sun, Y; Wen, Y | 1 |
| Maegawa, H; Nakamura, I; Tobe, K; Uno, S | 3 |
| Sotirakos, S | 1 |
| Christaki, M; Despotis, G; Filippas-Ntekuan, S; Kalambokis, GN; Milionis, H; Tsiakas, I | 1 |
| Hui, Y; Xu, Y; Yang, C; Yin, D | 1 |
| Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K | 1 |
| Ceriello, A; George, J; Kaspers, S; Nicolucci, A; Ofstad, AP; Zwiener, I | 1 |
| Bengtsson, O; DeMets, DL; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Davies, MJ; George, JT; Inzucchi, SE; Johansen, OE; Khunti, K; Sattar, N; Trivedi, P; Zwiener, I | 1 |
| Mori-Anai, K; Nakada, T; Nakamaru, Y; Saito, R; Takahata, T; Tashima, Y | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Penland, RC; Tang, W; Yu, H | 1 |
| Fatima, G; Fedacko, J; Isaza, A; Joshi, S; Kumar, P; Maheshwari, A; Mojto, V; Saboo, B; Saxena, M; Singh, RB; SinghVerma, N | 1 |
| Adachi, E; Gohda, T; Ichikawa, S; Koshida, T; Li, Z; Murakoshi, M; Suzuki, C; Suzuki, Y; Ueda, S | 1 |
| Khong, TK; Magavern, E | 1 |
| Ozer, O; Yorulmaz, G | 1 |
| Chang, WT; Chen, ZC; Cheng, JT; Fisch, S; Hong, CS; Kang, NW; Lin, YW; Shih, JY | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Lefor, AK; Ogura, M; Shinozaki, S; Tahara, T | 1 |
| Battisha, A; Chilton, R; Ghali, A; Nashawi, M; Sheikh, O | 1 |
| Anker, SD; Bocchi, EA; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Marx, N; Ofstad, AP; Packer, M; Perrone, SV; Pocock, SJ; Ponikowski, P; Schnaidt, S; Verma, S; Zannad, F | 1 |
| Blonde, L; Bookhart, B; Chen, YW; Patel, C; Pericone, CD; Wu, B | 1 |
| Bakris, GL; Cherney, DZI; Heerspink, HJL; Inzucchi, SE; Koitka-Weber, A; Kraus, BJ; Mattheus, M; Ritter, I; Sattar, N; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B | 1 |
| Adolph, TE; Folie, S; Haas, S; Haubner, BJ; Hornsteiner, F; Kaser, S; Radlinger, B; Ress, C; Salvenmoser, W; Salzmann, K; Schuetz, T; Tilg, H; Weiss, B | 1 |
| Karagiannis, A; Kotsa, K; Loutradis, C; Minopoulou, I; Papadopoulou, E; Sarafidis, P; Theodorakopoulou, MP; Tsapas, A; Tzatzagou, G; Zografou, I | 1 |
| Cho, I; Cho, IJ; Ha, JW; Han, G; Hong, GR; Jang, Y; Kang, SM; Lee, CJ; Lhagvasuren, P; Seo, J; Shim, CY | 1 |
| Deswal, A; Palaskas, NL | 1 |
| Bakker, SJL; Danser, AHJ; Ferrannini, E; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Post, A; Touw, DJ; van Berkel, M; van Bommel, EJM; van Raalte, DH | 1 |
| Garcia-Tsao, G; Saffo, S; Taddei, T | 1 |
| Aroda, VR; Sabatine, MS | 1 |
| Anker, SD; Elsasser, U; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Jamal, W; Johansen, OE; Kaspers, S; Lund, SS; Mattheus, M; McGuire, DK; Pocock, S; von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Wang, J; Wang, W; Wang, X; Yang, L; Zhou, L | 1 |
| Aponte-Ribero, V; Brand, S; Kansal, A; Pimple, P; Reifsnider, O; Shetty, S | 1 |
| Ferreira, JP; Fitchett, D; George, J; Inzucchi, SE; Lauer, S; Ofstad, AP; Verma, S; Wanner, C; Zinman, B; Zwiener, I | 1 |
| Beusekamp, JC; Boorsma, EM; Damman, K; Danser, AHJ; Figarska, SM; Heerspink, HJL; Ter Maaten, JM; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Choi, DJ; Chopra, V; Chuquiure, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Schnaidt, S; Schnee, JM; Senni, M; Seronde, MF; Shahzeb Khan, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zhang, J | 1 |
| Karagiannis, A; Kotsa, K; Loutradis, C; Papadopoulou, E; Sarafidis, P; Theodorakopoulou, MP; Tsapas, A; Tzanis, G; Tzatzagou, G; Zografou, I | 1 |
| Mannucci, E; Monami, M; Silverii, GA | 1 |
| Ding, LL; Qiu, M; Zhang, M; Zhou, HR | 1 |
| Khunti, K | 1 |
| Chen, LX; Fang, L; Tan, YY; Zhang, Q | 1 |
| Cauchon, M; Lanthier, L; Masse, M; Plourde, MÉ | 1 |
| Elmasry, MS; Hasan, MA; Hassan, WS; Merey, HA; Nour, IM | 1 |
| Arya, N; Greasley, PJ; Hammarstedt, A; Heerspink, HJL; Hesp, AC; Karlsson, C; Muskiet, MHA; Scholtes, RA; van Baar, MJB; van Raalte, DH | 1 |
| Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S | 1 |
| Papaetis, GS | 1 |
| Hoshide, S; Ishibashi, S; Kanegae, H; Kario, K; Kato, M; Okada, K | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Ahmad, A; Alanazi, FK; Aldughaim, MS; Alqahtani, A; Alqahtani, AS; Kazi, M; Noman, OM | 1 |
| Elkind-Hirsch, KE; Harris, R; Seidemann, E | 1 |
| Abraham, WT; Agostoni, P; Anker, SD; Brueckmann, M; Butler, J; Desai, AS; Filippatos, G; Fu, M; Gniot, J; Gullestad, L; Howlett, JG; Jamal, W; Krzysztof Wranicz, J; Lindenfeld, J; Nicholls, SJ; Nordaby, M; Peil, B; Ponikowski, P; Redon, J; Ritter, I; Salsali, A; Savarese, G; Schenkenberger, I; Silva-Cardoso, J; Störk, S; Ustyugova, A; Zeller, C | 1 |
| Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; de Boer, RA; Diez, M; Docherty, KF; Dukát, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Lang, NN; Lee, MM; Petrie, MC | 1 |
| Bergenheim, K; Bhatt, DL; Boyce, R; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Leiter, LA; McEwan, P; Morgan, AR; Mosenzon, O; Wilding, JPH | 1 |
| Boulton, D; Parkinson, J; Penland, RC; Shah, M; Sokolov, V; Stolbov, L; Tang, W; Yakovleva, T | 1 |
| Aberle, J; Birkenfeld, AL; Jaeckel, E; Menzen, M; Rohwedder, K; Scheerer, MF; Schmid, SM; Tang, W; Terkamp, C; Xu, J | 1 |
| Funayama, T; Furukawa, Y; Kadowaki, S; Kaga, H; Kakehi, S; Kawamori, R; Kiya, M; Nojiri, S; Sato, M; Satoh, H; Someya, Y; Sugimoto, D; Suzuki, R; Tamura, Y; Watada, H; Yamasaki, N | 1 |
| Al'Aref, SJ; Al-Hawwas, M; Fudim, M; Greene, SJ; Khan, MS; Lopes, RD; McGuire, DK; Mehta, JL; Mounsey, JP; Salah, HM; Vallurupalli, S | 1 |
| Connelly, KA; Gordon, M; Meagher, P | 1 |
| Acharya, Y; Dahal, R; Mukherjee, D | 1 |
| Bouchi, R; Fukuda, T; Itoh, J; Kishimoto, J; Ogawa, Y; Ono, Y; Sonoda, N; Takeuchi, T; Yamada, T | 1 |
| Guyatt, G; Hao, Q | 1 |
| Krejpcio, Z; Król, E; Kurek, JM | 1 |
| Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K | 1 |
| Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M | 1 |
| Chen, MB; Cui, WY; Wang, H; Xu, HL; Zheng, QH | 1 |
| Cao, Z; Guo, X; Ma, Y; Shao, Y; Sun, X; Yuan, G; Zhang, J | 1 |
| Chatzigeorgiou, A; Cholongitas, E; Chrysavgis, L; Papatheodoridi, AM | 1 |
| Azushima, K; Haruhara, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, Y; Kondo, Y; Misumi, T; Osada, U; Tamura, K; Terauchi, Y; Wakui, H; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Fukuda, S; Ishii, Y; Kemmochi, Y; Kuroki, F; Miyajima, K; Nakae, D; Ohta, T; Sano, R; Sasase, T; Sugimoto, M; Yamanaka, M; Yasui, Y | 1 |
| Nakamoto, K; Tsubakimoto, M; Yabiku, K | 1 |
| Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C | 1 |
| Kosiborod, M | 1 |
| Araújo, I; Cunha, GJL; Fonseca, C; Guerreiro, R; Henriques, C; Maltês, S; Presume, J; Rocha, BML; Rodrigues, C | 1 |
| Chadha, S; Jayasinghe, R; Niranjan, S; Oldfield, K | 1 |
| Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y | 1 |
| Hirose, T; Hiruma, S; Hisatake, S; Hori, M; Ikeda, T; Kumashiro, N; Mizumura, S; Shigiyama, F; Shiraga, N | 1 |
| Brodovicz, KG; Chung, WJ; Deruaz-Luyet, A; H-H Sheu, W; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Tan, EC; Yabe, D; Yasui, A | 1 |
| El Fayoumi, HM; Elkazzaz, SK; Khodeer, DM; Moustafa, YM | 1 |
| Cessario, J; Li, Z; Pierre-Louis, V; Wahl, J | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kogai, T; Saito, M; Sakurai, S; Tomaru, T; Usui, I; Wakamatsu, S | 1 |
| Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M | 2 |
| Lamotte, M; Men, P; Ramos, M; Salem, A; Ustyugova, A; Zhang, YJ | 1 |
| Bairaktari, E; Bletsa, E; Chasapi, S; Dafopoulos, P; Dimou, A; Ferrannini, E; Filippas-Dekouan, S; Kostara, C; Koutsovasilis, A; Pappa, E; Spyroulias, G; Tsimihodimos, V | 1 |
| Honda, Y; Imajo, K; Iwasaki, T; Kessoku, T; Kirikoshi, H; Kobayashi, T; Kurihashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Taguri, M; Yamanaka, T; Yoneda, M | 1 |
| Austin, B; Fong, MW; Hartupee, J; Husain, M; Inzucchi, SE; Khariton, Y; Kosiborod, MN; LaRue, SJ; Malik, AO; McGuire, DK; Nassif, ME; Ogunniyi, MO; Pitt, B; Scirica, BM; Tang, F; Umpierrez, G; Wenger, NK; Windsor, SL | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, I; Herrera, M; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Merlini, P; Mosenzon, O; Murphy, SA; O'Donoghue, ML; Raz, I; Sabatine, MS; Šmahelová, A; Tankova, T; Wilding, JPH; Wiviott, SD | 1 |
| Afseth, NK; Allwood, JW; Böcker, U; Lima, RCL; McDougall, GJ; Wubshet, SG | 1 |
| Doumas, M; Papadopoulos, C; Patoulias, D | 1 |
| Gregg, LP; Navaneethan, SD | 1 |
| Bian, F; Chen, L; Hao, X; Lei, P; Lu, W; Ma, W; Wang, Q; Zhang, L; Zhang, Y; Zhao, Y; Zheng, T | 1 |
| Chen, L; Cheng, Y; Fang, T; Han, L; Li, T; Liu, X; Meng, Z; Sun, B | 1 |
| Imai, Y; Kaneto, M; Nakatou, T; Senoo, M; Shimomura, Y; Teshigawara, S; Tone, A; Watanabe, S | 1 |
| Akinci, B | 2 |
| Huang, J; Lin, M; Tang, Z; Wei, G; Wu, S; Yang, F; Yu, W; Zeng, F | 1 |
| Abe, M; Fujikawa, K; Fujita, Y; Fukunami, M; Furukawa, Y; Hata, M; Kawahira, M; Kawai, T; Kawasaki, M; Kayama, K; Kikuchi, A; Morita, T; Nakamura, J; Sanada, S; Seo, M; Shintani, A; Tamaki, S; Tanabe, K; Taniuchi, S; Umayahara, Y; Watanabe, T; Yamada, T; Yamamoto, K | 1 |
| Diogo, V; Gourzoulidis, G; Ioannidis, I; Karpouzos, G; Kourlaba, G; Papageorgiou, G; Tsimihodimos, V; Tzanetakos, C | 1 |
| Drożdż, J; Gackowski, A; Gumprecht, J; Jankowska, EA; Kaźmierczak, J; Kukulski, T; Lelonek, M; Leszek, P; Nessler, J; Ponikowski, P; Rozentryt, P; Rubiś, P; Siniarski, A; Witkowski, A | 1 |
| Larmour, K; Levin, A | 1 |
| Bourron, O; Hartemann, A; Jeannin, AC; Laroche, S; Phan, F | 1 |
| Li, N; Li, SY; Tian, HM; Wang, MY; Zhang, R; Zhang, YG; Zhou, YL | 1 |
| Chen, Y; Hong, H; Li, H; Peng, X; Tao, H; Xu, G | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Packer, M; Pocock, SJ; Sattar, N; Zannad, F | 1 |
| Jojima, T | 1 |
| Athan, E; Bartolo, C; Friedman, ND; Fuller, A; Hall, V; Lanyon, C; Morrissey, CO | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Ferreira, JP; Fitchett, DH; George, JT; Koitka-Weber, A; Kraus, BJ; Lauer, S; Ofstad, AP; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| Fujihara, K; Kaku, K; Matsubayashi, Y; Oe, M; Sato, T; Sone, H; Suganami, H; Tanaka, S; Yaguchi, Y; Yamada, T; Yoshida, A | 1 |
| Barreto, J; Bonilha, I; Breder, I; Breder, JC; Carvalho, LSF; Cavalcante, P; Cintra, RMR; de Lima-Junior, JC; do Carmo, HRP; Kimura-Medorima, ST; Moreira, C; Moura, FA; Munhoz, DB; Nadruz, W; Oliveira, DC; Quinaglia, T; Soares, AAS; Sposito, AC | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Kosiborod, M; Kurlyandskaya, R; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC | 1 |
| Clark, D; Kotobuki, Y; Meinicke, T; Nishida, K; Seino, Y; Shiki, K; Suzaki, K; Yabe, D; Yasui, A | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| C, SS; Iqbal, M; Us, MR; Zin, T | 1 |
| Calefi, GS; Carrilho, AJF; da Rocha, AF; de Faria, EC; Marquezine, GF; Mazzuco, TL; Morimoto, HK; Pereira Junior, PS; Urbano, MR | 1 |
| Ishikawa, K; Kumagai, J; Maezawa, Y; Matumoto, A; Ochiai, H; Ohno, T; Ono, H; Takeda, K; Yokoh, H; Yokote, K | 1 |
| Beusekamp, JC; Boorsma, EM; Damman, K; Heerspink, HJL; Tromp, J; van der Meer, P; Voors, AA | 1 |
| Abe, M; Hoshino, K; Kai, T; Nakamura, J; Oka, S; Watanabe, A; Watanabe, K | 1 |
| Choi, H; Lim, S; Shin, Y | 1 |
| Kohn, OF | 1 |
| Brand, SB; Cragin, L; Fahrbach, K; Gandhi, PK; Kansal, AR; Pfarr, E; Reifsnider, OS; Ustyugova, A | 1 |
| Domon, A; Katayama, K; Sato, T; Suzuki, H; Tazaki, H; Tochigi, Y | 1 |
| Bellido, D; Bellido, V; Botana, MA; Caballero, I; Goñi, F; Mangas, MÁ; Morales, C; Palomares, R; Sevillano, C; Soto, A; Tejera, C | 1 |
| Agbaje, OF; Coleman, R; George, JT; Grempler, R; Holman, RR; Hundertmark, MJ; Lamlum, H; Lee, J; Mahmod, M; Milton, JE; Neubauer, S; Niessen, HG; Rider, O; Rodgers, CT; Valkovič, L; Wicks, E | 1 |
| Deacon, CF; Holst, JJ; Kuhre, RE; Wewer Albrechtsen, NJ | 1 |
| Abushanab, D; Ademi, Z; Al-Badriyeh, D; Liew, D | 1 |
| Anastasiou, G; Hatziagelaki, E; Liberopoulos, E | 1 |
| Inzucchi, SE; Johansen, OE; Kasai, T; Neeland, IJ; Wojeck, BS; Yaggi, HK | 1 |
| Brikman, S; Dori, G | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Niitani, T; Sagara, M; Tomaru, T; Usui, I | 1 |
| Ang, L; Dillon, B; Fang, F; Kidwell, KM; Leone, V; Mizokami-Stout, K; Pop-Busui, R; Reiss, J | 1 |
| Baggesen, LM; Holmgaard, PH; Kahlert, J; Knudsen, JS; Lajer, M; Sørensen, HT; Thomsen, RW; Ustyugova, A; Vedin, O | 1 |
| Goldhaber-Fiebert, JD; Heidenreich, PA; Khush, KK; Parizo, JT; Salomon, JA; Sandhu, AT; Spertus, JA | 1 |
| Choutka, J; Parkan, K; Pohl, R; Rahm, M; Vaňková, K | 1 |
| Claggett, B; de Boer, RA; DeMets, D; Hernandez, AF; Inzucchi, SE; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Öhrn, F; Petersson, M; Shah, SJ; Solomon, SD; Wilderäng, U | 1 |
| Inoue, D; Inoue, R; Nangaku, M; Nishi, H | 1 |
| Kato, M; Kuribayashi, N; Nagayama, D; Ohashi, H; Ohira, M; Saiki, A; Suzuki, D; Tatsuno, I; Uchida, D; Watanabe, Y; Yamaguchi, T | 1 |
| Barreto, J; Breder, I; Cintra, RM; de Carvalho, LSF; Guerra-Júnior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW | 1 |
| Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO | 1 |
| Dabal, TD; Jackson, CD; Patrick, SA | 1 |
| Buranapin, S; Chattipakorn, N; Euathrongchit, J; Leerapun, A; Phrommintikul, A; Phrueksotsai, S; Pinyopornpanish, K; Thongsawat, S | 1 |
| Fitchett, D; George, J; Inzucchi, SE; Kosiborod, MN; Leiter, LA; Mattheus, M; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B | 1 |
| Belosludtsev, KN; Belosludtsev, MN; Belosludtseva, NV; Dubinin, MV; Mikheeva, IB; Starinets, VS | 1 |
| Berrut, G; Boureau, AS; de Decker, L; Genet, B; Hanon, O; Trochu, JN | 1 |
| An, F; Jin, T; Liu, D; Liu, M; Pan, J; Suo, M; Tian, J; Wang, X; Zhang, M | 1 |
| Higashi, Y; Node, K; Okada, Y; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S | 2 |
| Bajaj, HS; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Persson, F; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Wheeler, DC | 1 |
| Adamski, J; Artati, A; Federici, M; Ghesquiere, B; Kappel, BA; Lehrke, M; Marx, N; Moellmann, J; Rau, M; Romeo, F; Schuett, K; Stoehr, R; Thiele, K | 1 |
| Cui, J; Klepser, DG; McAdam-Marx, C | 1 |
| Ahangar, H; Arsang-Jang, S; Dadashi, M; Fathi, M; Ghaffari, S; Ghanbari, S; Gohari, S; Ismail-Beigi, F; Khodabandehloo, H; Muhammadi, MJ; Reshadmanesh, T | 1 |
| Babazono, T; Sato, K | 1 |
| Bayés-Genís, A; de la Espriella, R; Lorenzo, M; Miñana, G; Núñez, E; Núñez, G; Núñez, J; Santas, E | 1 |
| Böhm, M; Korbinian Hartmann, NU; Lehrke, M; Marx, N; März, W; Möllmann, J; Rau, M; Scharnagl, H; Thiele, K; Wied, S | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Ye, Y | 1 |
| Davis, LS; Flanigan, K; Liles, JE | 1 |
| Brandt-Jacobsen, NH; Faber, J; Gustafsson, F; Gæde, P; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, C; Kjær, A; Rossing, P; Schou, M; Wiberg, M; Wolsk, E; Zerahn, B | 1 |
| Lang, CC; Singh, JS; Struthers, AD | 1 |
| Jhund, PS; Lee, MMY; McMurray, JJV; Petrie, MC; Sattar, N | 1 |
| Ghazal Asswad, R; Nicholson, MK; Wilding, JP | 1 |
| Alkabbani, W; Gamble, JM | 1 |
| Atallah-Lajam, F; Badimon, JJ; Fuster, V; Giannarelli, C; Lala, A; Macaluso, F; Mancini, D; Requena-Ibáñez, JA; Rodriguez-Cordero, A; Santos-Gallego, CG; Sanz, J; Sartori, S; Vargas-Delgado, AP | 1 |
| de Galan, BE; Tack, CJ; van Meijel, LA | 1 |
| Anker, SD; Asselbergs, F; Butler, J; Fitchett, D; Inzucchi, SE; Koudstaal, S; Lund, LH; Ofstad, AP; Savarese, G; Schrage, B; Uijl, A; Vedin, O; Wanner, C; Zannad, F; Zwiener, I | 1 |
| Fushimi, Y; Ikeda, T; Kaku, K; Kaneto, H; Mune, T; Nakanishi, S; Nogami, Y; Obata, A; Obata, Y; Sanada, J; Shimoda, M; Yamasaki, Y | 1 |
| Böhm, M; Hartmann, NK; Jankowski, J; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Thiele, K | 1 |
| Chew, DP; Chong, W; De Pasquale, C; De Pasquale, CG; Hecker, T; Horsfall, M; Ilyas, F; Jones, L; Mangoni, AA; Selvanayagam, JB; Stranks, S; Swan, A; Tee, SL; Thomas, S; Wollaston, F | 1 |
| Beddhu, S; Fouque, D; Kalantar-Zadeh, K; Kovesdy, CP; Kramer, HJ | 1 |
| Aso, Y; Hosonuma, S; Iijima, T; Jojima, T; Kajitani, H; Kurai, H; Sakurai, S; Tomaru, T; Usui, I | 1 |
| Abushanab, D; Ademi, Z; Al-Badriyeh, D; Liew, D; Marquina, C | 1 |
| AboGresha, NM; Ahmed, AAM; El-Sayed, N; El-Sayed, NM; Mahmoud, IZ; Mostafa, YM | 1 |
| Akhtar, M; Ali, J; Khan, S; Khan, T; Najmi, AK | 1 |
| Asai, K; Hoshika, Y; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K | 1 |
| Bhatt, DL; Cahn, A; Diaz, R; Gause-Nilsson, IAM; Goudev, A; Kuder, J; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Oyama, K; Park, KS; Raz, I; Sabatine, MS; Špinar, J; Wilding, JPH; Wiviott, SD | 1 |
| Gupta, A; Jamwal, V; Khalse, M; Malhotra, P | 1 |
| Aschenbrenner, DS | 3 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Solomon, SD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Wanner, C; Zannad, F; Zeller, C | 1 |
| Dey, J | 1 |
| Buchholt, AT; El Khoury, AC; Kamal, A; Schubert, A; Taieb, V | 1 |
| Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D | 1 |
| Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH | 1 |
| Lingvay, I | 1 |
| Kountz, DS | 1 |
| Antoine, N; Cuypers, E; Gilon, P; Gysemans, C; Kerselaers, S; Laureys, J; Lemaire, K; Mathieu, C; Mesuere, M; Philippaert, K; Pinto, S; Pironet, A; Rorsman, P; Schuit, F; Segal, A; Sones, W; Talavera, K; Tytgat, J; Vennekens, R; Vermeiren, L; Voets, T | 1 |
| Arsenović, M; Čapo, I; Ilić, V; Milijašević, B; Stilinović, N; Vukmirović, S | 1 |
| Gunji, R; Kaku, K; Senda, M; Tamura, M; Terauchi, Y | 2 |
| Bando, H; Imoto, I; Obata, F; Tabata, R; Tani, K; Yamaguchi, H | 1 |
| Scheen, AJ | 21 |
| Jain, RK | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Fadini, GP; Iori, E; Marescotti, MC; Vitturi, N; Zatti, G | 1 |
| Hongchao, X; Jiangang, L; Ni, Z; Qiujing, W; Tao, L; Weikang, H; Xiaohui, X; Xin, L; Zelin, Z; Zhao, S | 1 |
| Krzesinski, JM; Paquot, N; Piérard, L; Scheen, AJ | 1 |
| Albers, GW; Broedl, UC; Diener, HC; Fitchett, D; Inzucchi, SE; Johansen, OE; Kohler, S; Lachin, JM; Mattheus, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Chilton, R; Hehnke, U; Johansen, OE; Tikkanen, I; Woerle, HJ | 1 |
| Bain, S; Chudleigh, RA | 1 |
| Kajiya, S; Kawasoe, M; Kawasoe, S; Kubozono, T; Maruguchi, Y; Miyata, M; Ohishi, M; Uenomachi, H | 1 |
| Rajput, R; Ved, J | 2 |
| Avogaro, A; Bonora, E; Colivicchi, F; Ferrannini, E; Fioretto, P; Maggioni, AP; Perrone-Filardi, P; Sesti, G | 1 |
| Higashi, Y; Ikehara, Y; Inoue, T; Kawaguchi, A; Kimura, K; Machii, N; Maruhashi, T; Matsuzawa, Y; Node, K; Okada, Y; Oyama, JI; Sakuma, M; Sato, Y; Shima, KR; Shimabukuro, M; Sugiyama, S; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamaoka-Tojo, M; Yoshida, H | 1 |
| Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
| Burudpakdee, C; Cai, J; Divino, V | 1 |
| Aoki, C; Aso, Y; Kato, K; Niitani, T; Sagara, M; Suzuki, K; Wakamatsu, S; Yanagi, K | 1 |
| Avogaro, A; Del Prato, S; Fioretto, P; Genovese, S; Giaccari, A; Giorgino, F; Purrello, F | 1 |
| Cheung, BMY; Kumana, CR; Tan, KCB | 1 |
| Ahmed, M; Crowley, RK; McKenna, MJ | 1 |
| Chaudhuri, A; Dandona, P | 1 |
| Harindhanavudhi, T; Ruanpeng, D; Sangtian, J; Ungprasert, P | 1 |
| Bajaj, M; Birnbaum, Y; Perez-Polo, JR; Yang, HC; Ye, Y | 1 |
| Amino, N; Hayashizaki, Y; Hirosumi, J; Kurosaki, E; Minoura, H; Takakura, S; Takasu, T | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Tschöpe, D | 1 |
| Cejvanovic, V; Kjær, LK; Knop, FK; Larsen, EL; Poulsen, HE; Rungby, J; Vilsbøll, T | 1 |
| Hashimoto, N; Horikoshi, T; Ishikawa, K; Ishikawa, T; Kobayashi, K; Koshizaka, M; Kuribayashi, N; Nagashima, K; Sato, Y; Shimofusa, R; Takahashi, S; Takemoto, M; Tatsuno, I; Terano, T; Uchida, D; Yokote, K | 1 |
| Arya, N; Birkeland, KI; Bodegård, J; Cavender, MA; Fenici, P; Fu, AZ; Hammar, N; Holl, RW; Jørgensen, ME; Khunti, K; Kosiborod, M; Norhammar, A; Thuresson, M; Wilding, JP | 1 |
| Wanner, C | 3 |
| Chilton, R | 1 |
| Chilton, R; Pham, SV | 1 |
| Lehrke, M; Marx, N | 2 |
| Staels, B | 2 |
| Perreault, L | 2 |
| Fralick, M; Goldberg, N | 1 |
| Ekinci, EI; Hall, V; Johnson, D; Kwong, J | 1 |
| Gao, HK; Kengne, AP; Mazidi, M; Rezaie, P | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Burggraaf, B; Castro Cabezas, M | 1 |
| Greenfield, JR; Isaacs, M; Tonks, KT | 1 |
| Bailey, C; Blak, B; Emmas, C; Kok, M; Rigney, U; Wilding, J | 1 |
| Chen, S; Davidson, JA; Holland, WL; Lee, Y; Li, J; McCorkle, SK; Roth, MG; Scherer, PE; Unger, RH; Wang, MY; Wang, ZV; Yu, X | 1 |
| Hua, WC; Li, CM; Liu, Q; Wang, H; Wang, LG | 1 |
| Glodzik, W; Hohendorff, J; Kapusta, M; Kiec-Wilk, B; Klupa, T; Ludwig-Galezowska, A; Malecki, MT; Mrozinska, S; Parpan, T; Platek, T; Skupien, J; Szopa, M; Zapala, B | 1 |
| Chilton, RJ | 1 |
| Chilton, RJ; Pham, SV | 1 |
| Shao, Y; Wang, K; Wu, Y; Zhang, T; Zhu, Q | 1 |
| Iliev, H; Kaspers, S; Kohler, S; Zeller, C | 1 |
| Kaul, S | 2 |
| Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S; Ryder, REJ; Singh, R | 1 |
| Farhat, A; Hajjar, R; Hammoudi, N; Jeong, D; Komajda, M; Lebeche, D; Mayoux, E; Singh, R | 1 |
| Ishida, H; Nakamoto, S; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Gadzhanova, S; Pratt, N; Roughead, E | 1 |
| Cherney, DZI; Inzucchi, SE; Koitka-Weber, A; Mattheus, M; von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Adamson, KA; Bain, SC; Barnes, DJ; Chowdhury, TA; Chuah, LL; Morris, DS; Robinson, AM; Ryder, REJ; Thong, KY; Yadagiri, M | 1 |
| Ernest, P; Jandrain, B; Scheen, AJ; Wallemacq, C | 1 |
| Fukagawa, M; Miyauchi, M; Toyoda, M | 1 |
| de J Patiño-Laguna, A; Díaz-Cruz, C; González-Ortiz, M; Grover-Páez, F; López-Murillo, LD; Martínez-Abundis, E | 1 |
| Hirose, T; Ikehara, K; Kanda, E; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Drexler, A | 1 |
| Jabbour, S | 2 |
| Gürke, L; Tampaki, EC; Tampakis, A | 2 |
| Diener, HC; Inzucchi, SE; Zinman, B | 1 |
| Cutler, DL; Hickman, A; O'Gorman, M; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, Z | 1 |
| Molony, DA; Nguyen, JT | 1 |
| Dai, Q; Han, J; Shi, W; Song, Y; Tang, H; Zhai, S | 1 |
| Gupte, M; Lal, H; Umbarkar, P | 1 |
| Toto, RD | 1 |
| Akiyama, Y; Inoue, K; Inukai, K; Ito, D; Morimoto, Y; Noda, M; Saito, D; Shimada, A; Shimizu, S; Yanagisawa, M | 1 |
| Ishii, S; Koiwai, K; Mitsuyoshi, R; Okamura, T; Pfarr, E; Shiba, T | 1 |
| Broedl, UC; Heer, M; Heise, T; Heusser, K; Jordan, J; Lund, SS; Macha, S; Mattheus, M; Tank, J; Wanner, C; Woerle, HJ | 1 |
| Morillas, C | 1 |
| Anker, SD; Butler, J; Filippatos, G; Packer, M; Zannad, F | 1 |
| Ishii, S; Kato, H; Nagai, Y; Nakagawa, T; Nakamura, Y; Ohta, A; Sasaki, Y; Tanaka, Y | 1 |
| Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M | 2 |
| Black, RL; Irons, BK; Minze, MG; Terrell, BT; Will, KJ | 1 |
| Takeishi, S; Takekoshi, S; Tsuboi, H | 1 |
| Chang, A; Chauhan, K; Coca, SG; Ferket, B; Ferrandino, R; Grams, ME; Nadkarni, GN; Poojary, P; Saha, A; Surapaneni, A | 1 |
| Aronson, R; Brown, RE; Gupta, N | 1 |
| Brown, AJM; Lang, C; McCrimmon, R; Struthers, A | 1 |
| Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H | 1 |
| Broedl, UC; Cherney, DZI; Cooper, ME; Johansen, OE; Lund, SS; Pfarr, E; Tikkanen, I; Woerle, HJ | 1 |
| Breuer, TGK; Kampmann, K; Meier, JJ; Schmidt, WE; Steinfort, C; Uhl, W; Wutzler, A | 1 |
| Adamski, J; Artati, A; Kappel, BA; Lebherz, C; Lehrke, M; Marx, N; Schütt, K | 1 |
| Coppenrath, VA; Hydery, T | 1 |
| Colman, PG; Costello, AJ; Kumar, S | 1 |
| Bandyopadhyay, D; Hajra, A; Qureshi, A | 1 |
| Jumar, A; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Schneider, MP; Striepe, K | 1 |
| Fujimori, T; Ichikawa, K; Irahara, A; Kimata, K; Koketsu, Y; Nakano, A; Senda, E; Sumida, Y; Takata, E; Takeda, A; Yamada, H | 1 |
| Kruger, DF; Novak, LM | 1 |
| Iuchi, H; Kayama, Y; Matsutani, D; Minamisawa, S; Sakamoto, M; Suzuki, H; Takeda, N; Utsunomiya, K | 1 |
| Gallwitz, B | 1 |
| Bailey, CJ; Jabbour, S; Karup, C; Langkilde, AM; Scheen, A; Seufert, J | 1 |
| Avogaro, A; Bonora, E; Consoli, A; Fadini, GP; Sesti, G; Zatti, G | 1 |
| Barbosa, FT; Lima, FJC; Santos, LL; Sousa-Rodrigues, CF | 1 |
| Paneni, F | 1 |
| Butler, J; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Calogero, E; Di Bello, V; Fabiani, I; Natali, A; Nesti, L | 1 |
| Kaku, K; Suganami, H; Tobe, K | 1 |
| Baig, F; Choy, AM; Lang, CC; McCrimmon, RJ; Mordi, IR; Mordi, NA; Singh, JS; Struthers, AD | 1 |
| Kaira, K; Katoh, R; Kusano, M; Matsumoto, S; Okada, J; Okada, S; Saito, T; Yamada, E; Yamada, M; Yokoo, H | 1 |
| Bruno, RM; Ghiadoni, L; Giannini, L; Seghieri, M; Solini, A; Taddei, S; Vitolo, E | 1 |
| Bjornstad, P; Cherney, DZI; Lovshin, JA; Lytvyn, Y; Udell, JA | 1 |
| Lovshin, JA; McReelis, KD | 1 |
| Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS | 1 |
| Khunti, K; Kosiborod, M | 1 |
| Fushimi, Y; Hirukawa, H; Kaku, K; Kamei, S; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Fraser, S; Osgood, S | 1 |
| Abe, T; Fujihara, K; Ishizawa, M; Kaku, K; Matsubayashi, Y; Nojima, T; Osawa, T; Sone, H; Suganami, H; Tanaka, S; Yamamoto, M; Yoshida, A | 1 |
| Al-Omran, M; Fitchett, D; George, JT; Hehnke, U; Inzucchi, SE; Mazer, CD; Verma, S; Zinman, B | 1 |
| Ferdinand, KC; Salsali, A; Seman, L | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 3 |
| Brown, F; McColl, T | 1 |
| Coleman, CI; Nair, S; Nguyen, E; Weeda, ER | 1 |
| Abiru, N; Ando, T; Haraguchi, A; Hongo, R; Horie, I; Ito, A; Kawakami, A; Nakamura, T; Natsuda, S; Sagara, I | 1 |
| Matthews, DR; Neal, B; Perkovic, V | 1 |
| Ohno, Y; Suzuki, H; Takenaka, T | 1 |
| Anzai, N; Fujita, T; Fukunaka, Y; Hayashi, K; Jutabha, P; Kaku, K; Morita, A; Oba, K; Otani, N; Ouchi, M; Suganami, H; Suzuki, T; Yasutake, M; Yoshida, A | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 4 |
| Bilezikian, JP; Hanif, W; Keerthy, D; Kotsa, K; Nirantharakumar, K; Tahrani, AA; Thayakaran, R; Thomas, GN; Toulis, KA | 1 |
| Hattori, S | 1 |
| Bluhmki, E; Ferrannini, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Ohneberg, K; Schmoor, C; Schumacher, M; Wanner, C; Zinman, B | 1 |
| Ahlqvist, M; Gilmour, R; Kankkonen, C; Kehr, G; Knerr, L; Sadurní, A; Sjögren, HP; Wernevik, J | 1 |
| Kim, JH; Li, Y; Ma, J; Ptaszynska, A; Yang, W; Zhao, J; Zhou, Z | 1 |
| Hieshima, K; Jinnouchi, H; Jinnouchi, K; Jinnouchi, T; Kajiwara, K; Kurinami, N; Miyamoto, F; Nishimura, H; Sugiyama, S; Suzuki, T; Yoshida, A | 2 |
| Elisaf, MS; Filippatos, TD; Rizos, CV | 1 |
| Dull, RB; Knezevich, EL; Lau, BM; Spangler, ML | 1 |
| Suissa, S | 3 |
| Chang, B; Chen, W; Fan, R; Guo, Y; Liu, L; Pan, Y; Zhao, R | 1 |
| Chan, GCW; Tang, SCW | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kishi, S; Kitazawa, H; Okabe, M; Sato, M; Sato, T; Takahashi, M; Yuasa, S | 1 |
| Boemke-Zelch, F; Bosch, A; Kannenkeril, D; Karg, MV; Linz, P; Nagel, AM; Ott, C; Schmieder, RE; Schneider, MP; Striepe, K; Titze, J; Uder, M | 1 |
| Chen, Y; Hu, S; Ren, J; Wang, S; Zhou, H; Zhu, P | 1 |
| Bakris, G; Plutzky, J | 1 |
| Brandjes, DPM; Gerards, MC; Gerdes, VEA; Hageman, IMG; Hoekstra, JBL; Kross, M; Patberg, KW; Potter van Loon, BJ; Snijders, D; Venema, GE; Vriesendorp, TM | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P | 1 |
| Matsuba, I; Matsuba, R; Nagai, Y; Shimokawa, M; Tanaka, Y | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD | 1 |
| Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Solis-Herrera, C; Triplitt, C | 1 |
| Broedl, UC; Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Gourzoulidis, G; Ioannidis, I; Kourlaba, G; Maniadakis, N; Papageorgiou, G; Tsapas, A; Tzanetakos, C | 1 |
| Cain, V; Dekkers, CCJ; Heerspink, HJL; Sjöström, CD; Stefansson, BV; Wheeler, DC | 1 |
| Bell, KF; Chakravarty, A; Dhankhar, P; Rastogi, M | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Cracowski, JL; Khouri, C; Roustit, M | 1 |
| Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J | 1 |
| Covino, J; Hoffman, J | 1 |
| Lin, YH | 1 |
| Cos, X; Gillani, S; Khunti, K; Kunutsor, SK; Seidu, S | 1 |
| Azoulay, L; Filion, KB; Puckrin, R; Reynier, P; Saltiel, MP; Yu, OHY | 1 |
| Bain, SC; Bashir, J; Chudleigh, R; Nalla, P; Peter, R | 1 |
| Hirukawa, H; Iwamoto, M; Kaku, K; Kamei, S; Kameyama, M; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakanishi, S; Obata, A; Shimoda, M; Tatsumi, F | 1 |
| Bajaj, M; Birnbaum, Y; Yang, HC; Ye, Y | 1 |
| Avogaro, A; Baldi, I; Bottigliengo, D; Consoli, A; Fadini, GP; Giaccari, A; Sesti, G; Zatti, G | 1 |
| Hosaka, T; Inoue, K; Ishida, H; Ito, S; Itou, T; Kobayashi, H; Kondo, T; Nakagawa, T; Shimizu, Y; Tanabe, S; Yano, W; Yasumura, M | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Bortolozzi, M; Cappellari, R; Ceolotto, G; Fadini, GP; Menegazzo, L; Romanato, F; Scattolini, V; Vigili de Kreutzeberg, S | 1 |
| Chang, J; Goyat, R; Ponte, CD; Rai, P; Tan, X | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H | 1 |
| Cherney, DZ; Dekkers, CCJ; Gansevoort, RT; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Anzai, T; Asakura, M; Hamasaki, T; Hashimura, K; Imazu, M; Ito, S; Kitakaze, M; Mori, K; Watanabe, M; Yamamoto, H; Yasuda, S; Yasumura, Y; Yoshihara, F | 1 |
| Blonde, L; Bookhart, B; Chen, YW; Patel, C; Pfeifer, M; Wu, B | 1 |
| Abbate, A; Billingsley, HE; Buckley, LF; Buzzetti, R; Canada, JM; Carbone, S; Christopher, S; Dixon, DL; Kadariya, D; Markley, R; Medina de Chazal, H; Trankle, CR; Van Tassell, BW; Vo, C | 1 |
| Casciaro, F; Cortese, C; Cutruzzolà, A; Gnasso, A; Irace, C; Oliverio, R; Scavelli, FB | 1 |
| Hobson, D; Hughan, KS; Kaspers, S; Laffel, LMB; Marquard, J; Nock, V; Simons, G; Tamborlane, WV; Wu, J; Yver, A | 1 |
| Allison, DB; Kahathuduwa, CN; Siu, C; Thomas, DM | 1 |
| Bell, KF; Eudicone, JM; Gani, R; Huang, H; Krukas-Hampel, MR; Tugwell, CW | 1 |
| Bell, KF; Enhoffer, DM; Eudicone, JM; Green, JB; Latham, K; Wittbrodt, ET | 1 |
| Battson, ML; Ecton, KE; Gentile, CL; Hou, S; Jarrell, DK; Lee, DM; Weir, TL | 1 |
| Alghdban, MK; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
| Cherney, DZI; Heerspink, HJL; Inzucchi, SE; Kosiborod, M | 1 |
| Fujita, T; Kaku, K; Oba, K; Ouchi, M; Suganami, H; Suzuki, T; Yasutake, M; Yoshida, A | 1 |
| Cheng, G; George, J; Haneda, M; Kawamori, R; Lee, C; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Suzaki, K | 1 |
| Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kumashiro, Y; Matsui, T; Nakamura, T; Sugiyama, Y; Sun, J; Tahara, A; Tahara, N; Yamagishi, SI | 1 |
| Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B | 1 |
| Leiter, LA; Lingvay, I | 1 |
| Bodegård, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Thuresson, M | 3 |
| Birkeland, KI; Cavender, MA; Fenici, P; Fu, AZ; Hammar, N; Holl, RW; Jørgensen, ME; Khunti, K; Kosiborod, M; Norhammar, A; Thuresson, M; Wilding, JP; Wittbrodt, E | 1 |
| Fukuda, K; Imai, T; Koepsell, H; Masuda, T; Muto, S; Nagata, D; Ohara, K; Onishi, A; Vallon, V; Watanabe, M; Watanabe, Y | 1 |
| Akturk, HK; Garg, SK; Rewers, A | 1 |
| Castilho, PC; Spínola, V | 1 |
| Chua, CL; Lim, GJ; Low, SKM; Shao, Y; Sum, CF; Wong, YF; Yeoh, ECK | 1 |
| Fujimura, Y; Fukuda, T; Horikawa, T; Motonaga, R; Nomiyama, T; Ohsako, T; Shimono, D; Tanabe, M; Terawaki, Y; Yanase, T | 1 |
| Jeon, HJ; Ku, EJ; Oh, TK | 1 |
| Faramarzi, MA; Heydari, Z; Imanparast, S; Larijani, B; Mahdavi, M; Mohammadi-Khanaposhtani, M; Ranjbar, PR | 1 |
| Forest, CP; Tat, V | 1 |
| Ren, DY; Zhang, Y | 1 |
| Akiyama, N; Kashiwagi, A; Kazuta, K; Kosakai, Y; Nakamura, I; Sakatani, T; Takahashi, H; Ueyama, E | 1 |
| Aiello, V; Brancato, D; Di Noto, A; Fleres, M; Provenzano, F; Provenzano, V; Saura, G; Scorsone, A; Spano, L | 1 |
| Hieshima, K; Jinnouch, K; Jinnouchi, H; Jinnouchi, T; Kajiwara, K; Kurinami, N; Miyamoto, F; Sugiyama, S; Yoshida, A | 1 |
| Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH | 1 |
| Bell, DSH; Goncalves, E | 2 |
| Azuma, K; Iizuka, T; Inoue, K; Maruyama, S; Matsuzawa, Y; Mukai, S; Nakai, K; Nishikawa, T; Omura, M; Saito, J; Tsurutani, Y | 1 |
| Fuchigami, A; Hirose, T; Kumashiro, N; Shigiyama, F | 1 |
| Bansal, B; Choudhary, NS; Farooqui, KJ; Gill, HK; Jevalikar, G; Kaur, P; Krishan, S; Kuchay, MS; Mishra, SK; Mithal, A; Singh, MK; Wasir, JS | 1 |
| Bansilal, S; Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IA; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JP; Wiviott, SD | 1 |
| Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C | 1 |
| Abdelazeim, B; Abdelazeim, N; El Ashal, G; Elgebaly, A; Mattar, O; Namous, L; Nasreldin, N | 1 |
| Chou, YM; Goh, ZNL; Lin, CC; Seak, CJ; Seak, CK; Seak, JC | 1 |
| Kimura, Y; Kuno, A; Miki, T; Miura, T; Mizuno, M; Nakata, K; Oshima, H; Sato, T; Tanno, M; Yano, T | 1 |
| Frampton, JE | 1 |
| Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D | 1 |
| DeFronzo, RA; Kohler, S; Lee, C | 1 |
| Deng, L; Li, Z; Liang, R; Liao, R; Xu, X; Zhang, B; Zhang, L | 1 |
| Dunham, MW; Hurren, KM | 1 |
| Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ | 1 |
| Eriksson, JW; Forsberg, GB; Jansson, PA; Johansson, L; Kvarnström, M; Lind, L; Lundkvist, P; Miliotis, T; Moris, L; Oscarsson, J; Risérus, U | 1 |
| Adimadhyam, S; Calip, GS; Layden, BT; Lee, TA; Schumock, GT; Smith Marsh, DE | 1 |
| De Ponti, F; Fadini, GP; Marchesini, G; Poluzzi, E; Raschi, E | 1 |
| Engel, SS; Kaufman, KD; Lam, RLH; Morgan, J; O'Neill, EA; Raji, A; Scott, R; Zimmer, Z | 1 |
| Kondo, Y; Tahara, A; Takasu, T; Tomiyama, H | 1 |
| Acosta-Delgado, D; Hernandez-Quiles, C; Ramirez-Duque, N | 1 |
| Furukawa, E; Furukawa, S; Hiasa, Y; Matsuura, B; Miyake, T; Niiya, T; Sakai, T; Senba, H; Yamamoto, S | 1 |
| Aroor, AR; Carpenter, AJ; Chandrasekar, B; Das, NA; DeMarco, VG; Duta, C; Habibi, J; Hayden, MR; Jia, G; Manrique-Acevedo, CM; Martinez-Lemus, L; Mayoux, E; Nistala, R; Padilla, J; Ramirez-Perez, FI | 1 |
| Arbel, R; Azuri, J; Hammerman, A | 1 |
| Kulikov, NV; Obrezan, AG | 1 |
| George, J; Haneda, M; Kaku, K; Lee, C; Lee, G; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Tanaka, Y | 1 |
| Chang, TJ; Ji, L; Kaspers, S; Kohler, S; Lee, J; Lee, MK; Ma, RCW; Okamura, T; Seino, Y; Yabe, D; Yasui, A; Zeller, C | 1 |
| Frias, JP; McPheeters, JT; Parker, ED; Wittbrodt, ET | 1 |
| Iida, S; Ikeda, S; Kasahara-Ito, N; Portron, A; Saito, T; Schwab, D; Takano, Y | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Cappellari, R; Fadini, GP | 1 |
| Inzucchi, SE; Lupsa, BC | 1 |
| Cherney, DZI; Thomas, MC | 1 |
| Marx, N; Wanner, C | 1 |
| Arnold, SV; Ferdinand, KC; Goyal, A; Kosiborod, M; Mehta, SN; Peri-Okonny, PA; Seman, L; Sperling, LS; Tang, F | 1 |
| Anichini, R; Avogaro, A; Del Prato, S; Fadini, GP; Gatti, A; Manca, ML; Penno, G; Solini, A | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Ito, YM; Kurihara, Y; Manda, N; Miya, A; Miyoshi, A; Miyoshi, H; Nakamura, A; Niwa, H; Nomoto, H; Takahashi, K; Yamamoto, C | 1 |
| Alexandre, L; Assaly, R; Behr-Roussel, D; Bernabe, J; Compagnie, S; Giuliano, F; Gorny, D; Mayoux, E | 1 |
| Aronson, R; Bajaj, HS; Bhullar, L; Brown, RE; Kalra, S; Sohi, N | 1 |
| González-Ortiz, M; Martínez-Abundis, E; Ramírez-Rodríguez, AM | 1 |
| Akyol, PY; Karakaya, Z; Payza, U; Topal, F; Topal, FE | 1 |
| Goldman, JD | 1 |
| Katsiki, N; Triposkiadis, F | 1 |
| Aso, Y; Hiraishi, H; Iijima, M; Iijima, T; Jojima, T; Kato, K; Murohisa, T; Shimizu, M; Suzuki, K; Takekawa, H; Usui, I | 1 |
| Ando, Y; Hirose, T; Ikehara, K; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H; Yoshikawa, F; Yoshino, H | 1 |
| Henry, RR; Katz, A; Klein, D; Mansfield, T; Pettus, J; Shi, L; Strange, P; Zhou, R; Zhuplatov, SB | 1 |
| Guo, X; Li, D; Li, J; Li, S; Ren, G; Wang, N; Zhang, T | 1 |
| Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK | 1 |
| Abdul-Ghani, M; DeFronzo, RA; Fawaz, M; Jayyousi, A; Megahed, A; Migahid, O; Singh, R | 1 |
| Asahara, SI; Furubayashi, A; Kanno, A; Kawamura, M; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Ogawa, W; Okada, Y; Suzuki, E; Takai, T; Tsuchiya, S | 1 |
| Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Omori, K; Takase, T | 1 |
| Fitchett, D; George, JT; Hehnke, U; Inzucchi, SE; Kaspers, S; Kosiborod, M; Wanner, C; Zinman, B | 1 |
| Fukuda, A; Higashikawa, T; Iguchi, M; Ishigami, K; Ito, T; Kanda, T; Kasamaki, Y; Kohori, M; Mae, K; Mizuno, T; Okuro, M; Saito, A; Saito, H; Sangen, R; Usuda, D | 1 |
| Koh, KK | 1 |
| von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Orlova, VL; Shestakova, MV; Tretter, R; Verbovoy, AF; Wilding, JPH; Wilpshaar, W | 1 |
| Chen, L; Han, SL; Liu, X; Sun, XF; Wang, HY; Wang, SX; Xia, L; Zhang, YJ | 1 |
| Hantel, S; Kadowaki, T; Koitka-Weber, A; Nangaku, M; Okamura, T; von Eynatten, M; Wanner, C | 1 |
| Cain, VA; Hallow, MK; Heerspink, HJL; Inzucchi, SE; Rossing, P; Sartipy, P; Sjöström, CD; Stefansson, BV | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P | 1 |
| Dong, P; Liu, H; Zhao, D | 1 |
| Bassante, FEM; Cardoso, MHS; da Rosa, HS; Folmer, V; Puntel, GO; Salgueiro, ACF | 1 |
| Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J | 1 |
| Davis, SN; Hedrington, MS | 2 |
| Ares, J; Delgado, E; Maciá, C; Menéndez, E; Pujante, P; Rodriguez Escobedo, R | 1 |
| Kaneko, M; Narukawa, M | 2 |
| Lin, K; Liu, H; Lu, A; Qi, X; Sun, Z; Yu, K; Zhang, M; Zhu, J | 1 |
| Bhatt, DL; Connelly, KA; Verma, S | 1 |
| Bell, M; Blake, L; Griffin, MD; Griffin, TP; Islam, MN; O'Shea, PM | 1 |
| Arima, H; Fuse, K; Ida, S; Inoue, H; Kondo, K; Maegawa, H; Miura, K; Miyazawa, I; Morino, K; Murata, K; Ohashi, N; Sato, D; Sekine, O; Tanaka-Mizuno, S; Ugi, S; Yoshimura, M | 1 |
| Abe, K; Kimura, Y; Kuno, A; Miki, T; Miura, T; Mizuno, M; Nakata, K; Ohwada, W; Oshima, H; Sato, T; Tanno, M; Yano, T | 1 |
| Akkuş, G; Akkuş, O; Kaypaklı, O | 1 |
| Bookhart, B; Cai, J; Durkin, M; Kamstra, R; Lafeuille, MH; Lefebvre, P; Manceur, AM; Pilon, D; Tiggelaar, S | 1 |
| Antlanger, M; Burghart, L; Hecking, M; Kopecky, C; Pacini, G; Ristl, R; Säemann, MD; Schmaldienst, S; Schwaiger, E; Signorini, L; Tura, A; Werzowa, J; Wrba, T | 1 |
| Cannon, CP; Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Kaspers, S; McGuire, DK; Pfarr, E; Sambevski, S; Scirica, BM; Zinman, B | 1 |
| Bell, C; Biela, LM; Grimm, NC; Luckasen, GJ; Melby, CL; Newman, AA; Schoenberg, HM; Trikha, SRJ; Wilburn, JR | 1 |
| Culha, C; Gursoy, K; Kocer, U; Kuskonmaz, SM; Onder, CE | 1 |
| Arvapalli, R; Bandarupalli, VVK; Blough, ER; Ginjupalli, GK; Graffeo, VA; Manne, NDPK; Rice, KM | 1 |
| Åkerblom, A; Johansson, L; Karlsson, C; Latva-Rasku, A; Lisovskaja, V; Nuutila, P; Oldgren, J; Oscarsson, J | 1 |
| Abdul Rashid, AM; Adams, L; Agah, R; Ahmad Saad, FF; Akay, S; Appiah-Opong, R; Aronson, RD; Asbun, H; Ashong, Y; Ayi, I; Baez, P; Bar-Ad, V; Bay, JL; Bello-Pagan, M; Blackbourn, LAK; Bolan, C; Brierley, L; Cannaday, S; Cannon, TL; Caparrotta, TM; Capitano, M; Colhoun, HM; Coppola, D; Crees, ZD; Crites, D; Devaraj, K; Dumashie, E; Edil, BH; Endo, K; Ferrone, CR; Forcione, DG; Ford, J; Fortuna, D; Garcia, M; Gilad, GM; Gomez, V; Gonzalez, C; Gwira, TM; Han, JY; Hanaki, T; Hardacre, JM; Hester, D; Hidalgo, M; Hirschler, V; Hodul, PJ; Ikeguchi, M; Intersimone, P; Jang, JH; Ji, Z; Johnson, T; Kandel, P; Koh, R; Lee, G; Lee, IG; Leese, GP; Li, J; Liu, X; Lopez, MJ; Maccallini, G; Macdonald, DB; Malek, R; Maley, WR; Martel, G; McCrimmon, RJ; McGurnaghan, SJ; McKeigue, PM; McKnight, JA; Md Noh, MSF; Miao, Y; Mody, K; Molinari, C; Monroe, JF; Mora, HA; Morton, SM; Moyana, TN; Munoz-Jordan, J; Nakamura, S; Neaterour, P; Orcutt, ST; Palmer, JD; Paniccia, A; Park, J; Pearson, ER; Perez, NP; Petrie, JR; Pyatibrat, S; Rademacher, N; Raimondo, M; Ranasinha, N; Reyes, N; Richardson, LC; Ritter, AW; Rivera, A; Rivera-Garcia, B; Rosemurgy, AS; Ross, SB; Sama, A; Sattar, N; Sawata, T; Schulick, RD; Shang, D; Sharp, TM; Shimizu, T; Şirin, B; Sloboda, DM; So, E; Song, X; Srour, SA; Stauffer, J; Suzuki, K; Taguchi, T; Takawira, C; Torphy, R; Trump, DL; Tuffour, I; Ünsal, B; Van Dyne, EA; Vickers, MH; Vitulli, PL; Wallace, MB; Wang-Gillam, A; Waterman, SH; Wei, J; Weinstein, JC; Wild, SH; Williams, N; Winter, J; Woodward, TA; Wu, ES; Wu, J; Yeo, CJ; Yeo, TP; Yeung, V; Zhang, JB | 1 |
| Donnan, K; Segar, L | 1 |
| Asseburg, C; Neslusan, C; Willis, M | 1 |
| Han, S; Jin, K; Paek, JH; Park, H; Park, SB; Park, WY; Yeo, SM | 1 |
| Cai, X; Chen, Y; Gu, S; Ji, L; Nie, L; Shi, L; Yang, W | 1 |
| Chan, WK; Lai, LL; Mahadeva, S; Nik Mustapha, NR; Vethakkan, SR | 1 |
| Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K | 1 |
| Fujii, S; Fujiwara, H; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Cardone, RL; Kibbey, RG; Perry, RJ; Rabin-Court, A; Shulman, GI; Song, JD; Wang, Y | 1 |
| Chen, L; Cheng, Y; Han, F; Li, C; Li, T; Li, X; Liu, X; Lu, Y; Sun, B; Xu, L; Xue, M; Yu, X; Zhang, J | 1 |
| Castilho, PC; Llorent-Martínez, EJ; Spínola, V | 1 |
| Cancho-Grande, B; Carrasco-Pancorbo, A; Figueiredo-González, M; González-Barreiro, C; Reboredo-Rodríguez, P; Simal-Gándara, J | 1 |
| Elisaf, MS; Filippatos, TD; Liontos, A; Papakitsou, I | 1 |
| Chattipakorn, N; Chattipakorn, S; Gunaparn, S; Jaiwongkam, T; Kumfu, S; Phrommintikul, A; Wongcharoen, W | 1 |
| Böhm, M; Brueckmann, M; Ferreira, JP; Fitchett, D; George, J; Januzzi, J; Kaul, S; Ofstad, AP; Petrie, MC; Wanner, C; Zannad, F; Zeller, C | 1 |
| Briganti, EM; Cohen, ND; Gutman, SJ; Taylor, AJ | 1 |
| Garg, SK; Giordano, D | 1 |
| Ferdinand, KC; George, J; Izzo, JL; Lee, J; Meng, L; Salsali, A; Seman, L | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Kishi, H; Maejima, Y; Sakurai, S; Shimizu, M; Shimomura, K; Usui, I | 1 |
| Abe, T; Fujihara, K; Ishizawa, M; Kaku, K; Matsubayashi, Y; Nojima, T; Sone, H; Suganami, H; Tanaka, S; Yoshida, A | 1 |
| Chin, KL; Hird, TR; Liew, D; Magliano, DJ; Ofori-Asenso, R; Si, S; Zoungas, S | 1 |
| Aharon-Hananel, G; Raz, I | 1 |
| Khan, RS; Newsome, PN | 1 |
| Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Januzzi, J; Lund, LH; Ofstad, AP; Sattar, N; Savarese, G; Verma, S; Wanner, C; Zeller, C; Zinman, B | 1 |
| McMurray, JJV; Verma, S | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Desai, AS; Furtado, RHM; Gause-Nilsson, I; Goto, S; Johanson, P; Johansson, PA; Kato, ET; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Furtado, RHM; Gause-Nilsson, IAM; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Raz, I; Ruff, CT; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Bittencourt, RJ; Figueiredo, IR; Freire, NB; Patrocínio, MS; Pierdoná, N; Rose, SCP | 1 |
| Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Bosch, A; Dienemann, T; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
| Fernández-Ruiz, I | 1 |
| Bessette, LG; Brodovicz, KG; Déruaz-Luyet, A; Franklin, JM; Kulldorff, M; Najafzadeh, M; Patorno, E; Pawar, A; Sambevski, S; Santiago Ortiz, AJ; Schneeweiss, S | 1 |
| Dimitriadis, G; Hahalis, G; Katsiki, N; Mantzoros, C; Mikhailidis, DP; Papanas, N; Tentolouris, N; Triposkiadis, F; Tsimihodimos, V; Tsioufis, C | 1 |
| Arena, S; Avogaro, A; Berchialla, P; Bottigliengo, D; Buzzetti, R; D'Angelo, P; Fadini, GP; Franzetti, I; Sciannameo, V; Vinci, C | 1 |
| Tuttle, KR | 1 |
| Heerspink, HJL; Idzerda, NMA; Pena, MJ; Sjostrom, DC; Stefansson, BV; Wheeler, DC | 1 |
| Cheng, FR; Cui, HX; Fang, JL; Guo, Y; Yuan, K | 1 |
| Fujiwara, H; Gunji, R; Kaku, K; Kurihara, Y; Senda, M; Suganami, H; Tamura, M; Terauchi, Y | 1 |
| Abdelaziz, H; Al AdAwi, RM; Elgaily, D; Jassim, Z; Mohamed Ibrahim, MI; Sree, B | 1 |
| Baglioni, P | 1 |
| Raz, I; Sabatine, MS; Wiviott, SD | 1 |
| Guo, L; Li, J; Li, L; Li, X; Liu, H; Liu, R; Luo, Y; Mou, H; Yang, G; Yang, M; Zhang, C; Zhang, X; Zhang, Y | 1 |
| Kondo, H; Takahashi, N | 1 |
| Furukawa, S; Hiasa, Y; Matsuura, B; Miki, T; Miura, T; Ohnishi, H; Sato, T; Tanno, M | 1 |
| Polovina, MM; Seferović, JP; Seferović, PM | 1 |
| Al Rifai, M; Al-Mallah, MH; Jia, X; Martin, SS; Miedema, MD; Virani, SS | 1 |
| Aoshima, S; Arai, H; Inoue, T; Kosugi, R; Nakatani, E; Okamoto, K | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Davis, SN; Hedrington, M; Lamos, EM | 1 |
| Karagiannis, A; Loutradis, C; Papadopoulou, E; Sarafidis, P; Theodorakopoulou, M | 1 |
| Biancalana, E; Bruno, RM; Dardano, A; Ghiadoni, L; Giannini, L; Parolini, F; Rossi, C; Seghieri, M; Solini, A; Taddei, S | 1 |
| Brueckmann, M; Butler, J; Cheung, AK; Fitchett, D; George, J; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| de Boer, IH | 1 |
| Fujii, S; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Markham, A | 1 |
| Abraham, WT; Anker, SD; Brueckmann, M; Brun, M; Jamal, W; Lindenfeld, J; Macesic, H; Peil, B; Ponikowski, P; Salsali, A; Ustyugova, A; Zeller, C | 1 |
| Bruun, NE; Fosbøl, E; Frederiksen, PH; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Kitamura, K; Miyachi, Y; Mori, K; Nakamura, S; Ogawa, Y; Shiba, K; Tsuchiya, K | 1 |
| Hecking, M; Jenssen, T | 1 |
| Dhillon, S | 1 |
| Hwang, YC; Kim, JH; Lee, BW; Lee, WJ | 1 |
| Cooper, ME; Hantel, S; Inzucchi, SE; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Darshi, M; Heerspink, HJL; Kim, JJ; Laverman, GD; Mulder, S; Pena, MJ; Sharma, K | 1 |
| Chen, K; Jiang, Z; Liang, Y; Lu, M; Wang, Z; Zhou, J | 1 |
| Rothenberg, F; Schacht, S; Thompson, J | 1 |
| Bastie, CC; Kaira, K; Maeshima, A; Nakajima, Y; Okada, S; Shibusawa, R; Yamada, E; Yamada, M | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takahashi, K; Takase, T; Yamamoto, C; Yamauchi, Y; Yokota, I | 1 |
| George, JT; Kandaswamy, P; Kansal, A; Pfarr, E; Proskorovsky, I; Reifsnider, OS; Ruffolo, A; Zheng, Y | 1 |
| Fujii, K; Kin, H; Matsumoto, H; Matsumura, K; Otagaki, M; Park, H; Shibutani, H; Shiojima, I; Sugiura, T; Takahashi, H; Yamamoto, Y | 1 |
| Blak, BT; Fenici, P; Medina, J; Nolan, ST; Rigney, U; Wilding, JPH | 1 |
| Chen, H; Dong, T; Li, D; Li, J; Liu, H; Lou, Y; Song, X; Wang, J; Wang, Y; Xia, C; Zheng, T | 1 |
| Scholtes, RA; van Baar, MJB; van Raalte, DH | 1 |
| Chang, Y; Chen, L; Cheng, Y; Li, T; Li, X; Liu, X; Lu, Y; Sun, B; Wang, Y; Xu, L; Xue, M; Yu, X | 1 |
| Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L | 1 |
| Feng, M; Fu, S; Lv, H; Lyu, W; Wang, J; Xu, X | 1 |
| Alvarado-Díaz, CS; Gutiérrez-Méndez, N; Landeros-Martínez, LL; Leal-Ramos, MY; Mendoza-López, ML; Pérez-Vega, S; Quintero-Ramos, A; Rodríguez-Figueroa, JC; Rodríguez-Rodríguez, MZ; Rodríguez-Valdez, LM; Salmeron-Ochoa, I | 1 |
| Hishida, A; Hosoda, K; Koezuka, R; Makino, H; Matsuo, M; Miyamoto, Y; Ohata, Y; Son, C; Tamanaha, T; Tochiya, M; Tomita, T; Yasuda, S | 1 |
| Bailey, CJ; Del Prato, S; Reyner, D; Saraiva, G; Wei, C | 1 |
| Cho, YK; Jung, CH; Kang, YM; Lee, J; Lee, WJ; Park, JY; Yoo, JH | 1 |
| Cain, V; Chertow, GM; Goldenberg, R; Sartipy, P; Sjöström, CD; Stefánsson, BV; Toto, RD | 1 |
| Gan, N; Li, H; Sun, Q; Suo, Z; Tang, P; Wang, W; Wu, D; Zhao, L | 1 |
| Bodegard, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Rikner, K; Thuresson, M | 1 |
| Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM | 1 |
| Bailey, CJ; Gross, JL; Hennicken, D; Iqbal, N; List, JF; Mansfield, TA | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D | 1 |
| Anthony, S; Bajwa, H; Peter, R | 1 |
| Lam, SH; Lee, SS; Ruan, CT; Su, MJ | 1 |
| Elze, M; Hruba, V; Langkilde, AM; Parikh, S; Strojek, K; Yoon, KH | 2 |
| Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V | 2 |
| Del Prato, S; Nauck, M | 1 |
| del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, M; Parikh, SJ; Rohwedder, K | 1 |
| Kurosaki, E; Ogasawara, H | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Brownell, LA; Corneliusen, B; Jia, Q; Pantier, M; Yimam, M; Zhao, J | 1 |
| Ghosh, A; Heise, T; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S | 1 |
| Davis, SN; Lamos, EM; Younk, LM | 1 |
| Anuraj, NS; Jyoti, A; Mukesh, Y; Nishant, S; Prasoona, RK; Shobha, J | 1 |
| Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W | 1 |
| Traynor, K | 2 |
| Ikegai, K; Imamura, M; Kobayashi, Y; Koide, T; Kosakai, K; Kurosaki, E; Murakami, T; Nakanishi, K; Noda, A; Ohkura, Y; Ohta, M; Suzuki, T; Takeuchi, M; Tomiyama, H; Yokota, M | 1 |
| de Zeeuw, D; Lambers Heerspink, HJ; Leslie, B; List, J; Wie, L | 1 |
| Dobbins, RL; Hompesch, M; Hussey, EK; James, CD; Kapur, A; Mikoshiba, I; Nunez, DJ; O'Connor-Semmes, R; Polli, JW; Smith, GA; Tao, W | 1 |
| Curtin, CR; Devineni, D; Gutierrez, MJ; Murphy, J; Polidori, D; Rothenberg, PL; Rusch, S | 1 |
| Bode, B; Fung, A; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 1 |
| Bloomgarden, Z | 1 |
| Demaris, KM; White, JR | 1 |
| Elkinson, S; Scott, LJ | 1 |
| Lange-Chenier, H | 1 |
| Boulton, DW; Ching, A; DeFronzo, RA; Griffen, SC; Hompesch, M; Hong, Y; Kasichayanula, S; LaCreta, FP; Leslie, BR; Liu, X; Morrow, LA; Pfister, M | 1 |
| Harris, KB; Riser Taylor, S | 1 |
| Hardy, E; Johnsson, E; List, J; Parikh, S; Ptaszynska, A | 1 |
| Freeman, JS | 1 |
| Fukazawa, M; Fukuzawa, T; Honda, K; Kawabe, Y; Mori, T; Nagata, T; Nihei, T; Suzuki, Y; Takeda, M | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Maruyama, N; Susuta, Y; Yoshinari, T | 1 |
| Abdul-Ghani, MA; DeFronzo, RA | 1 |
| Gebel, E | 1 |
| Babu, A | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH | 1 |
| Diamant, M; Morsink, LM | 1 |
| Broedl, UC; Halabi, A; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ | 1 |
| Broedl, UC; Cinca, R; Macha, S; Mattheus, M; Pinnetti, S; Rose, P; Woerle, HJ | 1 |
| de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Stein, P; Vercruysse, F | 1 |
| Hach, T; Hantel, S; Jelaska, A; Pinnetti, S; Rosenstock, J; Seman, LJ; Woerle, HJ | 1 |
| Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ | 1 |
| Bolinder, J; Johansson, L; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sjöström, CD; Sugg, J; Wilding, J | 2 |
| Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V | 1 |
| Bergsma, TT; Gastonguay, MR; MacGregor, TR; Macha, S; Riggs, MM; Seman, L; Staab, A | 1 |
| Jungemann, S; Van Gilder, D | 1 |
| Broedl, UC; Häring, HU; Meinicke, T; Merker, L; Seewaldt-Becker, E; Weimer, M; Woerle, HJ | 2 |
| Kvapil, M | 2 |
| Broedl, UC; Kim, G; Ridderstråle, M; Svaerd, R; Woerle, HJ; Zeller, C | 1 |
| Hernandez, GT; Said, S | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Elisaf, MS; Rizos, EC | 1 |
| Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ | 1 |
| Bagga, P; Biswas, D; Kamal, MA; Rizvi, SM; Shaikh, S; Shakil, S | 1 |
| Fioretto, P; Kohan, DE; List, JF; Tang, W | 2 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Husser, C; Kawashima, K; Kemei, T; Kuhlmann, O; Pähler, A; Schwab, D; Uchimura, T; Yamane, M; Zell, M | 1 |
| An, Z; Li, S; Song, H; Wu, B; Zhang, L; Zhang, M | 1 |
| Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP | 1 |
| Kirk, R | 2 |
| Kilov, G; Leow, S; Thomas, M | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Akhtar, N | 1 |
| Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ | 1 |
| Vouyiouklis, M | 2 |
| le Roux, CW; Miras, AD | 1 |
| Che, WS; Chen, X; Leung, SW; Sun, YN; Zhou, Y | 2 |
| Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S | 1 |
| Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G | 1 |
| Bergenheim, K; McEwan, P; Pompen, M; Roudaut, M; Townsend, R; van Haalen, HG | 1 |
| Gilbert, RE | 2 |
| Baker, WL; Nigro, SC; Pheng, M; Riche, DM | 1 |
| Dietrich, E; Powell, J; Taylor, JR | 1 |
| Davis, SN | 1 |
| Mannucci, E; Monami, M; Nardini, C | 1 |
| Balis, DA; Meininger, G; Tong, C | 1 |
| Grassos, CE; Kallikazaros, IE; Katsi, VK; Lekakis, JP; Makris, TK; Michalakeas, CA; Stefanadis, CI; Tousoulis, D; Vamvakou, GD | 1 |
| Doggrell, SA; McIntyre, K | 1 |
| Iqbal, N; Ji, L; Li, H; List, JF; Ma, J; Mansfield, TA; Ptaszynska, A; T'joen, CL | 1 |
| Capuano, G; Fung, A; Nicolle, LE; Usiskin, K | 1 |
| Liu, X; Tan, J; Wang, B; Xiao, L; Yang, X; Zhou, X; Zhu, L | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD | 1 |
| García, SD | 1 |
| García, SD; Sanz, AD; Sanz, SD | 1 |
| Mauricio, D | 1 |
| Albarrán, OG; Ampudia-Blasco, FJ | 1 |
| Mikhail, N | 3 |
| Lee, J; Li, X; Lü, ZR; Park, YD; Shen, D; Sheng, Q; Shi, L; Yao, L; Zhang, Q; Zhang, X; Zhou, HM | 1 |
| Cefalu, WT | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Baldi, S; Broedl, UC; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Woerle, HJ | 1 |
| Seufert, J | 2 |
| Matthaei, S | 1 |
| Schnell, O | 1 |
| Gonzalez-Saldivar, G; Rodríguez-Gutiérrez, R | 1 |
| Keller, DL | 1 |
| Grandy, S; Langkilde, AM; Parikh, S; Sjöström, CD; Sugg, JE | 1 |
| Araki, E; Iwamoto, Y; Kaku, K; Ohtsuka, W; Suganami, H; Tanizawa, Y; Terauchi, Y; Tobe, K; Utsunomiya, K; Watada, H; Watanabe, D | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Capuano, G; Fung, A; Mayer, C; Nyirjesy, P; Sobel, JD; Usiskin, K; Ways, K | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Jones, B | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Broedl, UC; Delafont, B; Eilbracht, J; Kim, G; Roden, M; Weng, J; Woerle, HJ | 1 |
| Kumar, M; Kumar, R; Mahapatra, MK; Malla, P | 1 |
| Dungo, RT; Poole, RM | 1 |
| Araki, E; Iwamoto, Y; Kaku, K; Suganami, H; Tanizawa, Y; Terauchi, Y; Tobe, K; Ueda, M; Utsunomiya, K; Watada, H; Watanabe, D | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Gangadharan Komala, M; Mather, A | 1 |
| Bode, B; Desai, M; Fung, A; Harris, S; Mayer, C; Meininger, G; Shaw, W; Sinclair, A; Usiskin, K; Vijapurkar, U | 1 |
| Athanasiadou, E; Bekiari, E; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Sarigianni, M; Tsapas, A | 1 |
| Edwards, R; Kline, I; Usiskin, K; Weir, MR; Xie, J | 1 |
| Pafili, K; Papanas, N | 1 |
| Remuzzi, G; Ruggenenti, P | 1 |
| Barnett, AH; Broedl, UC; Jones, R; Manassie, J; Mithal, A; Rattunde, H; Woerle, HJ | 1 |
| Chen, Z; Chintala, M; Feng, W; Graziano, MP; Li, Q; Shang, J; Wang, M; Wu, W; Wu, Y | 1 |
| Plosker, GL | 3 |
| Bergenheim, K; Ekman, M; Granström, O; McEwan, P; Sabale, U | 1 |
| Poole, RM; Prossler, JE | 1 |
| Baggett, S; Elmore, LK; Kyle, JA; Skelley, JW | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J | 2 |
| Davis, CS; Fleming, JW; Warrington, LE | 1 |
| Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Tokudome, T; Ueda, N; Yang, J | 1 |
| Deng, YX; He, MY; Lv, Y; Shi, QZ; Zhang, XJ | 1 |
| Fung, A; Kline, I; Mayer, C; Meininger, G; Usiskin, K | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J | 1 |
| Goto, K; Kashiwagi, A; Kazuta, K; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Bluhmki, E; Broedl, UC; Ferrari, R; Fitchett, D; Hantel, S; Inzucchi, SE; Johansen, OE; Kempthorne-Rawson, J; Lachin, JM; Newman, J; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Bartaun, C; Gembardt, F; Hohenstein, B; Hugo, C; Jarzebska, N; Mayoux, E; Todorov, VT | 1 |
| Andersen, KR; Broedl, UC; Kim, G; Ridderstråle, M; Woerle, HJ; Zeller, C | 1 |
| Tahrani, AA | 1 |
| Chung, SH; Kim, GW | 1 |
| Broedl, UC; Haneda, M; Inagaki, N; Kadowaki, T; Koiwai, K; Rattunde, H; Taniguchi, A; Terauchi, Y; Woerle, HJ | 2 |
| Gastonguay, MR; Gillespie, W; MacGregor, TR; Macha, S; Riggs, MM; Seman, LJ; Staab, A; Woerle, HJ | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Angelopoulos, TP; Doupis, J | 1 |
| Doggrell, SA; Tuli, R | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Susuta, Y; Takahashi, N; Yoshinari, T | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Bouwens, L; Chellan, N; Cnop, M; Da Cunha, DA; Himpe, E; Joubert, E; Ladriere, L; Louw, J; Mathijs, I; Muller, C; Roux, CR | 1 |
| Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H | 1 |
| Beckers, J; Hrabé de Angelis, M; Huypens, P; Neschen, S; Rathkolb, B; Scheerer, M; Schultheiss, J; Seelig, A; Suhre, K; Wolf, E; Wu, M; Wurst, W | 1 |
| Apanovitch, AM; de Bruin, TW; Johnsson, KM; List, JF; Parikh, SJ; Ptaszynska, A | 1 |
| Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N | 1 |
| Huang, YL; Lai, D; Shen, HP; Yang, XP; Zhong, XY | 1 |
| Akiyama, N; Kadokura, T; Kageyama, S; Kashiwagi, A; Kazuta, K; Nagase, I; Smulders, R; Utsuno, A; Yoshida, S | 1 |
| Chanda, S; Choudhury, SR; Das, S; Datta, A; Pathak, AN | 1 |
| Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H | 1 |
| Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G | 1 |
| Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Maruyama, K; Mori, Y; Ojima, K; Yaguchi, A; Yokoyama, A | 1 |
| Broedl, UC; Koiwai, K; Macha, S; Sakamoto, W; Salsali, A; Sarashina, A; Sasaki, T; Tanaka, Y; Ueki, K; Woerle, HJ | 1 |
| Furihata, K; Inagaki, N; Ishii, M; Kondo, K; Kuki, H; Sakai, M; Yoshinari, T | 1 |
| Burgess, L; de Bruin, TW; Hamer-Maansson, JE; Hruba, V; Korányi, L; Schumm-Draeger, PM | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Dobbins, R; Dorey, DJ; Kler, L; Lorimer, JD; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO | 1 |
| Christensen, M; Gluud, LL; Knop, FK; Storgaard, H; Vilsbøll, T | 1 |
| Almond, SR; Dobbins, R; Kemp, GL; Kler, L; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO | 1 |
| Nauck, MA | 1 |
| Brunton, S; Reid, TS | 1 |
| Broedl, UC; Green, A; Narko, K; Salsali, A; Tikkanen, I; Woerle, HJ; Zeller, C | 1 |
| Scott, LJ | 1 |
| Barnett, AH; Jahagirdar, V | 1 |
| Hayashizaki, Y; Kurosaki, E; Tahara, A; Takakura, S; Takasu, T | 1 |
| Mediavilla Bravo, JJ | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, W; Leeflang, S; Nakajo, I; Smulders, R; Taniuchi, Y; Zhang, W | 1 |
| Lajara, R | 1 |
| Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Fung, A; Gilbert, RE; Januszewicz, A; Kline, I; Meininger, G; Vijapurkar, U; Weir, MR | 1 |
| Boyle, LD; Wilding, JP | 1 |
| Vallon, V | 1 |
| Bennett, H; Bergenheim, K; McEwan, P; Ward, T | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K | 1 |
| Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P | 1 |
| Buysman, EK; Chow, W; Henk, HJ; Rupnow, MF | 1 |
| Bailey, CJ; List, JF; Morales Villegas, EC; Ptaszynska, A; Tang, W; Woo, V | 1 |
| Svačina, S | 1 |
| Davidson, JA; Kuritzky, L | 1 |
| Carnovale, A; Durante, C; Filetti, S; Maranghi, M; Tarquini, G; Tiseo, G | 1 |
| Robson, AF; Shipman, KE | 1 |
| Hardy, E; Jabbour, S; Parikh, S; Wilding, J | 1 |
| Huang, W; Li, Y; Li, Z; Qian, H; Wang, X; Yang, B | 1 |
| Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K | 1 |
| Cherney, DZ; Škrtić, M | 1 |
| Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Al-Busaidi, N; Rizvi, AA; Rizzo, M | 1 |
| Narendran, P; Saeed, MA | 1 |
| Choksi, R; Epstein, B; Rosenwasser, JN; Rosenwasser, RF; Sutton, D | 1 |
| Almodóvar Carretón, MJ; Escudero Vilaplana, B; Herrero Hernández, S | 1 |
| Abad Paniagua, EJ; Betegón Nicolás, L; Brosa, M; Casado Escribano, P; Fernández Rodriguez, JM; Morales Escobar, FJ; Sánchez-Covisa, J | 1 |
| Cai, W; Jiang, L; Liu, W; Liu, Y; Xie, Y; Zhao, G | 1 |
| Barengo, NC; MacKinnon, I; Sposetti, G | 1 |
| Doggrell, S | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 2 |
| Bowering, K; Grohl, A; Matthaei, S; Parikh, S; Rohwedder, K | 1 |
| Rušavý, Z | 1 |
| Davis, PN; Ndefo, UA; Oliver, A | 1 |
| Mehr, SR; Zimmerman, MP | 1 |
| Broedl, UC; Hach, T; Inoue, K; Koiwai, K; Lund, SS; Nishimura, R; Salsali, A; Tanaka, Y | 1 |
| Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ | 1 |
| Dailey, G | 1 |
| Miller, SA; Powell, J; Taylor, JR | 1 |
| Pelikánová, T | 1 |
| Vivian, EM | 1 |
| Abdul-Ghani, M; Chavez-Velazquez, A; Daniele, G; DeFronzo, RA; Mari, A; Merovci, A; Solis-Herrera, C; Tripathy, D; Urban McCarthy, S; Xiong, J | 1 |
| White, JR | 1 |
| Abdul-Ghani, M | 1 |
| Bakris, GL; Majewski, C | 1 |
| Cornell, S | 1 |
| Huang, W; Jiao, L; Li, Z; Qian, H; Qiu, Q; Wang, X; Xu, X | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A | 1 |
| Kaku, S; Takakura, S; Takasu, T | 1 |
| Rupprecht, H | 1 |
| Bai, X; Bian, F; Chen, X; Chi, J; Jin, S; Li, W; Wu, D; Wu, G; Xing, S; Yang, X; Zhang, Y; Zheng, T | 1 |
| Araki, E; Broedl, UC; Kim, G; Koiwai, K; Salsali, A; Tanaka, Y; Taniguchi, A; Tanizawa, Y; Woerle, HJ | 1 |
| Aronson, R | 1 |
| Blevins, T | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Rupnow, MF; Vijapurkar, U | 1 |
| Prázný, M; Slíva, J | 1 |
| Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R | 2 |
| Broedl, UC; Cescutti, J; Meinicke, T; Ross, S; Thamer, C; Woerle, HJ | 1 |
| Miller, S; Onge, ES; Whalen, K | 1 |
| Alameddine, A; Ayer, A; Bourreau, J; Custaud, MA; Derbre, S; Fajloun, Z; Gauguier, D; Gauquelin-Koch, G; Navasiolava, N; Yuan, M | 1 |
| Han, J; Inaguma, T; Isoda, H; Matsukawa, T; Villareal, MO | 1 |
| Solini, A | 1 |
| Hashemi, M; Johnsson, E; Ptaszynska, A; Sjöström, CD; Sugg, J | 1 |
| Johansson, P; Johnsson, E; List, J; Ptaszynska, A; Sjöström, CD | 1 |
| Pickl, S | 1 |
| Broedl, UC; Christiansen, AV; Häring, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ | 1 |
| Broedl, UC; Jelaska, A; Kim, G; Rosenstock, J; Woerle, HJ; Zeller, C | 1 |
| Buschur, EO; Buse, JB; Cohan, P; Diner, JC; Hirsch, IB; Peters, AL | 1 |
| Blau, JE; Rother, KI; Taylor, SI | 1 |
| Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X | 1 |
| Broedl, UC; Christiansen, AV; Kim, G; Kovacs, CS; Merker, L; Roux, F; Salsali, A; Seshiah, V; Stella, P; Woerle, HJ | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Beck, A; Beyer, U; Boerlin, V; Christ, AD; Ciorciaro, C; Cynshi, O; Ikeda, S; Kadowaki, T; Meyer, M; Takano, Y; Tanaka, R | 1 |
| Crowe, S; Ferrannini, E; Ferrannini, G; Hach, T; Hall, KD; Sanghvi, A | 1 |
| Fath, R | 1 |
| Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J | 1 |
| Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE | 1 |
| Dohi, K; Fujii, E; Fujimoto, N; Ito, M; Moriwaki, K; Nakamori, S; Omori, T; Sato, Y; Takeuchi, T; Yamada, N | 1 |
| Clements, JN; D'Souza, JJ; Gentry, C; Gross, B; Hess, R; Reece, S; Shealy, K; Whitley, HP | 1 |
| Bagger, JI; Knop, FK; Rungby, J; Storgaard, H; Vilsbøll, T | 1 |
| Woo, V | 1 |
| Deeks, ED; Kim, ES | 1 |
| Broedl, UC; Christiansen, AV; Haering, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ | 1 |
| Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S | 1 |
| Hattersley, AT; Thorens, B | 1 |
| Broedl, UC; Cannon, CP; Chilton, R; Crowe, S; Johansen, OE; Tikkanen, I; Woerle, HJ | 1 |
| Bluhmki, E; Broedl, UC; Devins, T; Fitchett, D; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Stephens, JW; Williams, DM | 1 |
| Chirila, C; Davenport, E; Hach, T; Kaschinski, D; Palencia, R; Pfarr, E; Zheng, Q | 1 |
| Vivian, E | 1 |
| Kaneto, H; Matsuoka, TA; Miyatsuka, T; Shimo, N; Shimomura, I; Takahara, M; Takebe, S; Tochino, Y | 1 |
| Fioretto, P; Giaccari, A; Sesti, G | 1 |
| Ishii, S; Kato, H; Nagai, Y; Nakamura, Y; Nishine, A; Ohta, A; Tanaka, Y; Terashima, Y | 1 |
| Dailey, GE | 1 |
| Boulton, DW; Johnsson, E; LaCreta, F; Leil, TA; Tang, W | 1 |
| Broedl, UC; Mondick, J; Retlich, S; Riggs, M; Sarashina, A; Sasaki, T | 1 |
| Okada, J; Okada, S; Osaki, A; Saito, T; Shibusawa, R; Shimoda, Y; Tagaya, Y; Yamada, E; Yamada, M | 1 |
| Grandy, S; Rohwedder, K; Ryden, A; Sternhufvud, C; Sugg, J | 1 |
| Dixit, D; Mansukhani, RP; Volino, LR; Yoon, Y | 1 |
| Hayashi, A; Kawai, S; Shichiri, M; Takano, K | 1 |
| Abbas, A; Bustamante, M; Farah, Z; Gosavi, S; Mukherjee, D; Said, S; Shami, W; Syed, SH; Teleb, M | 1 |
| Hu, J; Tan, X | 1 |
| Yacoub, T | 1 |
| Abdul-Ghani, M; Cersosimo, E; Defronzo, RA; Solis-Herrera, C; Triplitt, C | 1 |
| Adkins, SE; Bokaie, BB; Shubrook, JH | 1 |
| Han, P; Iqbal, N; Johnsson, E; Mansfield, T; Min, KW; Ptaszynska, A; T'Joen, C; Wang, B; Yang, W | 1 |
| Muskiet, MH; Smits, MM; Tonneijck, L; van Bommel, E; van Bommel, EJ; van Raalte, DH | 1 |
| Ceriello, A; Genovese, S; Gronda, E; Mannucci, E | 2 |
| Connelly, KA; Gilbert, RE | 1 |
| Basu, S; Naci, H; Yudkin, JS | 1 |
| Ingelfinger, JR; Rosen, CJ | 2 |
| Hirano, T; Hiromura, M; Kohashi, K; Kushima, H; Mori, Y; Nagashima, M; Terasaki, M; Watanabe, T | 1 |
| Close, KL; Gao, HX; Regier, EE | 1 |
| Bloomgarden, ZT | 1 |
| Cain, VA; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA | 1 |
| Malhotra, S; Shafiq, N | 1 |
| Alessi, F; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA | 1 |
| Peters, MN; Pollock, JS; Rajagopalan, S | 1 |
| Hamamoto, H; Noda, M | 1 |
| McGuire, DK; Neeland, IJ; Salahuddin, U | 1 |
| Broedl, UC; Christiansen, AV; Kim, G; Merker, L; Roden, M; Roux, F; Salsali, A; Stella, P; Woerle, HJ | 1 |
| Astiarraga, B; Barsotti, E; Broedl, UC; Ferrannini, E; Heise, T; Mari, A; Muscelli, E; Nosek, L; Schliess, F; Woerle, HJ | 1 |
| Dixon, JB | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Mawatari, H; Nakajima, A; Ogawa, Y; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Mari, A; Merovci, A; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Shekelle, P | 1 |
| Nakamura, I; Sugamori, H; Terauchi, Y; Yokote, K | 2 |
| Chilton, R; Johansen, OE; Tikkanen, I | 1 |
| Weir, MR | 1 |
| Biagetti, B; Dalama, B; Mesa, J | 1 |
| Hayashizaki, Y; Takakura, S; Takasu, T; Toyoshi, T | 1 |
| Huang, Y; Lai, D; Yang, X; Ye, Y; Yu, B; Zhong, X | 1 |
| Chen, C; Huang, H; Huang, J; Li, J; Liu, P; Wang, Y; Ye, J | 1 |
| Miller, EM; Miller, K | 1 |
| Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR | 1 |
| Broedl, UC; Chilton, R; Crowe, S; Johansen, OE; Lund, SS; McGuire, DK; Neeland, IJ; Woerle, HJ | 1 |
| Cherney, DZ; Lytvyn, Y; Rajasekeran, H | 1 |
| Kamaruddin, NA; Kori, N; Mohd Noor, N; Mustafa, N; Othman, H; Rajoo, S; Sukor, N; Wahab, NA; Wan Seman, WJ | 1 |
| Fioretto, P; Johnsson, K; Kohan, DE; Parikh, S; Ptaszynska, A; Ying, L | 1 |
| Gause-Nilsson, I; Johansson, PA; Johnsson, E; Sonesson, C | 1 |
| Shyangdan, DS; Uthman, OA; Waugh, N | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Abdul-Ghani, M; Chilton, R; Clarke, G; DeFronzo, RA; Norton, L; Ryder, RE | 1 |
| Maltezos, ES; Papanas, N; Tsioufis, C | 1 |
| Ebell, MH | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Cain, VA; Gause-Nilsson, I; Heerspink, HJ; Johnsson, E; Sjöström, CD | 1 |
| Fu, XJ; Hou, S; Li, M; Yang, XH; Zhang, CZ; Zhang, XR; Zhu, DS | 1 |
| Geissel, W | 1 |
| Huan, Y; Liu, Z; Pan, X; Shen, Z | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Stiefelhagen, P | 2 |
| Zechmann, S | 1 |
| Inzucchi, SE; Lachin, JM; Zinman, B | 1 |
| Sarafidis, PA; Tsapas, A | 1 |
| Edwards, JL | 1 |
| Fischereder, M; Schönermarck, U | 1 |
| Hough, A; Rosenstein, R | 1 |
| Müller-Wieland, D | 1 |
| Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J | 1 |
| Bandyopadhyay, D; Biswas, M; Ghosh, RK; Gupta, A; Hajra, A | 1 |
| Kawai, T; Meguro, S; Sano, M; Suzuki, Y | 1 |
| Prasad, K; Rosano, GM; Vitale, C | 1 |
| Jäger, AK; Staerk, D; Trinh, BTD | 1 |
| Bonnes, H; Katz, A; Skolnik, N; Yeh, H | 1 |
| Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A | 1 |
| Atsumi, T; Ichiyama, M; Kameda, R; Miyoshi, H; Nakamura, A; Nomoto, H; Ono, K; Sugawara, H; Yamamoto, C; Yamamoto, K | 1 |
| Hirate, M; Kutoh, E; Murayama, T; Wada, A | 2 |
| Davies, MJ; Htike, ZZ; Khunti, K; Webb, DR; Youssef, D; Zaccardi, F | 1 |
| Ghosh, A; Gupta, R; Misra, A | 1 |
| Broedl, UC; Hantel, S; Kaspers, S; Kim, G; Kohler, S; Salsali, A; Woerle, HJ | 1 |
| Athyros, VG; Boutari, C; Imprialos, KP; Karagiannis, AI; Stavropoulos, K | 1 |
| Hemmingsen, B; Krogh, J; Metzendorf, MI; Richter, B | 1 |
| Mellbin, L; Rydén, L; Shahim, B | 1 |
| Kristensen, SL; McLaren, J; McMurray, JJ; Preiss, D; Sattar, N | 1 |
| Gupta, Y; Kalra, S; Kishor, K | 1 |
| Igarashi, K; Li, Y; Zang, Y | 1 |
| Laubner, K; Seufert, J | 1 |
| Farooq, S; Islam, N; Kiran, Z; Rashid, O | 1 |
| Ahmed-Sarwar, N; Nathan, KT; Werner, P | 1 |
| Edelsberger, T | 1 |
| Gunji, R; Kaku, K; Kameda, H; Kurihara, Y; Mihara, H; Senda, M; Shimmoto, N; Tamura, M; Utsunomiya, K | 1 |
| Araki, E; Asano, M; Ekholm, E; Johnsson, E; Kim, H; Onishi, Y; Yajima, T | 1 |
| Kashiwagi, A; Kawamuki, K; Kazuta, K; Kosakai, Y; Nakamura, I; Satomi, H; Takahashi, H; Ueyama, E; Yoshida, S | 1 |
| Hoshi, H; Niijima, Y; Okada, S; Ono, K; Osaki, A; Saito, T; Yamada, E; Yamada, M | 1 |
| Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S | 1 |
| Schernthaner, G; Schernthaner, GH; Schernthaner-Reiter, MH | 1 |
| Valek, R; Von der Mark, J | 1 |
| Kourlaba, G; Maniadakis, N; Tentolouris, N; Tzanetakos, C | 1 |
| Torjesen, I | 1 |
| Murín, J | 1 |
| Perseghin, G; Solini, A | 1 |
| Crowe, S; Hach, T; Lee, J; Nishimura, R; Salsali, A; Woerle, HJ; Yoon, KH | 1 |
| Arnheim, K | 1 |
| Alloju, S; Henry, RR; Mudaliar, S | 1 |
| Ferrannini, E; Mark, M; Mayoux, E | 1 |
| Boulton, DW; Ismat, FA; LaCreta, F; Tang, W; Tirucherai, GS | 1 |
| Levine, MJ | 1 |
| Boulton, DW; Hamrén, B; Johansson, CC; Parkinson, J; Tang, W | 1 |
| Broedl, UC; Fitchett, D; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Kawaguchi, M; Mori, H; Okada, Y; Tanaka, Y | 1 |
| Chellan, N; Joubert, E; Malherbe, CJ; Miura, Y; Muller, CJF; Yagasaki, K | 1 |
| Cain, VA; Fioretto, P; Johnsson, E; Sjöström, CD; Stefansson, BV | 1 |
| Cherney, D; Cooper, ME; Groop, PH; Kaspers, S; Lund, SS; Perkins, BA; Pfarr, E; von Eynatten, M; Woerle, HJ | 1 |
| Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
| Cha, BS; Chuang, LM; Kokubo, S; Lu, CH; Min, KW; Yoshida, S | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Qi, X; Wang, K; Wu, Y; Zhu, Q | 1 |
| Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y | 1 |
| Bonadonna, RC; Borghi, C; Consoli, A; Volpe, M | 1 |
| Broedl, UC; Hantel, S; Kim, G; Salsali, A; Woerle, HJ | 1 |
| Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Hsu, YH; Li, DD; Song, YQ; Tang, HL; Wang, TS; Zhai, SD; Zhang, JJ | 1 |
| Ishibashi, Y; Matsui, T; Yamagishi, SI | 1 |
| Bloch, MJ | 1 |
| Asahina, S; Ishihara, H; Nakao, I; Okitsu, A; Yamaguchi, S | 1 |
| DeFronzo, RA; Rajeev, SP; Wilding, JP | 1 |
| Busetto, L; Fioretto, P; Rossato, M; Vettor, R; Zambon, A | 1 |
| Carlson, CJ; Santamarina, ML | 1 |
| Lam, S | 1 |
| Billger, M; Johnsson, E; Johnsson, K; Mellander, A; Träff, AK; Yoshida, S | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K | 1 |
| Patel, BM; Shah, NR | 1 |
| Dicembrini, I; Mannucci, E; Monami, M | 1 |
| Broedl, UC; Hadjadj, S; Meinicke, T; Rosenstock, J; Woerle, HJ | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| Javor, E; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Grant, PJ | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Norton, L; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I | 1 |
| Cui, W; Li, D; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Albuquerque Rocha, N; McGuire, DK; Neeland, IJ; Pham, D | 1 |
| Hou, SK; Kao, WF; Li, SJ; Wang, AY | 1 |
| Ebihara, K; Ishibashi, S; Kotani, K; Okada, K; Yamazaki, H | 1 |
| Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Cain, VA; Ji, L; Johnsson, KM; Sjöström, CD; Yang, W; Zhou, Z | 1 |
| Del Gobbo, LC; Li, Y; Song, Y; Tang, H; Zhai, S; Zhang, J; Zhang, X | 1 |
| Mudher Mikhael, E | 1 |
| Knop, FK; Rungby, J; Røder, ME; Storgaard, H; Vilsbøll, T | 1 |
| Lei, H; Liu, J; Mei, Y; Ni, N; Niu, B; Wang, J; Xu, J; Yang, X | 1 |
| Hernández, C; Simó, R | 1 |
| Muskiet, MH; Smits, MM; Tonneijck, L; van Bommel, EJ; van Raalte, DH | 1 |
| Dalama, B; Mesa, J | 1 |
| Broedl, UC; Heer, M; Heise, T; Jordan, J; Lund, SS; Macha, S; Mattheus, M; Wanner, C; Woerle, HJ | 1 |
| Schatz, H | 1 |
| Khandelwal, S; Naing, S; Poliyedath, A; Sigala, T | 1 |
| Babu, RJ; Dash, RP; Srinivas, NR | 1 |
| Gao, G; Li, FF; Li, Q; Ma, JH; Su, XF; Wu, JD; Ye, L; Zhu, HH | 1 |
| Patel, T | 1 |
| Kaku, K; Kaneto, H; Kimura, T; Matsuoka, TA; Obata, A; Okauchi, S; Shimo, N; Shimoda, M | 1 |
| Wise, J | 1 |
| Emoto, N; Hattori, N; Nagamine, T; Nakamura, Y; Okajima, F; Sugihara, H | 1 |
| Broedl, UC; Gallwitz, B; Götz, S; Maldonado-Lutomirsky, M; Nordaby, M; Tinahones, FJ; Woerle, HJ | 1 |
| Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 2 |
| Di Franco, A; Luconi, M; Mannucci, E; Raimondi, L | 1 |
| Ahn, YB; Chung, S; Kim, ES; Kim, JW; Kim, MJ; Kim, SJ; Ko, SH; Lee, EM; Moon, SD; Shin, SJ; Yoo, YH | 1 |
| Koiwai, K; Okamura, T | 1 |
| Cusi, K | 1 |
| Dong, H; Gu, S; Mu, Y; Zeng, Y; Zhai, S; Zhen, X | 1 |
| Inzucchi, SE; Wanner, Ch; Zinman, B | 1 |
| Wakisaka, M | 1 |
| Chandurkar, N; Naidu, K; Pareek, A | 1 |
| Inzucchi, SE; Stamatouli, AM | 1 |
| Chan, P; Hu, M; Liu, ZM; Tomlinson, B; Zhang, Y | 1 |
| Liu, S; Mir, MU; Shao, H; Shi, L; Shi, Q; Zawadzki, NK; Zhai, S; Zou, D | 1 |
| Hu, J; Tan, X; Zhang, S; Zhou, M; Zou, P | 1 |
| Reed, JW | 1 |
| Bennett, C; Christensen, MB; Gluud, LL; Grøndahl, MF; Knop, FK; Storgaard, H; Vilsbøll, T | 1 |
| Kato, H; Nagai, Y; Ohta, A; Sada, Y; Tanaka, Y | 1 |
| Abdulsalim, S; Chakraborty, I; Devi, R; Mali, G; Unnikrishnan, MK | 1 |
| Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E | 1 |
| Davidson, JA; Sloan, L | 1 |
| Dong, Y; Fang, Z; Li, D; Shen, S; Tang, H; Wang, T | 1 |
| Rossello, X; Yellon, DM | 1 |
| Choi, SH; Han, JH; Jang, HC; Kim, KM; Kim, YB; Lee, DH; Lee, G; Lee, HS; Lim, S; Maeng, HJ; Oh, TJ; Park, KS | 1 |
| Chan, SP; Lim, LL; Moses, K; Rajadhyaksha, V; Tan, AT | 1 |
| Gerstein, H; Jaeschke, R | 1 |
| Kufel, WD; Scrimenti, A; Steele, JM | 1 |
| Boutari, C; Doumas, M; Imprialos, KP; Karagiannis, AI; Stavropoulos, K | 1 |
| Cefalu, WT; Grove, O; Hsia, DS | 1 |
| Kristensen, FB; Lindberg, MJ; Yildiz, A | 1 |
| Cherney, DZ; Udell, JA | 1 |
| Mende, CW | 1 |
| Broedl, UC; Cannon, CP; Johansen, OE; Ley, L; Mancia, G; Tikkanen, I; Woerle, HJ; Zeller, C | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takase, T; Yamamoto, C | 1 |
| Araki, E; Asano, M; Kim, H; Onishi, Y; Yajima, T | 1 |
| Andersen, G; Falk, A; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
| George, J; Kaku, K; Kaspers, S; Lee, J; Mattheus, M; Woerle, HJ | 1 |
| Node, K; Tanaka, A | 1 |
| Ayer, A; Cariou, B; Charpentier, F; Dollet, L; Jagu, B; Joubert, M; Le May, C; Magré, J; Manrique, A; Marechal, X; Montaigne, D; Prieur, X; Staels, B; Tesse, A; Toumaniantz, G | 1 |
| Ho, CT; Huang, MT; Li, S; Liu, Y; Pan, MH; Tang, W; Wu, JC | 1 |
| Fioretto, P; Inzucchi, SE; Vettor, R | 1 |
| Zimmermann, J | 1 |
| Almodóvar-Ruiz, F; Feo-Ortega, G; Gorgojo-Martínez, JJ; Sanz-Velasco, A; Serrano-Moreno, C | 1 |
| Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y | 1 |
| Fukui, T; Hayashi, T; Hirano, T; Ito, Y; Nakanishi, N; Ohara, M; Osamura, A; Tomoyasu, M; Yamamoto, S; Yamamoto, T | 1 |
| Aroor, AR; Barron, B; DeMarco, VG; Garro, M; Habibi, J; Hayden, MR; Jia, G; Mayoux, E; Rector, RS; Sowers, JR; Whaley-Connell, A | 1 |
| Cha, BS; Kang, ES; Kim, G; Kim, SR; Lee, BW; Lee, JY; Lee, YH | 1 |
| Dore, TM; Jesus, AR; Machuqueiro, M; Marques, AP; Rauter, AP; Vila-Viçosa, D | 1 |
| Nuffer, WA; Trujillo, JM | 1 |
| Clar, C; Clegg, A; Colquitt, J; Court, R; Cummins, E; Holt, T; Johnston, R; McGrane, D; O'Hare, JP; Royle, P; Shantikumar, S; Tan, BK; Uthman, O; Waugh, N | 1 |
| Lazaridis, AA; Ruilope, LM; Ruiz-Hurtado, G; Sarafidis, PA | 1 |
| Fujii, S; Fujiwara, H; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Shimmoto, N; Tamura, M; Utsunomiya, K | 1 |
| Bando, YK; Murohara, T | 1 |
| Forst, T; Plum-Mörschel, L; Weber, MM | 1 |
| Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Triplitt, C | 1 |
| Hammar, N; Hankins, M; Kim, J; Tsai, K | 1 |
| Boyland, EJ; Cuthbertson, DJ; Halford, JC; Harrold, JA; Kemp, GJ; Rajeev, SP; Roberts, C; Sprung, VS; Stancak, A; Wilding, JP | 1 |
| Bour, L; Brendel, M; Broedl, UC; Häring, HU; Haupt, A; Machicao, F; Salsali, A; Staiger, H; Woerle, HJ; Zimdahl, H | 1 |
| Garnock-Jones, KP | 1 |
| Kazazis, C; Trigkidis, K; Vallianou, NG | 1 |
| Bramlage, P; Friedrich, S; Jumar, A; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
| Li, D; Li, Y; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH | 1 |
| Turner, JR | 1 |
| Avogaro, A; Fioretto, P | 1 |
| Gause-Nilsson, I; Johnsson, E; Kosiborod, M; Sonesson, C; Xu, J | 1 |
| Kutoh, E; Murayama, T; Takizawa, Y; Wada, A | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, SI | 1 |
| Alzaid, A | 1 |
| Busch, S; Kostev, K; Pscherer, S; Rist, R; Scheerer, MF | 1 |
| Ejskjaer, N; Heinemann, L; Klonoff, D; Pfützner, A; Pickup, J | 1 |
| Goldstein, BJ; Jabbour, SA | 1 |
| Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V | 1 |
| Donnelly, R; Idris, I | 1 |
| Boulton, D; Geraldes, M; Komoroski, B; Kornhauser, D; Li, L; Pfister, M; Vachharajani, N | 1 |
| Feng, Y; Komoroski, B; Kornhauser, D; Li, L; Pfister, M; Vachharajani, N | 1 |
| Washburn, WN | 2 |
| Kipnes, M | 1 |
| Bastien, A; Fiedorek, FT; List, JF; Norwood, P; T'joen, C; Wilding, JP | 1 |
| Brooks, AM; Thacker, SM | 1 |
| Woo, VC | 1 |
| Calado, J | 1 |
| Amin, DM; Clark, RV; Dobbins, RL; Hussey, EK; Kipnes, MS; Layko, D; Leong, J; Murray, SC; Nunez, DJ; O'Connor-Semmes, RL; O'Driscoll, EC | 1 |
| Aragão, DM; da Costa, JC; Garcia, RM; Guarize, L; Lanini, J; Scio, E | 1 |
| Campbell, RK; Neumiller, JJ; White, JR | 1 |
| Chen, Y; Dong, J; Feng, Y; Lv, B; Seed, B; Sheng, Z; Welihinda, A; Xu, B; Xu, M; Zhang, W | 1 |
| Feng, Y; Kasichayanula, S; List, J; Pfister, M; Zhang, L | 1 |
| Sharma, K; Vallon, V | 1 |
| Ferrannini, E; List, JF; Ramos, SJ; Salsali, A; Tang, W | 1 |
| Forst, T; Hanefeld, M | 1 |
| Bailey, CJ; Bastien, A; Gross, JL; List, JF; Pieters, A | 1 |
| Hongu, M; Kawanishi, E; Kimata, H; Koga, Y; Nakayama, K; Nomura, S; Sakamaki, S; Sakamoto, T; Tsuda-Tsukimoto, M; Ueta, K; Yamamoto, Y | 1 |
| Jones, HB; Macdonald, FR; Mayers, RM; Peel, JE; Poucher, SM; Westgate, L; Whaley, JM | 1 |
| Goyal, RK; Vaidya, HB | 1 |
| Katsiki, N; Mikhailidis, DP; Papanas, N | 1 |
| Cano Megías, M; González Albarrán, O; Pérez López, G | 1 |
| Chang, CC; Chao, YS; Chen, CT; Chiu, CH; Chu, KF; Hsiao, WC; Hsieh, CJ; Hsieh, TC; Huang, CY; Hung, MS; Lee, JC; Liu, YW; Song, JS; Tsai, CH; Wang, MH; Wu, SH; Yao, CH; Yeh, TK; Yuan, MC | 1 |
| Boulton, DW; Chang, M; Hasegawa, M; Imai, Y; Kasichayanula, S; LaCreta, FP; Liu, X; Yamahira, N | 1 |
| Gong, N; Wang, YX; Zhang, WB | 1 |
| Chao, EC | 2 |
| Chien, S; Demarest, K; Devineni, D; Ghosh, A; Polidori, D; Rothenberg, P; Sha, S; Shalayda, K; Wexler, D | 1 |
| Cassader, M; Gambino, R; Musso, G; Pagano, G | 1 |
| Heger, M | 1 |
| Basile, J | 1 |
| Dobbins, RL; Golor, G; Hussey, EK; Kapitza, C; Kapur, A; Mikoshiba, I; O'Connor-Semmes, R; Tao, W | 1 |
| Chen, Y; Cheng, H; Ding, H; Dong, J; Du, J; Feng, Y; Li, S; Lv, B; Peng, K; Roberge, JY; Seed, B; Sheng, Z; Song, Y; Wang, C; Welihinda, A; Wu, Y; Xu, B; Xu, M; Zhang, T; Zhang, W; Zhu, L | 1 |
| Del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, MA; Parikh, SJ; Rohwedder, K | 1 |
| Akinlade, B; Klasen, S; Kowalski, D; Schwartz, SL; Wilpshaar, W; Zhang, W | 1 |
| Boustany-Kari, CM; Ghosh, A; Haddish-Berhane, N; Kimoto, E; Leininger, MT; Mascitti, V; Maurer, TS; Robinson, RP; Sawant-Basak, A; She, L; Tugnait, M; Yang, X; Zhu, T | 1 |
| Kadokura, T; Krauwinkel, WJ; Smulders, RA; Veltkamp, SA | 1 |
| Kardara, MS; Papazafiropoulou, AK; Pappas, SI | 1 |
| Ernest, P; Jandrain, BJ; Radermecker, RP; Scheen, AJ | 1 |
| Bakker, RA; Eckhardt, M; Eickelmann, P; Grempler, R; Himmelsbach, F; Klein, T; Mark, M; Sauer, A; Sharp, DE; Thomas, L | 1 |
| Bastien, A; Gerich, JE | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Noda, A; Qun, L; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 2 |
| Devineni, D; Hompesch, M; Morrow, L; Murphy, J; Schwartz, S; Skee, D; Vandebosch, A; Ways, K | 1 |
| Bolinder, J; Johansson, L; Kullberg, J; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sugg, J; Wilding, J | 1 |
| Barnett, AH; Bhartia, M; Tahrani, AA | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC | 1 |
| Burki, TK | 1 |
| Choksi, R; Deeb, WE; Epstein, BJ; Shah, NK | 1 |
| Fukazawa, M; Fukuzawa, T; Hagita, H; Honda, K; Ikeda, S; Kawabe, Y; Kawai, M; Kawai, T; Kobayashi, T; Ozawa, K; Sato, T; Suzuki, M; Takeda, M; Yata, T | 1 |
| Hennicken, D; Henry, RR; List, JF; Marmolejo, MH; Murray, AV; Ptaszynska, A | 1 |
| Smith, SA | 1 |
| Anderson, SL; Marrs, JC | 1 |
| List, JF; Rosenstock, J; Salsali, A; Vico, M; Wei, L | 1 |
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Ikegai, K; Imamura, M; Kobayashi, Y; Koide, T; Kosakai, K; Kurosaki, E; Murakami, T; Nakanishi, K; Noda, A; Ogiyama, T; Ohkura, Y; Ohta, M; Shiraki, R; Suzuki, T; Takeuchi, M; Tomiyama, H; Yokota, M | 1 |
| Simonyi, G | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
| Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y | 1 |
| Bailey, CJ; Iqbal, N; List, JF; T'joen, C | 1 |
| Collins, C; Kadokura, T; Smulders, RA; van Bruijnsvoort, M; van Dijk, J; Veltkamp, SA | 1 |
| Ahn, KH; Hagita, H; Ikeda, S; Kato, M; Kobayashi, T; Matsuoka, H; Morikawa, K; Nishimoto, M; Ohmori, M; Ohtake, Y; Ozawa, K; Sato, T; Suzuki, M; Taka, N; Takami, K; Takano, K; Yamaguchi, K; Yamaguchi, M; Yamamoto, K; Yeu, SY | 1 |
| Boulton, DW; Jabbour, SA; List, JF; Parikh, S; Poucher, SM; Reilly, TP; Saye, J; Tirmenstein, M; Whaley, JM | 1 |
| Shen, JK; Wan, HX | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; Lacreta, FP; Liu, X | 1 |
| Elvert, R; Glombik, H; Herling, AW; Wandschneider, J; Werner, U; Wille, A | 1 |
| Paisley, AJ; Paisley, AN; Rao-Balakrishna, P; Soran, H; Yadav, R; Younis, N | 1 |
| Chang, SS; Chen, CY; Chen, KC; Tsai, FJ | 1 |
| Dugi, KA; Koiwai, K; Negishi, T; Sarashina, A; Seman, LJ; Sesoko, S; Taniguchi, A; Woerle, HJ; Yamamura, N | 1 |
| Dhanjal, P; Ferrannini, E; Fonseca, VA; Houzer, A; Wilding, JP; Wilpshaar, W | 1 |
| Azuma, H; Hayashi, N; Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Matsuoka, O; Parikh, S; Tokudome, T | 1 |
| Boulton, DW; Humphreys, WG; Kasichayanula, S; LaCreta, FP; Liu, X; Pe Benito, M; Pfister, M; Yao, M | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K | 1 |
| Forst, T; Rosak, C | 1 |
| Chen, LH; Leung, PS | 1 |
| Hantel, S; Heise, T; Macha, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ | 1 |
| Ferrannini, E; Kadokura, T; Smulders, RA; Veltkamp, SA | 1 |
| Kolanczyk, DM; Nisly, SA; Walton, AM | 1 |
| Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ | 1 |
| Agger, A; Colombo, M; Gregersen, S; Hermansen, K; Jeppesen, PB; Jepsen, M; Kruhøffer, M; Orntoft, T; Rolfsen, SE; Xiao, J | 1 |
| Gregersen, S; Hermansen, K; Holst, JJ; Jeppesen, PB | 1 |
| Arakawa, K; Fujita, T; Ishihara, T; Matsumoto, Y; Nawano, M; Oku, A; Saito, A; Ueta, K | 1 |
| Abudula, R; Colombo, M; Dyrskog, SE; Hermansen, K; Jeppesen, PB | 1 |
| Donahue, EP; Fujimoto, Y; Shiota, M; Torres, TP | 1 |
| Isaji, M | 1 |
| Ashida, H; Fukuda, I; Horio, F; Hoshino, H; Ichi, T; Isa, Y; Kadowaki, M; Nishimura, N; Nishiumi, S; Sasaki, R; Tanaka, A; Tsuda, T | 1 |
| Biller, SA; Deshpande, PP; Discenza, L; Ellsworth, BA; Flint, OP; Girotra, RN; Hagan, DL; Han, S; Humphreys, WG; Janovitz, EB; Khanna, A; McCann, PJ; Meng, W; Morgan, N; Morrison, EP; Nirschl, AA; Obermeier, MT; Patel, M; Pullockaran, A; Robertson, JG; Sher, PM; Taylor, JR; Wang, A; Washburn, WN; Wetterau, JR; Whaley, JM; Wu, G; Zahler, R | 1 |
| Cheng, JT; Liu, IM; Liu, KY; Wu, YC; Yu, WC | 1 |
| Barriocanal, LA; Benitez, G; Benitez, S; Jimenez, JT; Jimenez, N; Palacios, M; Rojas, V | 1 |
| Ichiki, H; Ishihara, E; Komatsu, Y; Kubo, M; Miura, T; Okada, M; Tanigawa, K | 1 |
| Carlson, TJ; Fort, DM; Jolad, SD; King, SR; Luo, J; Mendez, CD; Ubillas, RP | 1 |
| Arakawa, K; Ishihara, T; Kitamura, K; Matsumoto, M; Nawano, M; Oku, A; Saito, A; Ueta, K | 1 |
| Hashimoto, I; Ichiki, H; Ishida, T; Ishihara, E; Iwamoto, N; Kato, M; Komatsu, Y; Kubo, M; Miura, T; Okada, M; Tanigawa, K | 1 |
| Prasad, K | 1 |
| Ichiki, H; Ishida, T; Iwamoto, N; Kato, M; Kubo, M; Miura, T; Okada, M; Sasaki, H; Seino, Y; Tanigawa, K | 1 |
| Alstrup, KK; Gregersen, S; Hermansen, K; Jeppesen, PB | 1 |
| Adachi, T; Fujimoto, S; Mukai, E; Nunoi, K; Okamoto, Y; Oku, A; Seino, Y; Shihara, N; Suzuki, N; Tamon, A; Tsuda, K; Yasuda, K | 1 |
357 review(s) available for glucose, (beta-d)-isomer and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
In brief: Dapagliflozin (Farxiga) for chronic kidney disease.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Review on Characteristics and Analytical Methods of Remogliflozin Etabonate: An Update.
Topics: Chromatography, Liquid; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry | 2022 |
Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Brachial Artery; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Vasodilation | 2022 |
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
Topics: Asia, Eastern; Benzhydryl Compounds; Delivery of Health Care; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
Topics: Adenosine Diphosphate; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1 | 2022 |
Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Multicenter Studies as Topic | 2022 |
Direct cardiac effects of SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Inflammation; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2022 |
Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review.
Topics: Aged; Benzhydryl Compounds; Dehydration; Diabetes Mellitus, Type 2; Glucosides; Heart Arrest; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin for the treatment of chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Stroke Volume; Ventricular Function, Left | 2022 |
Sodium-glucose cotransporter 2 inhibitor ameliorates high fat diet-induced hypothalamic-pituitary-ovarian axis disorders.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Polycystic Ovary Syndrome; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycogen; Glycogen Storage Disease Type I; Hypoglycemia; Rats | 2023 |
Cyanidin-3-O-glucoside as a Nutrigenomic Factor in Type 2 Diabetes and Its Prominent Impact on Health.
Topics: Anthocyanins; Diabetes Mellitus, Type 2; Glucosides; Humans; Nutrigenomics | 2023 |
Impact of tofogliflozin on hepatic outcomes: a systematic review.
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Glucosides; Humans; Liver; Non-alcoholic Fatty Liver Disease | 2023 |
Comprehensive review of SGLT2 inhibitors' efficacy through their diuretic mode of action in diabetic patients.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans; Observational Studies as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Thiophenes | 2019 |
Effect of Steviol Glycosides on Human Health with Emphasis on Type 2 Diabetic Biomarkers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diterpenes, Kaurane; Energy Intake; Glucosides; Humans; Insulin | 2019 |
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding Treatment | 2020 |
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2019 |
Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Diseases; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Non-alcoholic Fatty Liver Disease | 2020 |
Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Pharmaceutical Preparations | 2020 |
Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.
Topics: Diabetes Mellitus, Type 2; Drug Development; Glucosides; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Topics: Acid-Base Equilibrium; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Gas Analysis; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycerophosphates; Humans; Hypoglycemic Agents; Hysterectomy; Insulin; Middle Aged; Postoperative Complications; Sodium Bicarbonate; Sodium-Glucose Transporter 2 Inhibitors; Surgical Wound Infection | 2020 |
Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Topics: Accidental Falls; Benzhydryl Compounds; Bone Density; Bone Remodeling; Calcium; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Phosphates; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
Topics: Administration, Oral; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Primary Health Care; Sitagliptin Phosphate | 2020 |
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies.
Topics: Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Topics: Aged; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Body Mass Index; Case-Control Studies; Cause of Death; Clinical Trials as Topic; Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Patient Outcome Assessment; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Nervous System; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2021 |
Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.
Topics: Amputation, Surgical; Bayes Theorem; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
SGLT2 inhibitors in people with and without T2DM.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.
Topics: Benzhydryl Compounds; Cardiovascular System; Cause of Death; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Glycosides; Hospitalization; Humans; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2021 |
The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
An update on dapagliflozin for the treatment of heart failure.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucosides; Humans; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Arab Emirates | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.
Topics: Benzhydryl Compounds; Black or African American; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Treatment Outcome | 2016 |
[Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic | 2017 |
SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Mechanisms linking empagliflozin to cardiovascular and renal protection.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Consensus; Delphi Technique; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis | 2017 |
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Life Style; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors | 2017 |
A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin | 2017 |
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis | 2017 |
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Durability of response to dapagliflozin: a review of long-term efficacy and safety.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Neoplasms; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hyperuricemia; Hypoglycemia; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Uric Acid | 2018 |
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets | 2018 |
Bolstering your armamentarium with SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Medication Adherence; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Topics: Adult; Aged; Amputation, Surgical; Benzhydryl Compounds; Blood Volume; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Double-Blind Method; Female; Fractures, Spontaneous; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections | 2018 |
Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2017 |
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Current practices and future outlook on the integration of biomarkers in the drug development process.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Guidelines as Topic; Humans; Leukemia, Myeloid; Retinoic Acid Receptor alpha | 2017 |
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Down-Regulation; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid | 2018 |
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Medication Adherence; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2018 |
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors.
Topics: Administration, Oral; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Treatment Outcome | 2018 |
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United Kingdom | 2018 |
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Hypoglycemic Agents; Infections; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Risk; United States; United States Food and Drug Administration | 2018 |
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Hospitalization; Humans; Kidney; Protective Agents; Renal Elimination; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2018 |
Pyrano[3,2-c]quinoline Derivatives as New Class of α-glucosidase Inhibitors to Treat Type 2 Diabetes: Synthesis, in vitro Biological Evaluation and Kinetic Study.
Topics: alpha-Glucosidases; Cell Line, Tumor; Diabetes Mellitus, Type 2; Enzyme Assays; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Kinetics; Pyrans; Quinolines; Saccharomyces cerevisiae | 2019 |
The role of SGLT2 inhibitors in managing type 2 diabetes.
Topics: Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2018 |
Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Empagliflozin: A Review in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Peptides; Sodium-Glucose Transporter 1; Venoms | 2018 |
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Observational Studies as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
[Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment].
Topics: Benzhydryl Compounds; Chronic Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Topics: Adiposity; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide | 2018 |
Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Weight Loss | 2019 |
Oral semaglutide for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate | 2019 |
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Topics: Administration, Oral; Age Factors; Age of Onset; Benzhydryl Compounds; Body Weight; China; Cholesterol; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Expenditures; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Topics: Benzhydryl Compounds; Blood Pressure; Calcium; Canagliflozin; Cardiotonic Agents; Diabetes Mellitus, Type 2; Glucosides; Heart; Humans; Inflammation; Ketone Bodies; Mitochondria, Heart; Muscle Contraction; Myocytes, Cardiac; Natriuresis; Receptor, Angiotensin, Type 2; Sodium-Glucose Transporter 2 Inhibitors; Vasodilation | 2019 |
New Medications for the Treatment of Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Survival Rate | 2019 |
Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2019 |
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dicarboxylic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Patient Selection; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Topics: Animals; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiotonic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Protective Agents; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Remogliflozin Etabonate: First Global Approval.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; India; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Dapagliflozin: A Review in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Pregnancy; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Topics: Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canaglifozin (Invokana) for type 2 diabetes.
Topics: Animals; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: first global approval.
Topics: Animals; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Effects of dapagliflozin on cardiovascular risk factors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transport Proteins | 2013 |
Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney | 2013 |
Canagliflozin for the treatment of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
[New drugs in type 2 diabetes mellitus therapy].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Venoms | 2013 |
Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; United States | 2013 |
Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2014 |
SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Type 2 diabetes mellitus and Invokana: an FDA approved drug.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Female; Glucosides; Humans; Hypoglycemic Agents; India; Life Style; Male; Obesity; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Canagliflozin: Improving diabetes by making urine sweet.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; Treatment Outcome; Urinalysis | 2013 |
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Topics: Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Female; Fructose; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Homeostasis; Humans; Islet Amyloid Polypeptide; Lactones; Male; Minimally Invasive Surgical Procedures; Obesity, Morbid; Orlistat; Phentermine; Receptors, Glucagon; Topiramate; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2014 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: a novel treatment option for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome; Urinary Tract Infections | 2014 |
Canagliflozin: a new hope in the antidiabetic armamentarium.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Glucosides; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
Topics: Bariatric Surgery; Benzhydryl Compounds; Causality; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Disease Management; Evidence-Based Medicine; Exercise Therapy; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Obesity; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Topics: Adsorption; Animals; Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drugs, Investigational; Glucose; Glucosides; Glycosides; Glycosuria; Glycosuria, Renal; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Malus; Phlorhizin; Phytotherapy; Plant Bark; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Biological Transport, Active; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2013 |
[SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Kidney Concentrating Ability; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycemic Index; Glycosuria; Humans; Hypoglycemic Agents; Male; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Weight Gain | 2014 |
Empagliflozin for the treatment of Type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Odds Ratio; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Topics: Adult; Aged; Biomarkers; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Electrolytes; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Water-Electrolyte Imbalance | 2014 |
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
Topics: Aged; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Disease Management; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; United States | 2014 |
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2014 |
Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Topics: Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2014 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Feeding Behavior; Glucosides; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Nanotechnology; Prevalence; Risk Reduction Behavior; Stem Cell Transplantation; Urbanization | 2014 |
The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Thiophenes; Treatment Outcome | 2014 |
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Kidney; Lipids; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2014 |
Empagliflozin for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
[How are changing the therapy options in obese diabetic type 2 patients].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Obesity, Morbid | 2014 |
Dapagliflozin: a review of its use in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biological Availability; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transport Proteins; Treatment Outcome | 2014 |
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; Treatment Outcome | 2015 |
Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; Thiophenes; United States | 2014 |
Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Thiophenes | 2015 |
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2014 |
Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
[Dapagliflozin, a novel oral antidiabetic with an uncertain future].
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2014 |
Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Design; Drug Discovery; Glucosides; Glycosides; History, 20th Century; History, 21st Century; Humans; Hypoglycemic Agents; Monosaccharides; Phlorhizin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2015 |
Dapagliflozin: drug profile and its role in individualized treatment.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents | 2015 |
Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2015 |
Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans | 2015 |
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss | 2015 |
Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2015 |
[Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2015 |
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Topics: Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles | 2015 |
[Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Glyxambi--a new combination for type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Extra-glycaemic properties of empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents | 2016 |
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss | 2015 |
SGLT2 Inhibitors May Predispose to Ketoacidosis.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Susceptibility; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Topics: Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Pharmacovigilance; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic | 2015 |
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Urinary Tract Infections | 2015 |
SGLT2 inhibitors: new reports.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Research Report; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents | 2016 |
Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Models, Statistical; Randomized Controlled Trials as Topic; Renal Reabsorption | 2016 |
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; United States; Weight Loss | 2015 |
Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Dapagliflozin combination therapy in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Treatment Outcome | 2016 |
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucose; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin in the treatment of type 2 diabetes: evidence to date.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
Topics: Adult; Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Obesity in 2015: Advances in managing obesity.
Topics: Bariatric Surgery; Benzhydryl Compounds; Caloric Restriction; Diabetes Mellitus, Type 2; Disease Management; Exercise Therapy; Feeding Behavior; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Obesity | 2016 |
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Weight Loss | 2016 |
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Primary Health Care; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transport Proteins; Treatment Outcome | 2016 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss | 2016 |
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Global Health; Glucosides; Humans; Hypoglycemic Agents; Survival Rate | 2016 |
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Topics: B-Cell Activating Factor; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Network Meta-Analysis; Odds Ratio; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2016 |
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2016 |
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucose Intolerance; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
The cardiovascular phenotype: impact on choice of glucose- lowering therapy.
Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Glucosides; Heart Rate; Humans; Hypoglycemic Agents; Metformin; Obesity; Phenotype | 2016 |
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss | 2016 |
SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[Are some antidiabetic drugs also drugs useful for heart failure treatment?].
Topics: Benzhydryl Compounds; Cardiotonic Agents; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Risk Factors | 2016 |
The EMPA-REG outcome study: critical appraisal and potential clinical implications.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Outcome Assessment, Health Care; Risk Factors | 2016 |
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Treatment Outcome | 2016 |
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Potential of rooibos, its major C-glucosyl flavonoids, and Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid in prevention of metabolic syndrome.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspalathus; Beverages; Diabetes Mellitus, Type 2; Dietary Supplements; Ethnopharmacology; Flavonoids; Glucosides; Humans; Isomerism; Medicine, African Traditional; Metabolic Syndrome; Obesity; Phenylpropionates; Plant Extracts; Plant Leaves; Plant Stems; South Africa; Teas, Herbal | 2018 |
Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Incretins; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
Topics: Aged; Benzhydryl Compounds; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk Factors | 2016 |
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Incidence; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
▼ Empagliflozin, diabetes and outcomes.
Topics: Benzhydryl Compounds; Cardiovascular System; Contraindications; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
Topics: Algorithms; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Receptors, Glucagon; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Topics: Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2016 |
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Incidence; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT2 Inhibitors: Benefit/Risk Balance.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Ketosis; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Glucagon and heart in type 2 diabetes: new perspectives.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Odds Ratio; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2017 |
Impact of empagliflozin in patients with diabetes and heart failure.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Magnesium; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
[Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Impact of EMPA-REG OUTCOME
Topics: Benzhydryl Compounds; Body Weights and Measures; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Health Care; Randomized Controlled Trials as Topic; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.
Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Glucosides; Half-Life; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2 | 2017 |
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart; Humans; Hypoglycemic Agents; Kidney; Myocytes, Cardiac; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2016 |
Implications of the EMPA-REG Trial for Clinical Care and Research.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucose; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Topics: Animals; Antihypertensive Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Odds Ratio; Randomized Controlled Trials as Topic; Regression Analysis; Reproductive Tract Infections; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2017 |
Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype.
Topics: Asian People; Benzhydryl Compounds; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Membrane Transport Modulators; Middle Aged; Reproducibility of Results; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Topics: Benzhydryl Compounds; Blood Viscosity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Stroke | 2017 |
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Linagliptin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 1 | 2017 |
Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Treatment Outcome | 2016 |
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Econometric; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reference Values; Treatment Outcome | 2017 |
[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
Topics: Benzhydryl Compounds; Cardiologists; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides | 2017 |
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Hypoglycemic Agents | 2017 |
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
.
Topics: Angiotensins; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Protective Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction | 2017 |
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Renal Insufficiency; Reproducibility of Results; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2017 |
Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.
Topics: Adult; Animals; Antineoplastic Agents; Benzhydryl Compounds; Blood Pressure; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Humans; Hypoglycemic Agents | 2017 |
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2008 |
Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin: an emerging treatment option in type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Discovery; Drug Tolerance; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin: where does it fit in the treatment of type 2 diabetes?
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Delivery Systems; Glucosides; Humans; Hypoglycemic Agents; Life Style; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Delivery Systems; Drug Design; Glucosides; Humans; Hypoglycemic Agents; Patents as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Dapagliflozin: BMS 512148; BMS-512148.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Drugs, Investigational; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Topics: Absorption; Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Dapagliflozin: more than just another oral glucose-lowering agent?
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2010 |
[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Topics: Absorption; Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dogs; Double-Blind Method; Gluconeogenesis; Glucose; Glucosides; Glycosuria, Renal; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Kidney Tubules, Proximal; Mice; Phlorhizin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
[Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Topics: Benzhydryl Compounds; Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Thiophenes | 2012 |
A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Gluconeogenesis; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2011 |
Challenges for the treatment of diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Bile Acids and Salts; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucokinase; Glucosides; Humans; Hypoglycemic Agents; Molecular Targeted Therapy; Patents as Topic; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2011 |
SGLT-2 inhibitors in development for type 2 diabetes treatment.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Dapagliflozin for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phlorhizin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Topics: Benzhydryl Compounds; Biological Transport; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
[Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Molecular Structure; Monosaccharides; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2012 |
Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
[Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glipizide; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Topics: Animals; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Sodium-glucose cotransporter inhibitors for diabetes.
Topics: Animals; Carbonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Sodium-Glucose Transport Proteins | 2007 |
518 trial(s) available for glucose, (beta-d)-isomer and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Lipids; Randomized Controlled Trials as Topic | 2021 |
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Renal Plasma Flow; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
Topics: Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Subcutaneous; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Retina; Treatment Outcome | 2021 |
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Treatment Outcome; Uric Acid | 2022 |
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2022 |
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Incidence; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypothalamus; Insulin Resistance; Middle Aged; Prediabetic State | 2022 |
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
Topics: Benzhydryl Compounds; Blood Volume; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Medicare; Myocardial Infarction; United States | 2022 |
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Topics: Adiponectin; Adiposity; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Obesity | 2022 |
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucosides; Humans; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2022 |
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Treatment Outcome | 2022 |
Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
Topics: Aged; Benzhydryl Compounds; Biological Specimen Banks; Diabetes Mellitus, Type 2; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Heart Failure; Heart Transplantation; Heart Ventricles; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left | 2022 |
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2022 |
Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
Topics: Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glucosides; Humans; Ventricular Function, Left | 2022 |
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hemodynamics; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |
Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
Topics: Adult; Aged; Benzhydryl Compounds; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2022 |
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Flow Velocity; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Echocardiography, Doppler; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2022 |
Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Endothelium; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study.
Topics: Aged; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Thiophenes; Ventricular Function, Left | 2022 |
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2022 |
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; China; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypertension; Hypotension; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Topics: Acarbose; Benzhydryl Compounds; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2022 |
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Nephrolithiasis; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Calculi | 2022 |
Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Insulin; Lipid Metabolism; Male | 2022 |
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
Topics: Adolescent; Benzhydryl Compounds; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Prospective Studies; Treatment Outcome; Young Adult | 2022 |
Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucose; Glucosides; Humans; Hypoglycemic Agents; RNA, Ribosomal, 16S | 2022 |
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Appetite; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Ghrelin; Glucagon-Like Peptide 1; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Overweight; Peptide YY; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Ventricular Dysfunction, Left | 2022 |
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Prospective Studies; Pyrazoles; Treatment Outcome; Vildagliptin | 2022 |
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Frailty; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2022 |
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Topics: Acute Kidney Injury; Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angina, Unstable; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Treatment Outcome | 2022 |
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies | 2022 |
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
Topics: Benzhydryl Compounds; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.
Topics: Body Fluids; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Glycolipids; Humans; Liraglutide; Metabolic Syndrome; Quality of Life; Stroke Volume; Uric Acid; Ventricular Function, Left | 2022 |
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Heart Failure; Humans; Hyperuricemia; Male; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2022 |
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans | 2022 |
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Sulfonylurea Compounds | 2022 |
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
Topics: Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Isoprostanes; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Treatment Outcome | 2022 |
Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucosides; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Myocardial Infarction; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Positron Emission Tomography Computed Tomography; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pakistan; Vildagliptin | 2022 |
Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Ventricles; Humans; Oxygen; Sitagliptin Phosphate | 2022 |
Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function.
Topics: Benzhydryl Compounds; Blood Glucose; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2022 |
Impact of Empagliflozin on Left Ventricular Strain: Insights From the EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Predictive Value of Tests | 2022 |
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin; Insulin, Regular, Human; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2023 |
Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Interleukin-6; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha | 2023 |
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Plasma Volume; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiography, Impedance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart; Hemodynamics; Humans; Italy; Male; Middle Aged; Predictive Value of Tests; Single-Blind Method; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
The effect of circuit resistance training, empagliflozin or "vegeterranean diet" on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial).
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Body Composition; Body Weight; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Mediterranean; Diet, Vegetarian; Exercise; Female; Glucosides; Humans; Male; Resistance Training; Sodium-Glucose Transporter 2 Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2019 |
Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Topics: Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Ketone Bodies; Male; Middle Aged | 2019 |
Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes st
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Japan; Kidney; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2019 |
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucosides; Humans; Hypoglycemic Agents | 2020 |
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiotonic Agents; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glucosides; Humans; Middle Aged; Myeloid Progenitor Cells; Regeneration; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.
Topics: Benzhydryl Compounds; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate | 2020 |
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Glycemic Control; Humans; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Young Adult | 2020 |
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Male; Middle Aged; Prognosis; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2020 |
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Topics: Asian People; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Proportional Hazards Models; Quality-Adjusted Life Years; Treatment Outcome | 2019 |
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Stroke | 2019 |
Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sleep; Sleep Apnea, Obstructive; Treatment Outcome | 2019 |
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Exenatide; Fibrosis; Glucosides; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Prospective Studies | 2020 |
Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Treatment Outcome | 2020 |
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2019 |
Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged | 2020 |
Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Topics: Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Glucosides; Humans; Japan; Male; Middle Aged; Monokines; Muscle, Skeletal; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan | 2020 |
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Inpatients; Male; Registries; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Denmark; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney | 2020 |
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Vasoconstriction; Vasodilation | 2020 |
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Topics: Aged; Arterial Pressure; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glucosides; Humans; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2020 |
Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Feces; Female; Gastrointestinal Microbiome; Gliclazide; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2020 |
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2020 |
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Ketone Bodies; Length of Stay; Mortality; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Weight Loss | 2020 |
Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Topics: Anti-Infective Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Erythropoiesis; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Hepcidins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Middle Aged; Obesity; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult | 2020 |
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Topics: Anhydrides; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sorbitol; Treatment Outcome | 2020 |
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Topics: Adamantane; Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Humans; Liver; Metformin | 2020 |
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Brain Ischemia; Diabetes Mellitus, Type 2; Glucosides; Humans; Stroke | 2020 |
The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
Topics: Adipose Tissue; Aged; Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Pericardium; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Uric Acid; Young Adult | 2020 |
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors | 2020 |
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Kidney; Metabolomics; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2020 |
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Young Adult | 2020 |
Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Topics: Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Echocardiography; Glucosides; Humans; Ventricular Remodeling | 2020 |
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Risk Factors; Thrombolytic Therapy | 2020 |
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Placebos; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2020 |
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatme
Topics: Adult; Aged; Arterial Pressure; Arteries; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelial Cells; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycocalyx; Greece; Humans; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left | 2020 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2020 |
Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
Topics: Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Male; Medication Adherence; Metformin; Middle Aged; Therapeutic Equivalency; Young Adult | 2020 |
Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Glucosides; Humans; Hyperplasia; Japan; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2020 |
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exercise; Female; Glucosides; Glycated Hemoglobin; Healthy Lifestyle; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Recurrence; Remission Induction; Secondary Prevention; Time Factors; Treatment Outcome | 2020 |
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged | 2020 |
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2020 |
Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Gliclazide; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Vascular Stiffness | 2020 |
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial func
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Equivalence Trials as Topic; Glucocorticoids; Glucosides; Glycemic Control; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Isophane; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Reported Outcome Measures; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.
Topics: Adipose Tissue; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gluconeogenesis; Glucosides; Glycerol; Humans; Intra-Abdominal Fat; Liver; Male; Middle Aged; Obesity; Placebos; Weight Loss | 2020 |
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged | 2020 |
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin | 2021 |
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2021 |
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Topics: Aged; Benzhydryl Compounds; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Humans; Japan; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2020 |
The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2020 |
Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Brain Ischemia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Stroke; Treatment Outcome | 2021 |
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Prognosis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Incretins; Liraglutide; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Topics: Adiponectin; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Fibrinolysis; Glucosides; Humans; Leptin; Plasminogen Activator Inhibitor 1 | 2020 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Liver; Non-alcoholic Fatty Liver Disease; Prospective Studies | 2020 |
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Topics: 3-Iodobenzylguanidine; Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography, Ambulatory; Female; Glucosides; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Parasympathetic Nervous System; Radionuclide Imaging; Radiopharmaceuticals; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System; Uric Acid | 2020 |
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Humans; Incidence; Kidney Diseases; Male; Middle Aged; Prevalence; Risk Factors; Sleep; Sleep Apnea, Obstructive; Treatment Outcome | 2020 |
Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged | 2020 |
Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2020 |
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Intestinal Absorption; Kidney; Male; Middle Aged; Models, Biological; Postprandial Period; Pyrazoles; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Young Adult | 2020 |
Effects of empagliflozin on proinflammatory cytokines and other coronary risk factors in patients with type 2 diabetes mellitus: A single-arm real-world observation.
Topics: Benzhydryl Compounds; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors; Uric Acid | 2021 |
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Triglycerides; Waist Circumference; Weight Loss | 2021 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Sodium | 2021 |
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypoglycemic Agents; Pulse Wave Analysis; Treatment Outcome | 2021 |
Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left | 2021 |
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Topics: Acid-Base Equilibrium; Ammonium Compounds; Benzhydryl Compounds; Bicarbonates; Blood Glucose; Citrates; Diabetes Mellitus, Type 2; Electrolytes; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Humans; Hydrogen-Ion Concentration; Ketones; Kidney Tubules; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atherosclerosis; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Equivalence Trials as Topic; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Hospitalization; Humans; Incidence; Male; Middle Aged; Prognosis; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; United States; Young Adult | 2020 |
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Diseases; Humans; Kidney Diseases; Male; Metabolic Syndrome; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Middle Aged; Sodium | 2021 |
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Cardiovascular Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Glucosides; Humans; Treatment Outcome | 2021 |
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Natriuretic Agents; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary | 2021 |
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Japan; Treatment Outcome | 2021 |
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; Hypoglycemic Agents; Metformin; Overweight; Pregnancy; Prospective Studies; Single-Blind Method | 2020 |
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Treatment Outcome | 2021 |
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Hematocrit; Humans; Insulin; Male; Middle Aged; Reticulocyte Count | 2020 |
Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adipose Tissue; Aged; Benzhydryl Compounds; Body Composition; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Muscle, Skeletal; Organ Size; Resistance Training; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Lipids; Male; Middle Aged; Prospective Studies; Pulse Wave Analysis; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2021 |
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Pilot Projects; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure | 2021 |
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Lipids; Liver Neoplasms; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Topics: Adiposity; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Metabolism; Female; Glucosides; Glycated Hemoglobin; Heart; Humans; Male; Middle Aged; Myocardium; Primary Prevention; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tokyo; Treatment Outcome | 2021 |
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
Topics: Benzhydryl Compounds; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Humans; Phytosterols | 2021 |
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Greece; Humans; Male; Metabolome; Metformin; Middle Aged; Treatment Outcome; Urinalysis | 2021 |
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Japan; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies | 2021 |
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Lung; Quality of Life | 2021 |
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; COVID-19; Creatinine; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Glucosides; Heart Failure; Hospitalization; Humans; Japan; Kidney; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2021 |
Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Prospective Studies | 2021 |
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Blood Volume; Diabetes Mellitus, Type 2; Diuretics; Drug Synergism; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hematocrit; Humans; Male; Natriuretic Peptides; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Water-Electrolyte Imbalance | 2021 |
EMPEROR reduced - empagliflozin in patients with heart failure and reduced ejection fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Brazil; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucosides; Glyburide; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vasodilation | 2021 |
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Pharmaceutical Preparations; Quality of Life; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life | 2021 |
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adiponectin; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D).
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Prospective Studies; Treatment Outcome | 2021 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Ventricular Function, Left | 2021 |
A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin.
Topics: Aged; Anthropometry; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Proteins; Female; Glucosides; Humans; Insulin; Male; Middle Aged; Muscle, Skeletal; Organ Size; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glyburide; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Lactic Acid; Male; Metformin; Middle Aged; Pyrazoles | 2021 |
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Non-alcoholic Fatty Liver Disease | 2021 |
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluid Shifts; Glucosides; Humans; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Water-Electrolyte Balance | 2021 |
Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Glycated Hemoglobin; Humans; Inflammation Mediators; Iran; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Lipoproteins; Lipoproteins, LDL; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fractional Flow Reserve, Myocardial; Glucosides; Glycated Hemoglobin; Heart Disease Risk Factors; Humans; Male; Microcirculation; Middle Aged; Myocardial Perfusion Imaging; Negative Results; Positron Emission Tomography Computed Tomography; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tropism | 2021 |
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Japan; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Prognosis; Risk Factors; Stroke Volume | 2021 |
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Erythropoiesis; Glucosides; Humans; Hypoglycemic Agents; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial.
Topics: Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2021 |
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Myocardial Infarction; Prospective Studies; Water-Electrolyte Balance | 2022 |
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic | 2021 |
Empagliflozin and Major Renal Outcomes in Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Treatment Outcome; Young Adult | 2017 |
Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Male; Middle Aged; Particle Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Outcome Assessment, Health Care; Risk; Stroke | 2017 |
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Rate; Humans; Hypertension; Male; Middle Aged; Treatment Outcome | 2017 |
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Endothelial Cells; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adolescent; Adult; Aged; Benzhydryl Compounds; Biomarkers; Denmark; Deoxyguanosine; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Guanosine; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Nucleic Acids; Oxidative Stress; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2017 |
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Metformin; Prospective Studies; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Germany; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Internationality; Male; Middle Aged; Mortality; Norway; Registries; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Treatment Outcome; United Kingdom; United States | 2017 |
Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Thiophenes; Treatment Outcome; Waist Circumference | 2018 |
Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes.
Topics: Adipose Tissue; Arterial Pressure; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Viscera | 2017 |
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2 | 2017 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome; Young Adult | 2017 |
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Glucosides; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscle, Skeletal; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2017 |
Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Japan; Male; Membrane Transport Modulators; Middle Aged; Monitoring, Ambulatory; Risk; ROC Curve; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Progression; Double-Blind Method; Glucosides; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Magnetic Resonance Imaging; Proof of Concept Study; Prospective Studies; Research Design; Risk Factors; Scotland; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Germany; Glucosides; Hemodynamics; Humans; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Young Adult | 2017 |
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiomyopathies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Humans; Hypoglycemic Agents; Italy; Male; Middle Aged; Research Design; Ventricular Dysfunction, Left | 2017 |
Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Topics: Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Chronic Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Scotland; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Peripheral Arterial Disease; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Black or African American; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States | 2018 |
Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Male; Middle Aged; Prospective Studies; Triglycerides | 2018 |
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk Factors; Treatment Outcome | 2018 |
Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Asia; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome | 2018 |
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Humans; Male; Middle Aged; Muscle, Skeletal; Prospective Studies; Skin; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease.
Topics: Aged; Benzhydryl Compounds; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Glucose; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Length of Stay; Male; Middle Aged; Monitoring, Ambulatory; Prednisone; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Tissue | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2018 |
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Electric Impedance; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemia; Insulin Resistance; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin; Insulin Resistance; Japan; Male; Middle Aged; Risk; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2018 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged | 2018 |
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Mortality; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo.
Topics: Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Extracellular Traps; Female; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Neutrophils | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins | 2018 |
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Topics: Acute Kidney Injury; Adult; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hepatitis A Virus Cellular Receptor 1; Humans; Inflammation Mediators; Interleukin-6; Kidney Glomerulus; Kidney Tubules; Netherlands; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.
Topics: Benzhydryl Compounds; Body Mass Index; Cardiorespiratory Fitness; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Drug Interactions; Female; Glucosides; Heart; Heart Failure; Humans; Male; Middle Aged; Obesity; Oxygen Consumption; Pilot Projects; Respiratory System; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2018 |
Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
Topics: Administration, Oral; Adolescent; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Topics: Adamantane; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Male; Middle Aged | 2018 |
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Treatment Outcome | 2018 |
Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardio Ankle Vascular Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Female; Glucosides; Glycation End Products, Advanced; Humans; Japan; Liver; Male; Pilot Projects; Predictive Value of Tests; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2019 |
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Coronary Artery Bypass; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Risk; Treatment Outcome | 2018 |
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Male; Middle Aged; Risk Factors; Thiophenes; Treatment Outcome | 2018 |
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Topics: Adult; Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Sitagliptin Phosphate; Thiophenes | 2018 |
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Japan; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Topics: Adipose Tissue; Adiposity; Adult; Alanine Transaminase; Aspartate Aminotransferases; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2018 |
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Topics: Aged; Benzhydryl Compounds; Cerebral Infarction; Diabetes Mellitus, Type 2; Diuresis; Drug Monitoring; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections | 2018 |
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2018 |
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2018 |
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Carboxylic Acids; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Acids; Female; Glucose; Glucosides; Hepatocytes; Humans; Inflammation; Lipid Metabolism; Liver Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Sweden | 2018 |
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Least-Squares Analysis; Male; Middle Aged; Postprandial Period; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome | 2018 |
The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Obesity; Sleep Apnea Syndromes; Treatment Outcome; Young Adult | 2018 |
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Middle Aged | 2019 |
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Elimination; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Cells, Cultured; Cohort Studies; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Stem Cells; Young Adult | 2018 |
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Placebos; Prediabetic State; Treatment Outcome | 2020 |
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Elasticity Imaging Techniques; Female; Glucosides; Humans; Lipid Metabolism; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Administration Schedule; Energy Intake; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Self-Management; Treatment Outcome | 2019 |
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; Young Adult | 2018 |
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome | 2018 |
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Exenatide; Female; Glucosides; Humans; Insulin; Ketones; Male; Middle Aged; Pioglitazone; Qatar; Treatment Outcome | 2019 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Substitution; Energy Metabolism; Female; Glucosides; Humans; Male; Middle Aged; Pioglitazone; Treatment Outcome | 2019 |
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Russia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Topics: Albuminuria; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Cause of Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training.
Topics: Adaptation, Physiological; Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Endurance Training; Exercise Therapy; Female; Glucosides; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Physical Endurance; Sedentary Behavior; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2019 |
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart; Heart Ventricles; Hospitalization; Humans; International Cooperation; Magnetic Resonance Imaging; Metformin; Myocardial Contraction; Nuclear Medicine; Outcome Assessment, Health Care; Perfusion; Positron-Emission Tomography; Risk; Sample Size; Sodium-Glucose Transporter 2 | 2019 |
Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Inflammation Mediators; Lipids; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Troponin T; Vildagliptin | 2019 |
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged | 2019 |
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; gamma-Glutamyltransferase; Glucosides; Hepatitis; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Fat; Weight Loss | 2019 |
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
Topics: Adipose Tissue; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Lipolysis; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cause of Death; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Topics: Aged; Benzhydryl Compounds; Brain Ischemia; Cause of Death; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Time Factors; Treatment Outcome | 2019 |
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Benzhydryl Compounds; Biomarkers; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Humans; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Young Adult | 2019 |
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2019 |
[Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Marketing; Middle Aged; Patient Safety; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2019 |
Analysis from the EMPA-REG OUTCOME
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Male; Middle Aged; Protective Agents; Regional Blood Flow; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature.
Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Epigenesis, Genetic; Female; Glomerular Filtration Rate; Glucosides; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Italy; Male; MicroRNAs; Middle Aged; Prognosis; Renal Circulation; Sodium-Glucose Transporter 2 Inhibitors; Statistics, Nonparametric; Treatment Outcome; Up-Regulation | 2019 |
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Exercise Tolerance; Female; Glucosides; Heart Failure; Humans; Male; Patient Reported Outcome Measures; Physical Functional Performance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Ketone Bodies; Male; Metabolome; Metabolomics; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Magnesium; Magnesium Deficiency; Middle Aged; Placebos; Randomized Controlled Trials as Topic | 2019 |
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Treatment Outcome | 2013 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2013 |
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Long-Term Care; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glipizide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Male; Membrane Transport Modulators; Middle Aged; Overweight; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Topics: Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diarrhea; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Female; Glucosides; Headache; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Topics: Adult; Area Under Curve; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Glucuronides; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transport Proteins | 2013 |
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Topics: Adult; Aged; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Administration Schedule; Fasting; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Topics: Adult; Aged; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fasting; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Topics: Analysis of Variance; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Hematocrit; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2014 |
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Treatment Outcome | 2013 |
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Body Mass Index; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Topics: Absorption; Administration, Oral; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Feces; Glucose; Glucosides; Glucuronides; Healthy Volunteers; Humans; Male; Oxidative Stress; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Quality-Adjusted Life Years; Severity of Illness Index | 2014 |
Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol.
Topics: Blood Glucose; Canagliflozin; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Topics: Adult; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult | 2014 |
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Oxygen; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Time Factors | 2014 |
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, rand
Topics: Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Topics: Aged; Canagliflozin; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Mycoses; Thiophenes | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative
Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2014 |
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors | 2014 |
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Time Factors | 2014 |
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Topics: Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Fasting; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Topics: Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Thiophenes | 2015 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Research Design; Treatment Outcome; Young Adult | 2014 |
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome | 2014 |
Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Ketone Bodies; Lipids; Male; Middle Aged; Thiophenes; Treatment Outcome; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Topics: Blood Glucose; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose; Glucosides; Humans; Kidney; Male; Metformin; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiophenes; Tissue Distribution; Young Adult | 2014 |
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Thiophenes | 2014 |
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Topics: Aged; Canagliflozin; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Malaysia; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Vietnam | 2015 |
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
Topics: Adult; Aged; Area Under Curve; Asian People; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Thiophenes | 2014 |
Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Feasibility Studies; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; South Africa | 2015 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Weight Loss | 2015 |
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2015 |
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Topics: Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Postprandial Period; Time Factors; Treatment Outcome | 2015 |
Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Topics: Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glucosides; Humans; Hydrochlorothiazide; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonamides; Therapeutic Equivalency; Torsemide | 2015 |
Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
Topics: Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Treatment Outcome | 2015 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss | 2015 |
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Treatment Outcome | 2015 |
Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Topics: Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2015 |
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Female; Glucosides; Humans; Hyperglycemia; Hypertension; Hypoglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Detemir; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Fasting; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Ketones; Male; Metformin; Middle Aged | 2015 |
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2015 |
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
Topics: Aged; Arteriosclerosis; Benzhydryl Compounds; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Glucosides; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Risk; Vascular Resistance; Vascular Stiffness | 2015 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors | 2015 |
Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diagnostic Self Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Surveys and Questionnaires; Treatment Outcome | 2016 |
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos | 2016 |
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Blood Pressure Determination; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Hemorheology; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Renin-Angiotensin System; Systole; Uric Acid | 2016 |
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2016 |
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Tolerance Test; Glucosides; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Young Adult | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2016 |
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
Topics: Adiposity; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Weight Loss | 2016 |
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult | 2016 |
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged | 2016 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System | 2016 |
[New attempt in a benefit evaluation].
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds | 2015 |
[Empagliflozin improves cardiovascular prognosis].
Topics: Benzhydryl Compounds; Cause of Death; Diabetes Complications; Diabetes Mellitus, Type 2; Germany; Glucosides; Humans; Hypoglycemic Agents; Myocardial Infarction; Survival Rate | 2016 |
[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis | 2015 |
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds | 2016 |
Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prospective Studies; Thiophenes; Uracil | 2016 |
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Topics: Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Treatment Outcome | 2016 |
[Effect of dapagliflozin on cardiovascular risk factors].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrolytes; Endpoint Determination; Glucosides; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome | 2016 |
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Topics: Asia; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2016 |
[Empagliflozin also protects high risk patients].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Humans; Risk Factors; Survival Rate | 2016 |
Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Patient Satisfaction; Sodium-Glucose Transport Proteins; Treatment Outcome | 2016 |
Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney; Male; Microvessels; Middle Aged; Proportional Hazards Models; Risk Factors | 2016 |
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Thiophenes; Treatment Outcome | 2016 |
Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glucosides; Humans; Losartan; Male; Middle Aged; Paeonia; Phytotherapy; Plant Extracts; Plant Roots; Prospective Studies; Serum Albumin; Tumor Necrosis Factor-alpha | 2016 |
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Topics: Adiponectin; Aged; Asian People; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Reproductive Tract Infections; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2016 |
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Calorimetry, Indirect; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Glucagon; Glucosides; Humans; Insulin; Insulin Resistance; Ketones; Lipid Metabolism; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2016 |
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2016 |
Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Topics: Aged; Asia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos | 2017 |
Acetagastrodin effects on retinal oscillatory potentials in patients during the early stages of diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Electroretinography; Female; Glucosides; Hemoglobins; Humans; Male; Middle Aged; Neuroprotective Agents; Prospective Studies; Retina; Wavelet Analysis | 2017 |
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Oxidative Stress | 2016 |
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pancreatitis; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2017 |
Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Proinsulin; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure Determination; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Male; Prospective Studies; Reference Values; Severity of Illness Index; Treatment Outcome | 2016 |
Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Time Factors; Treatment Outcome | 2017 |
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome | 2017 |
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME
Topics: Aged; Asian People; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome | 2017 |
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Lipoproteins, HDL2; Male; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transport Proteins | 2017 |
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Topics: Adipose Tissue; Benzhydryl Compounds; Body Composition; Body Fat Distribution; Brain; Calorimetry, Indirect; Cross-Over Studies; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Energy Metabolism; Feeding Behavior; Food; Functional Neuroimaging; Glucosides; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Liver; Magnetic Resonance Imaging; Organ Size; Proton Magnetic Resonance Spectroscopy | 2017 |
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin Resistance; Laser-Doppler Flowmetry; Male; Microcirculation; Microvessels; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Topics: Adolescent; Adult; Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Placebos; Reproducibility of Results; Treatment Outcome; Young Adult | 2017 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult | 2009 |
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2009 |
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose Tolerance Test; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2009 |
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Treatment Outcome; Young Adult | 2009 |
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prodrugs; Water-Electrolyte Balance | 2010 |
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss | 2010 |
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet Therapy; Double-Blind Method; Exercise Therapy; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Placebos; Treatment Outcome | 2010 |
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Treatment Outcome | 2011 |
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Topics: Adolescent; Adult; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2011 |
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2011 |
Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2012 |
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Glipizide; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2011 |
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Topics: Adult; Blood Glucose; Blood Pressure Determination; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Glucose; Glucosides; Glycosuria; Heart Rate; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes; Young Adult | 2011 |
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2012 |
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin | 2012 |
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Antifungal Agents; Blood Glucose; Canagliflozin; Candida; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Vagina | 2012 |
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Osteoporosis; Time Factors; Treatment Outcome | 2012 |
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
Topics: Benzhydryl Compounds; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; India; Male; Mexico; Middle Aged; Puerto Rico; Russia; South Africa; Treatment Outcome; United States; Weight Loss | 2012 |
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Topics: Adolescent; Adult; Benzhydryl Compounds; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Glucosides; Glucuronosyltransferase; Humans; Hypoglycemic Agents; Male; Mefenamic Acid; Middle Aged; Rifampin; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2013 |
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Topics: Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Glucosides; Glycosuria; Half-Life; Humans; Male; Metabolic Clearance Rate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; United States | 2013 |
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Kidney Function Tests; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2013 |
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Weight Loss | 2013 |
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Germany; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Male; Membrane Transport Modulators; Middle Aged; Polyuria; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nasopharyngitis; Republic of Korea; Russia; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Thirst; Treatment Outcome; Ukraine; Urination Disorders; Weight Loss | 2013 |
Antihyperglycemic effects of stevioside in type 2 diabetic subjects.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Diuresis; Fatty Acids, Nonesterified; Female; Food; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Triglycerides | 2004 |
Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypotension; Insulin; Male; Middle Aged; Pilot Projects; Sweetening Agents | 2008 |
855 other study(ies) available for glucose, (beta-d)-isomer and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The effect of high temperature on kinetics of reactive species generation in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Inflammation; Ionomycin; NADP; NADPH Oxidases; Neutrophils; Phorbol Esters; Phosphoproteins; Temperature; Zymosan | 2022 |
The production of reactive oxygen species in TLR-stimulated granulocytes is not enhanced by hyperglycemia in diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cells, Cultured; Concanavalin A; Diabetes Mellitus, Type 2; Female; Granulocytes; Humans; Hyperglycemia; Lipopolysaccharides; Male; Middle Aged; Mitogen-Activated Protein Kinases; NADPH Oxidases; Reactive Oxygen Species; Toll-Like Receptors; Zymosan | 2013 |
Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fluoroquinolones; Humans; Male; Mexican Americans; Moxifloxacin; Neutrophils; Ofloxacin; Protein Kinase C; Quinolines; Respiratory Burst; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2007 |
Phagocytosis, bactericidal capacity, and superoxide anion (O2-) production by polymorphonuclear neutrophils from patients with diabetes mellitus.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Bactericidal Activity; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Middle Aged; Neutrophils; Phagocytosis; Staphylococcus; Superoxides; Zymosan | 1985 |
Leukocyte microbicidal activity assessed by chemiluminescence in elderly non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; In Vitro Techniques; Luminescent Measurements; Neutrophils; Reference Values; Zymosan | 1988 |
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Multi-Spectroscopic, thermodynamic and molecular dynamic simulation studies for investigation of interaction of dapagliflozin with bovine serum albumin.
Topics: Benzhydryl Compounds; Binding Sites; Diabetes Mellitus, Type 2; Glucosides; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Serum Albumin, Bovine; Sodium-Glucose Transporter 2 Inhibitors; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2022 |
Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiac Surgical Procedures; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans | 2022 |
Chebulagic acid attenuates HFD/streptozotocin induced impaired glucose metabolism and insulin resistance via up regulations of PPAR γ and GLUT 4 in type 2 diabetic rats.
Topics: Animals; Benzopyrans; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucosides; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; PPAR gamma; Rats; Rats, Wistar; Streptozocin | 2022 |
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.
Topics: Benzhydryl Compounds; Blood Glucose; Body Mass Index; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Tolerance Test; Glucosides; Humans; Male; Mice; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Philippines; Stroke Volume | 2021 |
Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
Topics: Adiposity; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucosides; Insulin Resistance; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin: The outcome of use as add-on therapy in real-life clinical setting -An Audit.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome | 2021 |
Current Role of Dapagliflozin in Clinical Practice.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Sodium-Glucose Transporter 2 | 2022 |
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cell Line; Cyclic AMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Epithelial Cells; Female; Follow-Up Studies; Glucosides; Humans; Male; MAP Kinase Signaling System; Middle Aged; Renal Elimination; Retrospective Studies; RNA-Seq; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |
Anthocyanins from
Topics: Anthocyanins; Diabetes Mellitus, Type 2; Elaeocarpaceae; Fatty Liver; Glucosides; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Olanzapine; Plant Extracts; Polyphenols | 2021 |
Orientin Improves Substrate Utilization and the Expression of Major Genes Involved in Insulin Signaling and Energy Regulation in Cultured Insulin-Resistant Liver Cells.
Topics: Aspalathus; Cell Line; Chalcones; Diabetes Mellitus, Type 2; Flavonoids; Gene Expression; Glucose; Glucosides; Hepatocytes; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Phosphatidylinositol 3-Kinases; Plant Extracts; Signal Transduction; Transcriptome | 2021 |
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glucuronosyltransferase; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2022 |
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2021 |
Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
Topics: Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Evaluation of therapeutic effect of Premna herbacea in diabetic rat and isoverbascoside against insulin resistance in L6 muscle cells through bioenergetics and stimulation of JNK and AKT/mTOR signaling cascade.
Topics: Animals; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Glucosides; Insulin; Insulin Resistance; Male; Molecular Docking Simulation; Muscle Cells; Phenols; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; TOR Serine-Threonine Kinases | 2021 |
Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Muscles; Natriuretic Peptide, Brain; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2021 |
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Medicare; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States | 2022 |
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus: A retrospective study of a patient cohort.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hydrocortisone; Renin; Retrospective Studies | 2021 |
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Hypoglycemic Agents; Insulin-Secreting Cells; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
[Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycemic Control; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Denmark; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents | 2022 |
The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Lipocalin-2; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Hospitalization; Humans; Insulins; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2022 |
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prospective Studies; United States | 2022 |
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Monocytes | 2021 |
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hematocrit; Humans; Risk Factors | 2022 |
A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Nutrition Surveys; Pregnancy; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes.
Topics: Diabetes Mellitus, Type 2; Digoxin; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Prospective Studies | 2021 |
Efficacy and Safety of Empagliflozin as Add on in Patients with Type II Diabetes Mellitus (DM) Inadequately Controlled on Triple Drug Combination.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans | 2022 |
The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
Topics: Animals; Atorvastatin; Benzhydryl Compounds; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Liraglutide; Male; Pyrroles; Rats; Thyrotropin | 2022 |
Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents | 2022 |
SGLT2 inhibitors may prevent diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Exploring the synergistic and complementary effects of berberine and paeoniflorin in the treatment of type 2 diabetes mellitus by network pharmacology.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drugs, Chinese Herbal; Glucosides; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Monoterpenes; Network Pharmacology; Phytotherapy | 2022 |
The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Neurovascular Coupling; Retina; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Endothelial Growth Factor A | 2022 |
Reply to: Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2022 |
Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2022 |
The effect of empagliflozin on P wave peak time and other P wave parameters in patients with diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2022 |
Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Prospective Studies; Quality-Adjusted Life Years; Spain | 2022 |
Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; United States | 2022 |
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection f
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters | 2022 |
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Colombia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India.
Topics: Adipose Tissue; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver | 2022 |
Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemia; Ketosis | 2022 |
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Insulins; Metformin; Prospective Studies; Stroke Volume | 2022 |
Benefit of empagliflozin in acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Incidence | 2022 |
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Glucosides; Humans; Hypoglycemic Agents; Ketones; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2022 |
Is Dapagliflozin future for CKD?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2022 |
Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
Topics: Benzhydryl Compounds; Brain; Cues; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Glucosides; Humans; Inflammation; Liraglutide; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin in young people with type 2 diabetes.
Topics: Adolescent; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2022 |
FDA Expands Empagliflozin Heart Failure Indication.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; United States | 2022 |
Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.
Topics: Benzhydryl Compounds; Citric Acid; Diabetes Mellitus, Type 2; Glucosides; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Kidney Calculi; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin.
Topics: Animals; Antigens, CD1; Benzhydryl Compounds; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Neoplasms; Male; Mice; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2022 |
In brief: Expanded heart failure indication for empagliflozin (Jardiance).
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2022 |
Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Prediabetic State | 2022 |
Paeoniflorin ameliorates diabetic liver injury by targeting the TXNIP-mediated NLRP3 inflammasome in db/db mice.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Liver; Glucosides; Inflammasomes; Mice; Molecular Docking Simulation; Monoterpenes; NLR Family, Pyrin Domain-Containing 3 Protein; Reactive Oxygen Species; Thioredoxins | 2022 |
Preventive effect of salicin ether against type-2 diabetes mellitus through targeting PPARγ-regulated gene expression.
Topics: AMP-Activated Protein Kinases; Benzyl Alcohols; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Diabetes Mellitus, Type 2; Ether; Gene Expression; Glucosides; Humans; PPAR gamma; Proto-Oncogene Proteins c-akt; Rosiglitazone | 2022 |
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney Transplantation; Male; Metabolic Syndrome; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Topics: Administration, Oral; Benzhydryl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate; Spain | 2022 |
Cyanidin-3-O-Glucoside Ameliorates Palmitic-Acid-Induced Pancreatic Beta Cell Dysfunction by Modulating CHOP-Mediated Endoplasmic Reticulum Stress Pathways.
Topics: Animals; Anthocyanins; Apoptosis; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Glucosides; Insulin-Secreting Cells; Mice; Palmitic Acid; Pancreatic Hormones; Signal Transduction; Transcription Factor CHOP | 2022 |
Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Endothelial Cells; Glucosides; Mice; Retina | 2022 |
Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Humans; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Streptozocin | 2022 |
Skin Dryness Induced in the KK-Ay/TaJcl Type 2 Diabetes Mouse Model Deteriorates Following Dapagliflozin Administration.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyaluronic Acid; Hypoglycemic Agents; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss | 2022 |
Dapagliflozin Attenuates Sympathetic and Pressor Responses to Stress in Young Prehypertensive Spontaneously Hypertensive Rats.
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Hypertension; Muscle Contraction; Rats; Rats, Inbred SHR; Sympathetic Nervous System | 2022 |
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Retrospective Studies | 2022 |
SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
Topics: Amino Acids, Branched-Chain; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glucosides; Mammals; Mice; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry | 2022 |
Novel Associations of Empagliflozin on the Gut Microbiome and Metabolome in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucosides; Humans; Metabolome | 2022 |
Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Insulin; Interleukin-6; Mice; Mice, Knockout, ApoE; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2022 |
SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Benzhydryl Compounds; Cardiomyopathies; Collagen; Diabetes Mellitus, Type 2; Fibrosis; Glucose; Glucosides; Heart Diseases; Inflammation; Mice; NF-kappa B; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Male; Pancreatitis; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glucose; Glucosides; MicroRNAs; Rats; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2022 |
Pharmacological analysis of Empagliflozin: Acting through the CaMKII pathway in type 2 diabetes and acute cardiovascular events.
Topics: Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Molecular Docking Simulation | 2022 |
Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Proprotein Convertase 9; Sodium-Glucose Transporter 2; Subtilisins | 2022 |
Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Heart Ventricles; Humans; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2022 |
Authors' reply to the letter to the editor regarding "Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Proprotein Convertase 9; Subtilisins | 2022 |
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Prediabetic State; Stroke Volume | 2022 |
Letter to editor regarding effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Proprotein Convertase 9; Subtilisins | 2022 |
Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Glucosides; Glycocalyx; Humans; Inflammation | 2022 |
Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Models, Economic | 2022 |
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model.
Topics: Acetates; Animals; Antioxidants; Benzhydryl Compounds; Blood Glucose; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Endoribonucleases; Glucose Transporter Type 4; Glucosides; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Leukotriene Antagonists; Metformin; Muscle, Skeletal; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Response Elements; Streptozocin; Sulfides | 2022 |
Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
Topics: Animals; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Fibrosis; Fructose; Glucose; Glucosides; Heart Diseases; Insulin Resistance; Mitochondria; Oxidative Stress; Palmitates; Palmitic Acid; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin in patients hospitalized for acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy.
Topics: Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Glucosides; Heart Failure; Male; Mice; Mitochondria; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Polydatin prevents lipotoxicity-induced dysfunction in pancreatic β-cells by inhibiting endoplasmic reticulum stress and excessive autophagy.
Topics: Animals; Apoptosis; Autophagy; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Fatty Acids, Nonesterified; Glucosides; Insulin Resistance; Insulin-Secreting Cells; Mice; Palmitates; Stilbenes; Tunicamycin | 2022 |
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrimidines; Republic of Korea; Thiazolidinediones; Treatment Outcome | 2022 |
Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients.
Topics: Benzhydryl Compounds; C-Reactive Protein; Cardiomyopathies; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Heart Failure; Humans; Interleukin-6; Tumor Necrosis Factor-alpha | 2022 |
Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chitosan; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Pharmaceutical Preparations | 2022 |
Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hypoglycemic Agents; Mice; Stroke Volume | 2022 |
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; COVID-19; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Morbidity; Pandemics; Prospective Studies; Pulse Wave Analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome; Vascular Stiffness | 2022 |
Response to Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases.
Topics: Adolescent; Benzhydryl Compounds; Delivery of Health Care; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; State Medicine; Stroke Volume | 2023 |
Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota.
Topics: Albumins; Animals; Anti-Bacterial Agents; Bacteria; Benzhydryl Compounds; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Volatile; Gastrointestinal Microbiome; Glucosides; Lipopolysaccharides; Mice; Occludin; RNA, Ribosomal, 16S; Sodium; Sodium-Glucose Transporter 2; Streptozocin | 2022 |
The position of SGLT2 inhibitors in current medical practice - update 2022.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.
Topics: Albumins; Animals; Benzhydryl Compounds; Caspase 3; Chemokines; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Interleukin-10; Mice; Network Pharmacology; PPAR gamma; RNA, Long Noncoding; RNA, Messenger; Sequence Analysis, RNA; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta | 2022 |
Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin.
Topics: Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Prospective Studies; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
Topics: Acetonitriles; Animals; Benzhydryl Compounds; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glucuronosyltransferase; Liver Neoplasms; Rats; Reproducibility of Results; RNA, Messenger; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib; Tandem Mass Spectrometry; Uridine Diphosphate | 2022 |
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2022 |
A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; United States | 2022 |
Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; South Africa | 2023 |
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; White | 2023 |
Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2022 |
The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus.
Topics: Arrhythmias, Cardiac; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male | 2023 |
Taxifolin-3-O-glucoside from Osbeckia nepalensis Hook. mediates antihyperglycemic activity in CC1 hepatocytes and in diabetic Wistar rats via regulating AMPK/G6Pase/PEPCK signaling axis.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glucosides; Hepatocytes; Hypoglycemic Agents; Liver; Molecular Docking Simulation; Rats; Rats, Wistar | 2023 |
Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Drug eruption associated with empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Treatment Outcome | 2022 |
Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Is Dapagliflozin a Cardiac Anti-Aging Drug?
Topics: Aging; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2023 |
Trace element equilibrium in acute heart failure and the effect of empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Trace Elements | 2023 |
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies | 2023 |
Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2023 |
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Horse Diseases; Horses; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
[In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?]
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic | 2023 |
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Heart Failure, Diastolic; Hospitalization; Humans; Male; Medicare; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2023 |
Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucose; Glucosides; Humans; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2023 |
In brief: Expanded heart failure indication for dapagliflozin (Farxiga).
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Oral Empagliflozin Receives FDA Approval for Children With Diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Child; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; United States; United States Food and Drug Administration | 2023 |
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Topics: Benzhydryl Compounds; Cohort Studies; Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2023 |
Empagliflozin (Jardiance) for type 2 diabetes in children.
Topics: Benzhydryl Compounds; Child; Diabetes Mellitus, Type 2; Glucosides; Humans | 2023 |
Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Stroke Volume | 2023 |
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2023 |
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
Topics: Aged; Asian People; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
Topics: Adult; Age Factors; Aged; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Medicare; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Statistics, Nonparametric; Vascular Stiffness | 2020 |
Optimal designs for regional bridging studies using the Bayesian power prior method.
Topics: Bayes Theorem; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Development; Glucosides; Humans; Models, Statistical; Research Design; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Decision-Making; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Hospitalization; Humans; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protective Factors; Research Design; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sarcopenia; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of sodium-glucose co-transporter-2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: A multi-institutional cohort study.
Topics: Aged; Alanine Transaminase; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Taiwan | 2020 |
Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hyperglycemia; Kidney Tubules, Proximal; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Nephrology; Pharmacists; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2019 |
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiophenes | 2019 |
Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucose; Glucosides; Glutamate Plasma Membrane Transport Proteins; Hypoglycemic Agents; Kidney; Kidney Diseases; Non-alcoholic Fatty Liver Disease; Oryzias; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
A new perspective on lowering CV risk from hypoglycaemia.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia | 2020 |
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Administration Routes; Drug Administration Schedule; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Econometric; Models, Statistical; Network Meta-Analysis; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Spain | 2020 |
Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Topics: Benzhydryl Compounds; Body Weight; Cardiometabolic Risk Factors; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Female; Glucose; Glucosides; Hemodynamics; Humans; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.
Topics: Animals; Azoxymethane; Benzhydryl Compounds; Blood Glucose; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hypoglycemic Agents; Mice; Mice, Inbred NOD; Mice, Obese; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha | 2019 |
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Topics: Benzhydryl Compounds; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Middle Aged; Sitagliptin Phosphate; United States; Weight Loss | 2019 |
Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus.
Topics: Adiposity; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fibrosis; Glucosides; Heart Function Tests; Heart Ventricles; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardium; Triglycerides | 2019 |
Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Topics: Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Erythrocyte Count; Erythrocytes; Erythropoietin; Ferritins; Glucosides; Hematocrit; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Sodium Glucose Cotransporter 2 Inhibitors: Searching for Mechanisms in the Wake of Large, Positive Cardiovascular Outcomes Trials.
Topics: Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renin-Angiotensin System; Risk Factors; Uric Acid | 2020 |
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Lipolysis; Male; Melatonin; Mice; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2 inhibitors for primary prevention of cardiovascular events.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Prevention; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Novel polydatin-loaded chitosan nanoparticles for safe and efficient type 2 diabetes therapy: In silico, in vitro and in vivo approaches.
Topics: Animals; Biomarkers; Body Weight; Chitosan; Chlorocebus aethiops; Diabetes Mellitus, Type 2; Drug Carriers; Drug Liberation; Glucosides; Hypoglycemic Agents; Male; Molecular Conformation; Molecular Dynamics Simulation; Nanoparticles; Particle Size; Rats; Rats, Wistar; Safety; Stilbenes; Vero Cells | 2020 |
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Topics: Animals; Atrial Fibrillation; Atrial Function, Left; Atrial Remodeling; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucosides; Heart Rate; Male; Membrane Potential, Mitochondrial; Mitochondria, Heart; Mitochondrial Proteins; Organelle Biogenesis; Oxidative Stress; Rats, Sprague-Dawley; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2019 |
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Duration of Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Italy; Male; Middle Aged; Patient Safety; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progression; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rodentia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eligibility Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Reproducibility of Results; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain | 2019 |
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiology; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Europe; Glucagon-Like Peptide-1 Receptor; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2020 |
Class effect: dapagliflozin reduces cardiovascular and kidney events.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Kidney Diseases | 2020 |
The authors reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hemodynamics; Humans; Renal Insufficiency, Chronic | 2020 |
Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Glucosides; Hemodynamics; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction; Vasodilation; Young Adult | 2020 |
Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose; Glucosides; Humans; Mitochondria; Rats; Sodium; Sodium-Glucose Transporter 2; Streptozocin | 2020 |
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Japan; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2020 |
Topics: Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Heart Failure; Humans; Male; Mortality; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2020 |
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Linagliptin; Machine Learning; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
Topics: Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Epithelial Cells; Gene Expression Regulation; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Kidney; Kidney Tubules, Proximal; Oxidative Stress; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Dapagliflozin restores insulin and growth hormone secretion in obese mice.
Topics: Animals; Benzhydryl Compounds; Body Composition; Diabetes Mellitus, Type 2; Energy Metabolism; Gene Expression; Glucosides; Growth Hormone; Humans; Insulin; Insulin Resistance; Insulin Secretion; Mice, Inbred C57BL; Mice, Knockout; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
Topics: ADAM10 Protein; Amyloid Precursor Protein Secretases; Antineoplastic Agents; Benzhydryl Compounds; Carcinoembryonic Antigen; Cell Adhesion; Cell Line, Tumor; Collagen Type I; Collagen Type IV; Colonic Neoplasms; Diabetes Mellitus, Type 2; Discoidin Domain Receptor 1; Fibronectins; Gene Knockdown Techniques; Glucosides; Glucuronosyltransferase; Humans; Laminin; Membrane Proteins; Phosphorylation; RNA, Small Interfering; Sodium-Glucose Transporter 2 Inhibitors; Vitronectin | 2020 |
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Heart Ventricles; Hemodynamics; Humans; Hypertrophy, Right Ventricular; Lung; Male; Models, Animal; Monocrotaline; Mortality; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Sprague-Dawley; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors; Vascular Remodeling | 2020 |
Dapagliflozin Cut Risk of Worsening Heart Failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Topics: Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Glucose; Glucosides; Humans; Lipid Metabolism; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice.
Topics: AMP-Activated Protein Kinases; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzhydryl Compounds; Blotting, Western; Cell Line; Chromatin Immunoprecipitation; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Type 2; Glucosides; HEK293 Cells; Humans; Hyperuricemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2020 |
Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucosides; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Benzhydryl Compounds; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Male; Plasma; Triglycerides | 2020 |
Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Denmark; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Research Subjects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2020 |
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Observational Studies as Topic; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Models, Biological; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Systems Biology | 2020 |
Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction.
Topics: Aged; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Tremor; Valproic Acid; Weight Loss | 2020 |
It's Not All About the Cardiomyocyte: Fibroblasts, Empagliflozin, and Cardiac Remodelling.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Extracellular Matrix; Fibroblasts; Glucosides; Humans; Myocytes, Cardiac; Myofibroblasts; Ventricular Remodeling | 2020 |
Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial".
Topics: Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
SGLT2i and postglomerular vasodilation.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation | 2020 |
The authors reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation | 2020 |
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2020 |
Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats.
Topics: Animals; Benzhydryl Compounds; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression Profiling; Genomics; Glucose; Glucosides; Liver; Male; Rats; Rats, Wistar; RNA-Seq; Signal Transduction; Transcriptome | 2020 |
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzhydryl Compounds; Brain; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucosides; Male; Mice; Mice, Transgenic | 2020 |
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuresis; Natriuretic Agents; Prospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
[Sodium glucose co-transporter 2 inhibitors in heart failure therapy].
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diastole; Diuresis; Female; Glucosides; Glycosuria; Heart Failure; Heart Ventricles; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Myocardium; Natriuresis; Physical Endurance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Walk Test | 2020 |
Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
Comparison of the effect of dapagliflozin on contrast to standard therapy of the patients with type 2 diabetes mellitus and concomitant obesity, their effect on laboratory and anthropometric parameters.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Treatment Outcome | 2020 |
SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stem Cells | 2020 |
SGLT-2 Inhibitors and Regenerative Cell Exhaustion.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stem Cells | 2020 |
The insulin-sensitising properties of the ellagitannin geraniin and its metabolites from
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Biological Transport; Cell Differentiation; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucosides; Hydrolyzable Tannins; Hyperglycemia; Insulin; Lipolysis; Mice; Obesity; Plant Extracts; Sapindaceae | 2020 |
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Disease Progression; Enzyme Activation; Fibrosis; Glucosides; Inflammasomes; Male; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred C57BL; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Purinergic P2Y Receptor Antagonists; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ticagrelor; TOR Serine-Threonine Kinases; Ventricular Function, Left; Ventricular Remodeling | 2020 |
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucosides; Immunohistochemistry; Kidney Function Tests; Kidney Glomerulus; Linagliptin; Mice; Mice, Inbred Strains; Mice, Transgenic; Podocytes; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients.
Topics: Benzhydryl Compounds; Blood Flow Velocity; Diabetes Mellitus, Type 2; Glucosides; Humans; Ultrasonography; Ultrasonography, Doppler, Color | 2020 |
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Male; Prognosis; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Norway; Proportional Hazards Models; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Sweden | 2020 |
Empagliflozin improves left ventricular diastolic function of db/db mice.
Topics: Amino Acids, Branched-Chain; Animals; Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fat; Glucose; Glucosides; Humans; Hypoglycemic Agents; Ketone Bodies; Male; Mice; Mice, Transgenic; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Ventricular Function, Left | 2020 |
Effects of sodium glucose co-transporter 2 inhibitors on genital infections in female patients with type 2 diabetes mellitus- Real world data analysis.
Topics: Adult; Benzhydryl Compounds; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Israel; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2020 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2020 |
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Mortality; Sodium-Glucose Transporter 2 Inhibitors; Treatment Failure; Treatment Outcome | 2020 |
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebo Effect; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Italy; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Humans; Hypernatremia; Hypoglycemic Agents; Hypokalemia; Insulin; Intestinal Pseudo-Obstruction; Kidney Pelvis; Metformin; Patient Discharge; Sodium-Glucose Transporter 2 Inhibitors; Ureter; Withholding Treatment | 2020 |
Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Sitagliptin Phosphate; Young Adult | 2020 |
Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin).
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Diet, Ketogenic; Female; Fluid Therapy; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Time-to-Treatment | 2020 |
[Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2020 |
Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications.
Topics: Adult; Antimanic Agents; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Lithium Compounds; Male; Medication Adherence; Metformin; Psychotic Disorders; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucosides; Metformin; Random Allocation; Rats; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
Topics: Administration, Oral; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Metformin | 2020 |
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Topics: Adult; Aged; Benzhydryl Compounds; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Female; Glucosides; Heart Failure; Hospital Costs; Humans; Incidence; Male; Middle Aged; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
An Escape From Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin Glargine; Metformin | 2020 |
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult | 2020 |
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Biomechanical Phenomena; Bone Density; Bone Matrix; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Liraglutide; Mice; Osteogenesis | 2020 |
Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Intraoperative Complications; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thoracic Surgical Procedures | 2021 |
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endocrine Cells; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glucosides; Insulin; Insulin-Secreting Cells; Male; Mice; Proprotein Convertase 1; Regeneration; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin (Farxiga) - a new indication for heart failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Netherlands; Quality-Adjusted Life Years | 2021 |
Dapagliflozin for heart failure: is it a class effect?
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Topics: Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Models, Biological; Randomized Controlled Trials as Topic; Renal Insufficiency; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
Topics: Adamantane; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Metformin; Prospective Studies; Randomized Controlled Trials as Topic | 2021 |
Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
Topics: Animals; Benzhydryl Compounds; C-Peptide; Cardiotonic Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Heart Failure; Humans; Hyperinsulinism; Hypertension; Male; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertrophy, Left Ventricular; Predictive Value of Tests; Ventricular Function, Left | 2021 |
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Economic; Outcome Assessment, Health Care; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Correction of anemia by dapagliflozin in patients with type 2 diabetes.
Topics: Anemia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Serum Albumin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Topics: Acute Coronary Syndrome; Adolescent; Adsorption; Adult; Aged; Animals; Aspergillus; Aspergillus oryzae; Benzhydryl Compounds; Biocatalysis; Biological Availability; Biomarkers; Biomass; Brain; Brain Injuries, Traumatic; Cadmium; Calorimetry, Differential Scanning; Carbon; Carcinoma, Transitional Cell; Catalysis; Cell Death; Cells, Immobilized; Child; Child, Preschool; China; Chitosan; Creatine Kinase, MB Form; Cyclodextrins; Defibrillators, Implantable; Dendritic Spines; Diabetes Mellitus, Type 2; Diastole; Directed Molecular Evolution; Disease Models, Animal; Disease Progression; Down-Regulation; Electric Countershock; Electrolytes; Electrophoresis, Polyacrylamide Gel; Endopeptidase K; Environmental Monitoring; Esterification; Esters; Feasibility Studies; Female; Fruit; Gene Library; Glial Fibrillary Acidic Protein; Glucosides; Hippocampus; Humans; Hydrogen-Ion Concentration; Hydrolysis; Infant; Infant, Newborn; Inflammation; Ions; Kinetics; Lipase; Liver Cirrhosis; Logistic Models; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malus; Maze Learning; Melatonin; Mercury; Mice; Mice, Inbred C57BL; Middle Aged; Mining; Molecular Docking Simulation; Molecular Weight; Molybdenum; Motor Cortex; Mutagenesis, Site-Directed; Mutation; Neoplasm Recurrence, Local; Nephrectomy; Nephroureterectomy; Neurons; Oxidative Stress; Patient Discharge; Proof of Concept Study; Propionates; Prospective Studies; Protein Engineering; Protein Structure, Quaternary; Protons; PrPC Proteins; PrPSc Proteins; Rats; Rats, Wistar; Recovery of Function; Registries; Retrospective Studies; Rivers; ROC Curve; Scrapie; Sodium-Glucose Transporter 2 Inhibitors; Solubility; Solvents; Spatial Memory; Stereoisomerism; Synapses; Temperature; Time Factors; Treatment Outcome; Troponin T; Urinary Bladder Neoplasms; Urinary Tract; Ventricular Function, Left; Ventricular Remodeling; Water; Water Pollutants, Chemical; Water Purification; X-Ray Diffraction; Young Adult; Zebrafish | 2021 |
Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Membrane Permeability; Cholinesterases; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Glycoside Hydrolases; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Molecular Structure; Phosphorylation; Polyphenols; Proto-Oncogene Proteins c-fyn; tau Proteins | 2020 |
Single-pill Combination of Empagliflozin and Linagliptin in Real World Indian Type 2 Diabetes Patient (GRID).
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; India; Linagliptin; Male; Prospective Studies | 2020 |
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Topics: Benzhydryl Compounds; Biphenyl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Gastric Emptying; Glucagon; Glucosides; Glycerol; Half-Life; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Product Surveillance, Postmarketing; Thiophenes | 2021 |
Evaluation of dapagliflozin in the treatment of heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis.
Topics: Ascites; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hydrothorax; Liver Cirrhosis, Biliary; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Volume; Computer Simulation; Diabetes Mellitus, Type 2; Diuresis; Glomerular Filtration Barrier; Glucosides; Heart Failure; Hematocrit; Hemodynamics; Humans; Models, Theoretical; Natriuresis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Male; Mice; Mice, Obese; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.
Topics: Adult; Benzhydryl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Female; Glucosides; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
Topics: Aged; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Female; Glucosides; Humans; Male; Middle Aged; Myocardium; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; United States | 2021 |
Cardioprotective effects of short-term empagliflozin treatment in db/db mice.
Topics: Animals; Benzhydryl Compounds; Body Weight; Cardiotonic Agents; Citrate (si)-Synthase; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, Western; Gene Expression Regulation; Glucosides; Male; Mice; Myocardium; Phosphorylation; Proto-Oncogene Proteins c-akt; Treatment Outcome | 2020 |
In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans | 2020 |
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Outcome Assessment, Health Care; Polyuria; Sodium-Glucose Transporter 2 Inhibitors; Tertiary Care Centers; Urinary Tract Infections; Young Adult | 2021 |
EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors | 2020 |
Inhibition of HMGB1 involved in the protective of salidroside on liver injury in diabetes mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cell Line; Cytokines; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hepatitis; HMGB1 Protein; Humans; Hypoglycemic Agents; Liver; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Phenols; Receptor for Advanced Glycation End Products; Signal Transduction; Toll-Like Receptor 4 | 2020 |
Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Quality of Life; Quality-Adjusted Life Years; Sitagliptin Phosphate; United States | 2021 |
Cardioprotective effects of polydatin against myocardial injury in diabetic rats via inhibition of NADPH oxidase and NF-κB activities.
Topics: Animals; Cardiomyopathies; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Fallopia japonica; Glucosides; Heart; Male; Myocardium; NADPH Oxidases; NF-kappa B; Oxidative Stress; Rats, Sprague-Dawley; Stilbenes | 2020 |
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
Topics: Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Compounding; Glucosides; Humans; Hypoglycemic Agents; Linagliptin | 2021 |
Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus.
Topics: Animals; Area Under Curve; Benzhydryl Compounds; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Drug Liberation; Emulsions; Glucosides; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Mice; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Plant Oils; Rats; Rats, Wistar; Sitagliptin Phosphate; Solubility; Surface Properties | 2021 |
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Incidence; Stroke Volume | 2021 |
EMPEROR-REDUCED reigns while EMPERIAL whimpers.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Insulin; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Inflammasomes; Liraglutide; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Peripheral Arterial Disease; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Steviol Glycosides Supplementation Affects Lipid Metabolism in High-Fat Fed STZ-Induced Diabetic Rats.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Supplements; Diterpenes, Kaurane; Glucosides; Lipid Metabolism; Male; Rats; Rats, Wistar | 2020 |
Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis
Topics: Animals; Antioxidants; Benzhydryl Compounds; Cell Line; Diabetes Mellitus, Type 2; Diet, High-Fat; Forkhead Box Protein O1; Gene Expression Regulation; Gluconeogenesis; Glucose; Glucosides; Humans; Male; Mice; Mice, Obese; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Random Allocation; Resveratrol; Sodium-Glucose Transporter 2 Inhibitors; Up-Regulation | 2021 |
Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Sodium, Dietary | 2021 |
Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Glucosides; Hyperglycemia; Male; Obesity; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Topics: Animals; Ascites; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drug Therapy, Combination; Furosemide; Glucosides; Hemodynamics; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
Topics: Diabetes Mellitus, Type 2; Diamond; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2021 |
Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions.
Topics: Aged; Benzhydryl Compounds; Brain Neoplasms; Coronary Angiography; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Echocardiography; Glucosides; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Nivolumab; Sodium-Glucose Transporter 2 Inhibitors; Takotsubo Cardiomyopathy | 2021 |
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes Mellitus, Type 2; Drainage; Female; Fournier Gangrene; Glucosides; Hospitals, Rural; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Obesity; Perineum; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2021 |
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia, Eastern; Benzhydryl Compounds; Data Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Risk; Treatment Outcome; Young Adult | 2021 |
Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Glucosides; Inflammation; Kidney; Male; Rats; Sodium-Glucose Transporter 2 Inhibitors; Vascular Endothelial Growth Factor A | 2021 |
Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cell Death; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
Topics: Benzhydryl Compounds; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Treatment Outcome | 2021 |
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Disease Risk Factors; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Magnetic ligand fishing using immobilized DPP-IV for identification of antidiabetic ligands in lingonberry extract.
Topics: Animals; Anthocyanins; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Galactosides; Glucosides; Humans; Hypoglycemic Agents; Ligands; Magnetic Phenomena; Magnetics; Plant Extracts; Swine; Vaccinium vitis-idaea | 2021 |
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?
Topics: Benzhydryl Compounds; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Phytosterols | 2021 |
Early eGFR decline after SGLT2i initiation: knowns and unknowns.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Salidroside alleviates diabetic neuropathic pain through regulation of the AMPK-NLRP3 inflammasome axis.
Topics: AMP-Activated Protein Kinases; Analgesics; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Ganglia, Spinal; Glucosides; Hypoglycemic Agents; Inflammasomes; Insulin Resistance; Male; Neuralgia; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Pain Threshold; Phenols; Rats, Sprague-Dawley; Signal Transduction | 2021 |
The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Interleukin-17; Interleukin-23; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; RAW 264.7 Cells; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; TOR Serine-Threonine Kinases | 2021 |
Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Glucosides; Humans; Hypertriglyceridemia; Male; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fluorescent Dyes; Glucosides; Kidney; Liver; Mice; Sodium-Glucose Transporter 2 | 2021 |
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years | 2021 |
Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Expert Testimony; Female; Glucosides; Heart Failure; Humans; Male; Poland; Quality of Life; Stroke Volume; Ventricular Function, Left | 2021 |
Slowing Progression in CKD: DAPA CKD and Beyond.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Glucosides; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans | 2021 |
Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Tertiary Care Centers | 2021 |
Isolation and characterization of novel process-related impurities in empagliflozin.
Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Contamination; Glucosides; Humans; Magnetic Resonance Spectroscopy | 2021 |
Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption.
Topics: Benzhydryl Compounds; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Motivation; Phytosterols; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports.
Topics: Aged; Benzhydryl Compounds; Candidiasis; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmaceutical Preparations; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Pharmaceutical Preparations; Plasma Volume; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2021 |
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Topics: Animals; Aquaporin 2; Body Fluids; Diabetes Mellitus, Type 2; Diuresis; Drinking; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Osmolar Concentration; Pioglitazone; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effect of syringin (eleutheroside B) on the physiological and hematological parameters in STZ induced Type II diabetic Wistar rats.
Topics: Administration, Oral; Animals; Blood Cell Count; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drinking; Glucosides; Hypoglycemic Agents; Male; Phenylpropionates; Rats, Wistar; Streptozocin | 2020 |
Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Growth Hormone; Humans; Hypoglycemic Agents; Male; Prediabetic State | 2021 |
Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Eating; Glucose; Glucosides; Hypothalamic Area, Lateral; Phosphorylation; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Potassium; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
Topics: Benzhydryl Compounds; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Standard of Care | 2021 |
Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyperglycemia; Kidney; Kidney Diseases; Male; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Retrospective Studies; Sitagliptin Phosphate; Spain; Treatment Outcome | 2021 |
First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Qatar | 2022 |
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Primary Prevention; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Sleep Apnea, Obstructive | 2021 |
Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Sleep Apnea, Obstructive | 2021 |
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Topics: Acute Disease; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Population Surveillance; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome | 2021 |
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Facile Approach to C-Glucosides by Using a Protecting-Group-Free Hiyama Cross-Coupling Reaction: High-Yielding Dapagliflozin Synthesis.
Topics: Benzhydryl Compounds; Catalysis; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2021 |
Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Male | 2021 |
Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; DNA, Mitochondrial; Dynamins; Gene Dosage; Glucosides; GTP Phosphohydrolases; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Obesity; Oxidative Phosphorylation; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Random Allocation; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2021 |
[Empagliflozin in the elderly].
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fat; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibroblasts; Fibrosis; Glucosides; Male; Mesoderm; Rats; Signal Transduction; Smad4 Protein; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta | 2021 |
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metabolome; Mice; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
Topics: Administration, Oral; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate; United States | 2021 |
Successful withdrawal of erythropoiesis-stimulating agent after administration of an SGLT2 inhibitor, tofogliflozin, in people with diabetes.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Erythropoiesis; Female; Follow-Up Studies; Glucosides; Hematinics; Humans; Male; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Withholding Treatment | 2022 |
Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies | 2021 |
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
Topics: Albumins; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Benzhydryl Compounds; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eosine Yellowish-(YS); Glucose; Glucosides; Hematoxylin; Inflammasomes; Insulins; Kidney; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Periodic Acid; Proto-Oncogene Proteins c-akt; Ticagrelor | 2022 |
Association of IL-17 Inhibitor and SGLT2 Inhibitor with Candida Pyelonephritis.
Topics: Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Candida glabrata; Candidiasis, Invasive; Dermatologic Agents; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin Detemir; Liraglutide; Middle Aged; Psoriasis; Pyelonephritis; Recurrence; Sepsis; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2021 |
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume | 2021 |
Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume | 2021 |
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Combinations; Glucosides; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, Protein-Restricted; Glucose; Glucosides; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidas
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucose; Glucosides; Humans; Hypoglycemic Agents; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2021 |
Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
Topics: Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin | 2022 |
Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.
Topics: Animals; Benzhydryl Compounds; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Electrocardiography; Erythropoietin; Glucosides; Male; MAP Kinase Signaling System; Myocardium; Rats, Wistar; Streptozocin | 2021 |
Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Fructose; Glucosides; Hyperglycemia; Inflammation Mediators; Mice; Mice, Inbred C57BL; Nanoparticles; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Linagliptin; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |
Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2021 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left | 2017 |
Diabetes Drug Receives New Indication.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Labeling; Drug Repositioning; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Steviol glycosides enhance pancreatic beta-cell function and taste sensation by potentiation of TRPM5 channel activity.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Diterpenes, Kaurane; Female; Glucosides; HEK293 Cells; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Mice; Mice, Knockout; Patch-Clamp Techniques; Sweetening Agents; Taste; TRPM Cation Channels | 2017 |
Insight into anti-diabetic effect of low dose of stevioside.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diterpenes, Kaurane; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Mice; Phytotherapy; Plant Extracts; Stevia | 2017 |
Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Polydatin impairs mitochondria fitness and ameliorates podocyte injury by suppressing Drp1 expression.
Topics: Animals; Apoptosis; Blood Glucose; Cell Line; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Dynamins; Glucosides; Mice, Inbred C57BL; Mitochondria; Mitochondrial Dynamics; Podocytes; Reactive Oxygen Species; RNA Interference; Signal Transduction; Stilbenes; Transfection | 2017 |
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Topics: Adult; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Obesity; Plasma Volume; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Real world points to SGLT-2 blockers advantage.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Abnormalities; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Canagliflozin; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Retrospective Studies; United States; Young Adult | 2017 |
Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Education as Topic; Patient Selection; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Topics: Adamantane; AMP-Activated Protein Kinases; Animals; Apoptosis; Benzhydryl Compounds; CARD Signaling Adaptor Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fibroblasts; Fibrosis; Glucosides; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mice, Obese; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Function, Left | 2017 |
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Topics: Absorptiometry, Photon; Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus - Is it empaglifozin or the class?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Introduction.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Urinary Bladder Neck Obstruction; Urinary Tract Infections | 2017 |
Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Practice Patterns, Physicians'; Primary Health Care; Time Factors; Treatment Outcome; United Kingdom; Weight Loss | 2017 |
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rodentia; Signal Transduction; Sodium-Glucose Transporter 2 | 2017 |
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Creatinine; Deoxyglucose; Diabetes Mellitus, Type 2; Female; Glucokinase; Glucosides; Glycosuria; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Male; Middle Aged; Mutation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |
Introduction.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Paeoniflorin prevents TLR2/4-mediated inflammation in type 2 diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; China; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Medicine, Chinese Traditional; Mice; Monoterpenes; Protective Agents; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2017 |
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2017 |
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Treatment Outcome | 2017 |
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Calcium-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Male; Mice; Models, Genetic; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Ventricular Dysfunction, Left | 2017 |
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
Topics: Australia; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Electronic Health Records; Female; General Practice; Glucosides; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2017 |
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.
Topics: Aged; Benzhydryl Compounds; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Medical Audit; Middle Aged; Mycoses; Odds Ratio; Recurrence; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; United Kingdom | 2018 |
[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Liraglutide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2017 |
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Resistance; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Renin-Angiotensin System; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Can we go beyond surrogates?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors | 2017 |
Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors | 2017 |
Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2017 |
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Genetic; Ventricular Dysfunction, Left | 2017 |
Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials.
Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Risk Factors; Treatment Outcome; Young Adult | 2017 |
Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Topics: Benzhydryl Compounds; Blood Vessels; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Kidney Tubules, Proximal; Myocardium; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchangers | 2017 |
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Intra-Abdominal Fat; Lipids; Liver; Magnetic Resonance Spectroscopy; Male; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed | 2017 |
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden | 2018 |
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Morbidity; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Topics: Acute Kidney Injury; Aged; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Hemoglobins; Humans; Hypoglycemic Agents; Incidence; Kidney; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2017 |
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2018 |
[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].
Topics: Benzhydryl Compounds; Blood Glucose; Critical Care; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fluid Therapy; Glucosides; Humans; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucosides; Humans; Male; Metabolomics; Middle Aged; Myocardium; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fournier Gangrene; Genital Diseases, Male; Glucosides; Humans; Insulin; Male; Metformin; Scrotum | 2017 |
Cardiovascular safety of canagliflozin.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2017 |
Reply to: Cardiovascular safety of canagliflozin.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2017 |
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Ferritins; Glucosides; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2; Thiophenes | 2017 |
Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
Topics: Animals; Blood Glucose; Body Temperature; Circadian Rhythm; Diabetes Mellitus, Type 2; Drinking; Eating; Energy Metabolism; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Crowdsourcing; Data Mining; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2017 |
Empagliflozin across the stages of diabetic heart disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans | 2018 |
Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Carcinoembryonic Antigen; Cetuximab; Colonic Neoplasms; Diabetes Mellitus, Type 2; Glucosides; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glucosides; Humans; Kidney; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness | 2017 |
Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Benzhydryl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Ketosis; Middle Aged; Young Adult | 2018 |
Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Outcome Assessment, Health Care; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2018 |
Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Topics: Adipose Tissue; Animal Feed; Animals; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Solutions; Sugars; Thiophenes | 2018 |
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report.
Topics: Abdominal Pain; Anorexia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2; Vomiting | 2018 |
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Costs; Female; Glucosides; Humans; Male; Middle Aged; Morbidity; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome | 2018 |
Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Energy Intake; Female; Glucosides; Humans; Hyperphagia; Male; Middle Aged; Sodium-Glucose Transport Proteins; Sugars; Surveys and Questionnaires; Young Adult | 2018 |
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 | 2017 |
Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 | 2018 |
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Registries; Thiophenes; Treatment Outcome; Triglycerides | 2018 |
Initiation of dapagliflozin and treatment-emergent fractures.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors | 2018 |
Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fluorine; Glucosides; Glycosylation; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Topics: Adipose Tissue; Adiposity; Benzhydryl Compounds; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Prospective Studies | 2018 |
Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Infections; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Topics: Benzhydryl Compounds; Bias; Canagliflozin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Mortality; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
[Triperygium wilfordii multiglucoside ameliorates kidney damage in diabetic rats by inhibiting the expressions of MBL and MASP2].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression; Glucosides; Male; Mannose-Binding Lectin; Mannose-Binding Protein-Associated Serine Proteases; Phytotherapy; Plant Preparations; Rats, Sprague-Dawley; Tripterygium | 2017 |
SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2018 |
The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Topics: Adipose Tissue; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Multidetector Computed Tomography; Pericardium; Plasminogen Activator Inhibitor 1; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Endothelial Cells; Glucosides; Heart Injuries; Humans; Mice; Mitochondria; Mitochondrial Dynamics; Protein Kinases | 2018 |
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium | 2018 |
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome | 2018 |
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Health Expenditures; Health Resources; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years; Sulfonylurea Compounds; Thiazolidinediones; United Nations; United States | 2018 |
[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Skin Diseases; Thiophenes; Treatment Outcome | 2018 |
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Glucosides; Hypoglycemic Agents; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Foot; Glucosides; Humans; Hypoglycemic Agents; Leg; Male; Middle Aged; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
Topics: Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors | 2018 |
A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors.
Topics: Adult; Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2018 |
Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus.
Topics: Asian People; Benzhydryl Compounds; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Electric Impedance; Female; Glucosides; Humans; Japan; Male; Middle Aged; Retrospective Studies | 2018 |
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Topics: Adamantane; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammasomes; Inflammation Mediators; Kidney; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Italy; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Dietary Carbohydrates; Fatty Acids; Glucosides; Hypoglycemic Agents; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
Topics: Benzhydryl Compounds; Canagliflozin; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Practice Patterns, Physicians'; Propensity Score; Research Design; Retrospective Studies; United States | 2018 |
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Topics: Abdominal Fat; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
Topics: Benzhydryl Compounds; Canagliflozin; Cause of Death; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate | 2018 |
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.
Topics: Aged; Benzhydryl Compounds; Blood Viscosity; Carotid Artery, Common; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Incretins; Liraglutide; Male; Middle Aged; Prospective Studies; Regional Blood Flow; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Stress, Mechanical; Time Factors; Treatment Outcome | 2018 |
Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Uric Acid | 2018 |
A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2018 |
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Hypertension; Kidney; Losartan; Male; Mice, Inbred C57BL; Nephrectomy; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gastrointestinal Microbiome; Glucosides; Intestines; Male; Mice; Muscle, Smooth, Vascular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Stiffness; Vasodilation | 2018 |
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Uric Acid | 2018 |
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2018 |
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2018 |
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2018 |
Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2018 |
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
Topics: Animals; Body Composition; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drinking; Eating; Epithelial Sodium Channels; Glucosides; Male; Natriuresis; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 3; Thiophenes; Time Factors; Water-Electrolyte Balance | 2018 |
Madeira moneywort (
Topics: alpha-Amylases; Antioxidants; Diabetes Mellitus, Type 2; Glucosidases; Glucosides; Lipase; Obesity; Oxidative Stress; Pharmaceutical Preparations; Phenols; Phytochemicals; Plant Extracts | 2019 |
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Renal Insufficiency, Chronic | 2018 |
The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Fasting; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Islam; Ketosis; Kidney; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2018 |
Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged | 2018 |
Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Subcutaneous Fat, Abdominal; Treatment Outcome | 2018 |
Increase in glycated haemoglobin concentrations after unwarranted prescription changes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Foot; Disease Progression; Dose-Response Relationship, Drug; Drug Substitution; Glucosides; Glycated Hemoglobin; Humans; Medical Futility; Practice Patterns, Physicians'; Retrospective Studies; Up-Regulation | 2018 |
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
Topics: Abdominal Pain; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dyspnea; Fatigue; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Nausea; Vomiting | 2018 |
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
Topics: Animals; Autophagy; Benzhydryl Compounds; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Male; Microscopy, Electron; Mitochondria, Heart; Mitochondrial Proteins; Mitochondrial Size; Myocardial Infarction; Myocytes, Cardiac; Rats, Inbred OLETF; Reactive Oxygen Species; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides; Vacuoles | 2018 |
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.
Topics: Adenosine Diphosphate; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; Glucosides; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Molecular Structure; Nitric Oxide; Platelet Aggregation; Rabbits; Structure-Activity Relationship; Venous Thrombosis | 2018 |
Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Incidence; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Ghrelin; Glucosides; Hypoglycemic Agents; Male; Postprandial Period; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Middle Aged; Prospective Studies; Treatment Outcome | 2019 |
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Endothelium, Vascular; Female; Glucosides; Glycosuria; GPI-Linked Proteins; Humans; Kidney; Mice, Inbred C57BL; Mice, Mutant Strains; Pulsatile Flow; Renal Circulation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness; Vasodilation | 2018 |
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Costs; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Incidence; Japan; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Safety; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Topics: Adult; Benzhydryl Compounds; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Medicare Part D; Metformin; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Sitagliptin Phosphate; United States | 2019 |
Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry.
Topics: Aged; Benzhydryl Compounds; Black or African American; Blood Pressure; Blood Pressure Determination; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Intersectoral Collaboration; Male; Middle Aged; Multicenter Studies as Topic; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Registries; Translational Research, Biomedical; Treatment Outcome; United States | 2019 |
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Italy; Kidney; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Treatment Outcome | 2019 |
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2019 |
The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Erectile Dysfunction; Glucosides; Male; Penile Erection; Rats; Rats, Inbred Strains; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Benzhydryl Compounds; Canada; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Registries; Retrospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Coma; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Antihyperglycemic medications for cardiovascular disease risk reduction.
Topics: Benzhydryl Compounds; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2018 |
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Resistance; Glucosides; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Water-Electrolyte Balance | 2019 |
Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fibroblast Growth Factors; Glucose; Glucosides; Homeostasis; Humans; Hyperglycemia; Insulin; Insulin Resistance; Kidney; Male; Mice; Mice, Inbred C57BL; PPAR delta; Sodium-Glucose Transporter 2 | 2018 |
Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Insulin; Insulin-Secreting Cells; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Dehydration; Diabetes Mellitus, Type 2; Electrolytes; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Young Adult | 2018 |
Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Asian People; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Topics: Aged; Albumins; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors | 2019 |
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Pancreatitis; Propensity Score; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Urinary Tract Infections; Venous Thromboembolism | 2018 |
Predictive antidiabetic activities of plants used by persons with Diabetes mellitus.
Topics: Apigenin; Bauhinia; Blood Glucose; Brazil; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Magnoliopsida; Male; Medicine, Traditional; Middle Aged; Passiflora; Patient Acceptance of Health Care; Phytochemicals; Phytotherapy; Plant Preparations; Plants, Medicinal; Syzygium | 2018 |
Dapagliflozin DECLAREd safe.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (Swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Blood Glucose; Cucurbitaceae; Diabetes Mellitus, Type 2; Diet, High-Fat; Fruit; Gluconeogenesis; Glucosides; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Plant Extracts; Protein Kinases; Streptozocin | 2019 |
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2018 |
Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
Topics: Aged; Aldosterone; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Renin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2019 |
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Male; Metabolome; Myocardial Infarction; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Electrocardiography; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Male; Middle Aged; Retrospective Studies | 2019 |
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Health Expenditures; Humans; Hypoglycemic Agents; Models, Economic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.
Topics: Benzhydryl Compounds; Blood Glucose; Body Composition; Body Fluids; Diabetes Mellitus, Type 2; Early Medical Intervention; Female; Follow-Up Studies; Glucosides; Graft Rejection; Graft Survival; Humans; Insulin; Islets of Langerhans Transplantation; Male; Middle Aged; Patient Safety; Pilot Projects; Postoperative Complications; Prognosis; Prospective Studies; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fournier Gangrene; Glucosides; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Research Design; Sweden; Treatment Outcome | 2019 |
Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Administration Schedule; Glucosides; Kidney; Maintenance Chemotherapy; Male; Obesity; Rats; Rats, Zucker; Time Factors | 2020 |
Topics: Adult; Aged; Animals; Antigens, Helminth; Apoptosis; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Carcinogenesis; Cardiovascular Diseases; Cell Line; Cell Nucleus; Cell Proliferation; Databases, Factual; Diabetes Complications; Diabetes Mellitus, Type 2; Endosonography; Feces; Female; Glomerular Filtration Rate; Glucosides; Glutathione; Humans; Logistic Models; Male; Middle Aged; Ovum; Oxidative Stress; Pancreas; Pancreatic Elastase; Pancreatitis, Chronic; Patient Safety; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Prospective Studies; Prostate; Risk Factors; Schistosoma; Schistosomiasis; Scotland; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Systole; Treatment Outcome | 2017 |
Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Ketosis; Renal Replacement Therapy; Saline Solution; Sodium Bicarbonate; Young Adult | 2019 |
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Biopsy; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Waist Circumference | 2020 |
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Topics: Appetite; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Eating; Female; Follow-Up Studies; Ghrelin; Glucosides; Glycated Hemoglobin; Glycemic Index; Humans; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Prognosis; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
Topics: Animals; Benzhydryl Compounds; Dehydration; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucocorticoids; Glucose; Glucosides; Humans; Insulin; Ketosis; Lipolysis; Liver; Male; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-1; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Topics: Animals; Antioxidant Response Elements; Antioxidants; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Glucosides; Mice, Inbred C57BL; Myocardium; NF-E2-Related Factor 2; Oxidative Stress; Phosphorylation; Signal Transduction; Smad Proteins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Polyphenols of Myrica faya inhibit key enzymes linked to type II diabetes and obesity and formation of advanced glycation end-products (in vitro): Potential role in the prevention of diabetic complications.
Topics: Aldehyde Reductase; alpha-Amylases; alpha-Glucosidases; Anthocyanins; Anti-Obesity Agents; Antioxidants; Azores; Diabetes Complications; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Flavonoids; Glucosides; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Lipase; Myrica; Obesity; Phytochemicals; Plant Extracts; Polyphenols; Portugal; Serum Albumin, Bovine | 2019 |
The involvement of phenolic-rich extracts from Galician autochthonous extra-virgin olive oils against the α-glucosidase and α-amylase inhibition.
Topics: Aldehydes; alpha-Amylases; alpha-Glucosidases; Cyclopentane Monoterpenes; Diabetes Mellitus, Type 2; Flavonoids; Glucosides; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Iridoid Glucosides; Iridoids; Olive Oil; Phenols; Plant Extracts; Pyrans; Spain | 2019 |
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prognosis; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Topics: Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Pharmacovigilance; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Metformin; Probability | 2019 |
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemia; Ketosis; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Non-alcoholic Fatty Liver Disease | 2020 |
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Topics: Benzhydryl Compounds; Cause of Death; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Stratifying the effects of SGLT2i.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Topics: Aged; Benzhydryl Compounds; Comparative Effectiveness Research; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; United States | 2019 |
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2019 |
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.
Topics: Adamantane; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Glucosides; Humans; Incretins; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2019 |
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Ameliorative Effect and Mechanism of the Purified Anthraquinone-Glycoside Preparation from
Topics: Animals; Anthraquinones; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Oxidative Stress; Pancreas; Rats; Rats, Sprague-Dawley; Rheum; Superoxide Dismutase | 2019 |
Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Qatar; Treatment Outcome | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Circulating complement-1q tumor necrosis factor-α-related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin.
Topics: Benzhydryl Compounds; Biomarkers; Case-Control Studies; Collagen; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Humans; Insulin Resistance; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucosides; Humans; Longitudinal Studies; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction | 2019 |
Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left | 2019 |
Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Energy Intake; Female; Fibroblast Growth Factors; Glucosides; Humans; Male; Middle Aged | 2019 |
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The expanding résumé of SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Patient Safety; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adiposity; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Fibrosis; Glucosides; Inflammation Mediators; Insulin Resistance; Macrophages; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Obesity; Paracrine Communication; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Vascular Remodeling; Vascular System Injuries | 2019 |
Considerations for SGLT2 inhibitor use in post-transplantation diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Transplantation; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Topics: Adult; Aged; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Republic of Korea; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2019 |
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Global Health; Glucosides; Humans; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucosides; Lipid Metabolism; Male; Metformin; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Cell Death; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Epithelial Cells; Glucose; Glucosides; Humans; Kidney; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Liver; Female; gamma-Glutamyltransferase; Glucosides; Humans; Male; Middle Aged; Remission Induction; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Waist Circumference | 2019 |
Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Models, Economic; Patient Simulation; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diastole; Female; Glucosides; Humans; Male; Middle Aged; Myocardial Contraction; Sodium-Glucose Transporter 2 Inhibitors; Systole | 2019 |
Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Primary Health Care; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; United Kingdom | 2019 |
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucosides; Mice; Mice, Inbred C57BL; Molecular Structure; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spiro Compounds; Structure-Activity Relationship | 2019 |
SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Topics: Animals; Benzhydryl Compounds; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Glucosides; Heart; Humans; Male; Mice; Oxidative Stress; Signal Transduction; Soluble Guanylyl Cyclase | 2019 |
Inhibitory effect of saccharides and phenolic compounds from maize silks on intestinal α-glucosidases.
Topics: alpha-Glucosidases; Blood Glucose; Diabetes Mellitus, Type 2; Flavonoids; Flowers; Glucosides; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Intestines; Kinetics; Molecular Docking Simulation; Phenols; Plant Extracts; Polyphenols; Zea mays | 2019 |
Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Glucosides; Heart Diseases; Humans; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left | 2020 |
Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Benzhydryl Compounds; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult | 2019 |
Binding properties of sodium glucose co-transporter-2 inhibitor empagliflozin to human serum albumin: spectroscopic methods and computer simulations.
Topics: Benzhydryl Compounds; Binding Sites; Circular Dichroism; Diabetes Mellitus, Type 2; Glucosides; Humans; Molecular Docking Simulation; Protein Binding; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Symporters; Thermodynamics | 2020 |
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sweden | 2019 |
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Topics: Benzhydryl Compounds; Blood Volume; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics; Glucose; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Multicenter Studies as Topic; Myocardial Infarction; Natriuresis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Stroke; Stroke Volume | 2019 |
Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperlipidemias; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
Hypoglycemic action of borapetoside A from the plant Tinospora crispa in mice.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Diterpenes; Gluconeogenesis; Glucose; Glucosides; Glycogen; Hypoglycemic Agents; Insulin; Interleukin-6; Liver; Male; Mice; Mice, Inbred ICR; Muscles; Phosphoenolpyruvate Carboxykinase (GTP); Phytotherapy; Plant Extracts; Plants, Medicinal; Signal Transduction; Tinospora | 2013 |
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
UP780, a chromone-enriched aloe composition improves insulin sensitivity.
Topics: 3T3-L1 Cells; Adiponectin; Aloe; Animals; Benzophenones; Blood Glucose; Chemistry, Pharmaceutical; Chromones; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucosides; Humans; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Phytotherapy; Plant Preparations; Polysaccharides; Tyrosine | 2013 |
Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors.
Topics: Algorithms; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Inhibitory Concentration 50; Quantitative Structure-Activity Relationship; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Canagliflozin approved for type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Topics: Animals; Azulenes; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Tolerance Test; Glucosides; Glycosuria; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
US approves "new class" of diabetes drug, under review in Canada.
Topics: Canada; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; United States | 2013 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Female; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Kidney; Losartan; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2013 |
A novel approach.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
SGLT2 inhibitors for diabetes: turning symptoms into therapy.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2013 |
Treating type 2 diabetes with canagliflozin.
Topics: Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Dapagliflozin (Forxiga) for type 2 diabetes?
Topics: Adult; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; United Kingdom; Weight Loss | 2013 |
Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Topics: Alzheimer Disease; Animals; Canagliflozin; Cholinesterase Inhibitors; Computer Simulation; Databases, Protein; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Molecular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Diabetes: Efficacy of dapagliflozin associated with renal function.
Topics: Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins | 2013 |
Diabetes: efficacy of dapagliflozin associated with renal function.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2013 |
The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Research Design; Sodium-Glucose Transport Proteins; Weight Gain | 2013 |
Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial).
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2014 |
Canagliflozin - something new for type 2 diabetes, but is it safe and efficacious?
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2014 |
Glucosidase inhibitory activity and antioxidant activity of flavonoid compound and triterpenoid compound from Agrimonia Pilosa Ledeb.
Topics: Agrimonia; alpha-Glucosidases; Antioxidants; beta Carotene; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Flavonoids; Free Radical Scavengers; Glucosides; Glycoside Hydrolase Inhibitors; Hyperglycemia; Kinetics; Lipid Peroxidation; Oxidation-Reduction; Oxidative Stress; Plant Extracts; Postprandial Period; Quercetin; Triterpenes | 2014 |
Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
[Introduction].
Topics: Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Safety of canagliflozin in patients with type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Lipids; Male; Thiophenes; Urinary Tract Infections; Urination | 2014 |
Effect of Ca(2+) on the activity and structure of α-glucosidase: inhibition kinetics and molecular dynamics simulations.
Topics: alpha-Glucosidases; Amino Acid Sequence; Binding Sites; Calcium; Catalytic Domain; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Kinetics; Molecular Dynamics Simulation; Molecular Sequence Data; Osteoporosis; Protein Binding; Protein Structure, Secondary; Saccharomyces cerevisiae Proteins | 2014 |
Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Insulin; Male; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dapagliflozin approved for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; United States; United States Food and Drug Administration | 2014 |
Canagliflozin.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Thiophenes | 2014 |
Canagliflozin.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Thiophenes | 2014 |
In reply.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Thiophenes | 2014 |
Chronic kidney disease: empagliflozin-one step closer to glycaemic control in patients with type II diabetes and CKD?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic | 2014 |
SGLT2 versus DPP4 inhibitors for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Dapagliflozine (Farxiga) for type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Ipragliflozin: first global approval.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The perils of clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Thiophenes; Young Adult | 2014 |
Tofogliflozin: the road goes ever on.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dreaming of normoglycaemia with fewer diet restrictions.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic | 2014 |
Zucker Diabetic Fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Benzhydryl Compounds; Blood Coagulation; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Factor Xa Inhibitors; Female; Glucosides; Hypoglycemic Agents; Platelet Aggregation; Pyrazoles; Pyridones; Rats; Rats, Zucker; Thrombophilia; Thrombosis | 2014 |
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality-Adjusted Life Years; Scandinavian and Nordic Countries; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2015 |
Tofogliflozin: first global approval.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Comparative pharmacokinetic investigation on baicalin and wogonoside in type 2 diabetic and normal rats after oral administration of traditional Chinese medicine Huanglian Jiedu decoction.
Topics: Administration, Oral; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Flavanones; Flavonoids; Glucosides; Hypolipidemic Agents; Male; Medicine, Chinese Traditional; Plant Extracts; Rats; Rats, Sprague-Dawley; Scutellaria baicalensis | 2014 |
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Topics: Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney Function Tests; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Severity of Illness Index; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Female; Glucosides; Hypertension; Hypertrophy; Hypoglycemic Agents; Kidney; Mice; Mice, Obese; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dapagliflozin--do we need it registered for type 2 diabetes?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles | 2014 |
Phenylpropenoic acid glucoside augments pancreatic beta cell mass in high-fat diet-fed mice and protects beta cells from ER stress-induced apoptosis.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Size; Cells, Cultured; Crosses, Genetic; Diabetes Mellitus, Type 2; Diet, High-Fat; Endoplasmic Reticulum Stress; Fructose; Glucosides; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipotropic Agents; Male; Mice, Transgenic; Obesity; Phenylpropionates; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; RNA Interference; Up-Regulation | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2014 |
Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemic Agents; Metformin; Mice, Knockout; Mice, Obese; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Isoindoles; Niacinamide; Rats; Rats, Zucker; Streptozocin | 2015 |
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Japan; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Empagliflozin (Jardiance) for diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Pregnancy; Pregnancy in Diabetics; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
[Contributions of SGLT-2 and new drugs under investigation].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2014 |
Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Japan; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Diuresis; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Sodium-Glucose Transporter 2; Thiophenes | 2014 |
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Models, Economic; Risk Factors; Sulfonylurea Compounds; United Kingdom | 2015 |
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice, Inbred C57BL; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles | 2014 |
Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medicare Part C; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome; United States | 2015 |
Dapagliflozin does not show improvement in glycemic control in moderate renal impairment: a question of analytical rigor?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
The authors reply.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
C-Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodium-Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice; Random Allocation; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transport Proteins; Structure-Activity Relationship | 2015 |
Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Lipids | 2015 |
[Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Models, Econometric; Spain | 2015 |
Author’s response.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles | 2014 |
[New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2; Treatment Outcome | 2014 |
[Empagliflozin: another of silent revolutioners].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 | 2014 |
What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Formularies as Topic; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Will the new SGLT2 inhibitor empagliflozin help us reduce the risk of hypoglycemia?].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Quality of Life; Sodium-Glucose Transporter 2; Treatment Outcome | 2014 |
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Humans; Male; Metformin | 2015 |
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Design, Synthesis and in vivo Evaluation of Novel C-Aryl Glucosides as Potent Sodium-Dependent Glucose Cotransporters Inhibitors for the Treatment of Diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Hypoglycemic Agents; Male; Mice; Pancreas; Sodium-Glucose Transport Proteins | 2015 |
Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3β pathway.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatocytes; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; Oxygen Consumption; Pancreas; Phenols; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2015 |
Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
[Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Czech Republic; Diabetes Mellitus, Type 2; Drug Approval; European Union; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model.
Topics: Animals; Aorta; Blood Pressure; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucose Intolerance; Glucosides; Guanylate Cyclase; Heart Rate; Hyperglycemia; Hypertension; Male; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Phenols; Rats; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation | 2015 |
Cyanidin-3-glucoside derived from black soybeans ameliorate type 2 diabetes through the induction of differentiation of preadipocytes into smaller and insulin-sensitive adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; Anthocyanins; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Diabetes Mellitus, Type 2; Glucose Transporter Type 4; Glucosides; Glycerolphosphate Dehydrogenase; Glycine max; Hypoglycemic Agents; Insulin; Ion Channels; Male; Mice; Mitochondrial Proteins; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Plant Extracts; PPAR gamma; Sirtuin 1; Transcription Factors; Triglycerides; Tumor Necrosis Factor-alpha; Uncoupling Protein 3 | 2015 |
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
[Weight also counts for patients].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Obesity; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2015 |
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
In brief: ketoacidosis with SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss | 2015 |
[Positive experience with SGLT-2 inhibitor in general practice].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2015 |
Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney Tubules, Proximal; Male; Medication Therapy Management; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Topics: Adult; Benzhydryl Compounds; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Personal Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred ICR; Niacinamide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes; Time Factors | 2016 |
Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Bezafibrate; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Glucosides; Hypoglycemic Agents; Islets of Langerhans; Lipids; Mice | 2015 |
Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Effect of dapagliflozin on colon cancer cell [Rapid Communication].
Topics: Antineoplastic Agents; Apoptosis; Benzhydryl Compounds; Cell Count; Colonic Neoplasms; Diabetes Mellitus, Type 2; Glucosides; Glucuronosyltransferase; HCT116 Cells; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2015 |
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sodium-Glucose Transport Proteins; State Medicine; United Kingdom | 2015 |
SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Antibodies; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
Understanding EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Understanding EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Understanding EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Preventing cardiovascular events with empagliflozin: at what cost?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2015 |
Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Foam Cells; Gene Expression; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Macrophages, Peritoneal; Male; Mice; Mice, Knockout; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
European Association for the Study of Diabetes 51st Annual Meeting.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Superiority trials: statistical trickery or mass blindness?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis | 2016 |
[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Topics: Belgium; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperphagia; Male; Sodium-Glucose Transporter 1; Weight Gain | 2015 |
Empagliflozin/metformin (Synjardy) for type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Drug Costs; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Selection; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Insulin Resistance; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2015 |
ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Product Surveillance, Postmarketing; Surveys and Questionnaires; Thiophenes | 2016 |
[Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Glucosides; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Female; Germinal Center Kinases; Glucosides; Hep G2 Cells; Hepatocytes; Humans; Hydrogen Bonding; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Palmitic Acid; Proprotein Convertase 9; Proprotein Convertases; Protein Binding; Protein Conformation; Protein Serine-Threonine Kinases; Receptors, LDL; RNA Interference; Serine Endopeptidases; Stilbenes; Time Factors; Transfection | 2016 |
Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Natriuresis; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Salidroside-regulated lipid metabolism with down-regulation of miR-370 in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Down-Regulation; Glucosides; Insulin; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Phenols | 2016 |
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution | 2016 |
Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
Topics: Animals; CHO Cells; Cricetulus; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship; Tetrahydroisoquinolines | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
[Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2016 |
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections | 2016 |
Increased grip strength with sodium-glucose cotransporter 2.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Screening for potential α-glucosidase and α-amylase inhibitory constituents from selected Vietnamese plants used to treat type 2 diabetes.
Topics: alpha-Amylases; alpha-Glucosidases; Benzopyrans; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hydrolyzable Tannins; Hypoglycemic Agents; Medicine, Traditional; Molecular Structure; Plant Extracts; Plants, Medicinal; Vietnam | 2016 |
Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies | 2016 |
Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
Topics: Adult; Aged; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Obesity; Thiophenes; Young Adult | 2016 |
[New fixed combination in type 2 diabetes].
Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Ketosis; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2016 |
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Insulin; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[The cardiovascular outcome is critical].
Topics: Benzhydryl Compounds; Biosimilar Pharmaceuticals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine | 2016 |
Gliflozins: ketoacidosis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-A(y) mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, Carbohydrate Loading; Flavones; Glucosides; Hypoglycemic Agents; Insulin; Lipid Metabolism; Liver; Luteolin; Male; Mice; Mice, Transgenic | 2016 |
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
[XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transport Proteins | 2016 |
Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Greece; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Three new treatments for diabetes recommended by NICE.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Practice Guidelines as Topic | 2016 |
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Energy Metabolism; Glucosides; Heart; Humans; Hypoglycemic Agents; Kidney; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart; Humans; Hypoglycemic Agents; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transport Proteins | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male | 2016 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Safety; Urinary Tract Infections | 2016 |
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Treatment Outcome | 2016 |
SGLT2 inhibitors and renal function.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred C57BL; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Metformin; Off-Label Use; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors and the Diabetic Kidney.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Renin-Angiotensin System; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phenylpropionates; Pyrroles | 2016 |
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Thiophenes; Young Adult | 2016 |
Secoisolariciresinol diglucoside rich extract of L. usitatissimum prevents diabetic colon cancer through inhibition of CDK4.
Topics: Animals; Biomarkers, Tumor; Butylene Glycols; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Cytokines; Diabetes Mellitus, Type 2; Female; Flax; Gene Expression Regulation, Neoplastic; Glucose Tolerance Test; Glucosides; Hyperglycemia; Inflammation Mediators; Male; Phytochemicals; Plant Extracts; Proliferating Cell Nuclear Antigen; Rats, Sprague-Dawley; RNA, Messenger | 2016 |
Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Product Surveillance, Postmarketing; Risk Factors; Surveys and Questionnaires; Thiophenes | 2016 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
London buses: A cardiovascular outcome trial equivalent?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Protective Factors; Risk Factors; Treatment Outcome | 2016 |
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
Renoprotection in LEADER and EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 | 2016 |
Stronger Warning for Two Diabetes Drugs.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Labeling; Glucosides; Humans; Hypoglycemic Agents; United States; United States Food and Drug Administration | 2016 |
After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Liraglutide | 2016 |
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2016 |
NICE recommends new triple therapy option for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Practice Guidelines as Topic; Sulfonylurea Compounds; United Kingdom | 2016 |
Diabetes News.
Topics: Benzhydryl Compounds; Congresses as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Peptides; Treatment Outcome; Venoms | 2017 |
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Homeostasis; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Thiophenes | 2016 |
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Topics: Aldosterone; Animals; Benzhydryl Compounds; Chymosin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Hyperglycemia; Kidney; Lipid Peroxidation; Male; Rats, Inbred OLETF; Renin-Angiotensin System; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Multicenter Studies as Topic | 2016 |
Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2016 |
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
Topics: Acarbose; Benzhydryl Compounds; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 | 2016 |
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2017 |
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2017 |
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE
Topics: Adipose Tissue; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apolipoproteins E; Atherosclerosis; Benzhydryl Compounds; Blotting, Western; CD11c Antigen; Cell Line; Cell Proliferation; Diabetes Mellitus, Type 2; Diet, Western; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Insulin Resistance; Liver; Male; Mice; Rats; Real-Time Polymerase Chain Reaction; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Treatment Outcome | 2016 |
A Case of Septic Shock Due to Serratia marcescens Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin.
Topics: Aged; Bacteremia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Male; Pyelonephritis; Serratia Infections; Serratia marcescens; Shock, Septic | 2017 |
Obesity Week 2016 Annual Meeting.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss | 2017 |
[Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
Topics: Benzhydryl Compounds; Cardiologists; Clinical Decision-Making; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Patient Selection; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Topics: Adiposity; Adult; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Lipotropic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Glucosides; GTP-Binding Protein gamma Subunits; Heart; Heterotrimeric GTP-Binding Proteins; Hyperglycemia; Hypoglycemic Agents; Lipodystrophy; Magnetic Resonance Imaging; Mice; Mice, Knockout; Myocardium; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Ventricular Dysfunction, Left; Ventricular Function | 2017 |
Anti-diabetic activities of cis- and trans-2,3,5,4'-tetrahydroxystilbene 2-O-β-glucopyranoside from Polygonum multiflorum.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Enzyme Inhibitors; Fallopia multiflora; Glucosides; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Phosphoenolpyruvate Carboxykinase (ATP); Stilbenes | 2017 |
Possible survivorship bias rather than reverse causality in EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Bias; Causality; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Survival Rate; Survivorship; Treatment Outcome | 2017 |
Reverse causality in Empa-Reg Outcome: The proverbial elephant?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Causality; Diabetes Mellitus, Type 2; Elephants; Glucosides; Humans; Hypoglycemic Agents; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2; Treatment Outcome | 2017 |
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spain; Time Factors; Treatment Outcome; Weight Loss | 2017 |
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Incidence; Kidney; Kidney Diseases; Male; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2017 |
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diastole; Disease Models, Animal; Female; Glucosides; Glycemic Index; Mice; Mice, Inbred C57BL; Mice, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies | 2017 |
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
Topics: Chalcones; Diabetes Mellitus, Type 2; Glucosides; HEK293 Cells; Humans; Membranes, Artificial; Molecular Docking Simulation; Phosphatidylcholines; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Product Surveillance, Postmarketing; Sodium-Glucose Transport Proteins | 2017 |
Asian Perspective of the EMPA-REG OUTCOME Study.
Topics: Asian People; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Outcome Assessment, Health Care | 2017 |
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Registries; Risk Factors; Sweden | 2017 |
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Ketones; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; General Practitioners; Germany; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult | 2017 |
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Polymorphism, Single Nucleotide; Sodium-Glucose Transporter 2 | 2017 |
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans | 2017 |
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics, Osmotic; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Longitudinal Studies; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sodium-Glucose Transport Proteins | 2017 |
Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Topics: Atherosclerosis; Blood Glucose; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Thiophenes; Triglycerides | 2017 |
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Approval; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Mortality; Multicenter Studies as Topic; Survival Analysis | 2017 |
Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged; Primary Health Care; Retrospective Studies | 2017 |
Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2017 |
Hypoglycemic effects of Cecropia pachystachya in normal and alloxan-induced diabetic rats.
Topics: Alloxan; Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Cecropia Plant; Diabetes Mellitus; Diabetes Mellitus, Type 2; Flavonoids; Free Radical Scavengers; Glucose Tolerance Test; Glucosides; Glyburide; Hypoglycemic Agents; Male; Medicine, Traditional; Metformin; Phenols; Plant Extracts; Rats; Rats, Wistar | 2010 |
Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Topics: Animals; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spiro Compounds | 2010 |
Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Biological Availability; Canagliflozin; Carbonates; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Male; Mice; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiophenes | 2010 |
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Hyperglycemia; Islets of Langerhans; Obesity; Pancreas; Rats; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Male; Mice; Mice, Inbred ICR; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship; Xylose | 2011 |
New diabetes drugs go beyond insulin to flush out excess sugar.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Thiophenes | 2011 |
C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2011 |
Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Models, Biological; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
[Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transport Proteins | 2011 |
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Glucosides; Hypoglycemic Agents; Monosaccharide Transport Proteins; Rats; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
Dapagliflozin--redefining treatment of T2DM?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastrointestinal Tract; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred ICR; Phlorhizin; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
FDA rejects novel diabetes drug over safety fears.
Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; United States; United States Food and Drug Administration | 2012 |
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Kidney; Male; Mice; Mice, Inbred Strains; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
Still uncertain about sodium-glucose cotransporter inhibitors despite 2 centuries of study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Sodium-Glucose Transport Proteins | 2012 |
Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; CHO Cells; Cricetinae; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Inhibitory Concentration 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Macaca fascicularis; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred ICR; Models, Molecular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spectrometry, Mass, Electrospray Ionization | 2012 |
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Kidney; Male; Mice; Mice, Inbred ICR; Niacinamide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2012 |
Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Kidney; Male; Peptides; Rats; Rats, Zucker; Receptors, Glucagon; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2013 |
Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
Topics: Asian People; Binding Sites; Caffeic Acids; Coumarins; Diabetes Mellitus, Type 2; Glucosides; Humans; Hydrogen Bonding; Hypoglycemic Agents; Insulysin; Medicine, Chinese Traditional; Molecular Docking Simulation; Molecular Dynamics Simulation; Structure-Activity Relationship | 2013 |
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cell Line; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Fasting; Gene Expression Profiling; Glucagon; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Islets of Langerhans; Kinetics; Male; Rats; Rats, Wistar | 2003 |
Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
Topics: Administration, Oral; Animals; Carbonates; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet; Disease Models, Animal; Enzyme Inhibitors; Female; Glucose; Glucose Tolerance Test; Glucosides; Hyperglycemia; Insulin Resistance; Male; Membrane Glycoproteins; Monosaccharide Transport Proteins; Rats; Rats, Inbred Strains; Rats, Wistar; Sodium; Sodium-Glucose Transporter 1; Time Factors | 2005 |
Preventive effects of a soy-based diet supplemented with stevioside on the development of the metabolic syndrome and type 2 diabetes in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Diterpenes, Kaurane; Fasting; Fatty Acids, Nonesterified; Glucosides; Male; Metabolic Syndrome; Rats; Rats, Zucker; Soy Foods; Sweetening Agents; Triglycerides | 2005 |
Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Carbonates; Carrier Proteins; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucokinase; Glucose; Glucose-6-Phosphatase; Glucosides; Glycogen; Glycogen Synthase; Hyperglycemia; Insulin; Liver; Liver Glycogen; Male; Muscle, Skeletal; Phosphorylases; Rats; Rats, Zucker | 2006 |
Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice.
Topics: Adipokines; Adiponectin; Adipose Tissue, White; Animals; Anthocyanins; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Glucose Tolerance Test; Glucose Transporter Type 4; Glucose-6-Phosphatase; Glucosides; Hyperglycemia; Inflammation Mediators; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Molecular Structure; Receptors, Adiponectin; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism | 2008 |
Molecule of the month. Dapagliflozin.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Delivery Systems; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2007 |
Release of acetylcholine by syringin, an active principle of Eleutherococcus senticosus, to raise insulin secretion in Wistar rats.
Topics: Acetylcholine; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eleutherococcus; Glucosides; Insulin; Insulin Secretion; Male; Muscarinic Antagonists; Phenylpropionates; Phytotherapy; Piperidines; Rats; Receptor, Muscarinic M3 | 2008 |
New antidiabetic compounds, mangiferin and its glucoside.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyperinsulinism; Hypoglycemic Agents; Male; Mice; Xanthenes; Xanthones | 1998 |
Antihyperglycemic acetylenic glucosides from Bidens pilosa.
Topics: Acetylene; Animals; Asteraceae; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL | 2000 |
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Topics: Animals; Blood Glucose; Carbonates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon; Glucose Tolerance Test; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Kidney Glomerulus; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Obese; Microvilli; Monosaccharide Transport Proteins; Pancreas; Phenotype; Sodium-Glucose Transporter 1 | 2001 |
Antidiabetic activity of a xanthone compound, mangiferin.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnoliopsida; Male; Mice; Phytotherapy; Plant Extracts; Xanthenes; Xanthones | 2001 |
Secoisolariciresinol diglucoside from flaxseed delays the development of type 2 diabetes in Zucker rat.
Topics: Animals; Antioxidants; Blood Glucose; Butylene Glycols; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Flax; Glucosides; Glycated Hemoglobin; Malondialdehyde; Oxidative Stress; Rats; Rats, Zucker; Triglycerides | 2001 |
Antidiabetic activity of the rhizoma of Anemarrhena asphodeloides and active components, mangiferin and its glucoside.
Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Mice; Phytotherapy; Plant Extracts; Plants, Medicinal; Tolbutamide; Xanthenes; Xanthones | 2001 |
Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats.
Topics: Animals; Area Under Curve; Diabetes Mellitus, Type 2; Disease Models, Animal; Diterpenes; Diterpenes, Kaurane; Glucagon; Glucose; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Injections, Intravenous; Insulin; Male; Phytotherapy; Plant Extracts; Rats; Rats, Inbred Strains; Rats, Wistar; Terpenes | 2002 |
Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters.
Topics: Animals; Arginine; Blood Glucose; Calcium; Carbonates; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Monosaccharide Transport Proteins; Rats; Rats, Wistar | 2002 |